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INTRODUCTION 
The human lower urinary tract (LUT), comprising the urinary bladder, the 
urethra and the external urethral sphincter, has two opposing functions [1]: 
1) the low pressure, continent, and symptom free storage of urine which is 
constantly draining from the kidneys, and 2) the periodical, voluntarily 
controlled, unobstructed, and complete release of the stored urine. 
The correct progression of each phase and particularly the switch from one 
phase to the other requires the orchestration of a neural network of afferent 
and efferent pathways involving different levels of the nervous system, i.e. 
peripheral autonomic and somatic nerves, spinal neurons and tracts, and 
finally supraspinal processes to enable voluntary control and judgement of 
appropriateness (Figure 1-1). 
Hence, it is not surprising that neurological diseases or lesions that interfere 
with such complex neuronal control easily lead to dysfunction and / or 
symptoms in the LUT. Indeed, the prevalence of LUT dysfunction and 
symptoms in neurological conditions such as spinal cord injury (SCI), 
multiple sclerosis (MS), Parkinson’s disease (PD), and stroke, can reach 
almost 100% (Table 1-1, Table 1-2). 
Lower urinary tract symptoms (LUTS) such as urinary frequency, urgency, 
and incontinence or urinary retention are highly bothersome [2, 3] and 
severely reduce quality of life (QoL) [4] particularly in neurological patients 
as they often already struggle with the comorbidities of their neurological 
disease / lesion, such as impaired mobility. Hence, restoration of bladder 
function is one of the top priorities of individuals with neurogenic lower 
urinary tract dysfunction (NLUTD), such as SCI patients [5]. 
In addition, the underlying dysfunction of LUTS (Table 1-3, Table 1-4) can 
bear certain health risks. The most relevant sequelae that are associated 
with NLUTD are upper urinary tract (UUT) damage, i.e. impairment of kidney 
function, and recurrent urinary tract infections [6-14]. 
Chapter 1 
3 
 
Figure 1-1 Schematic illustration of spinal cord and brain stem regions involved in lower 
urinary tract (LUT) control and their most relevant neuronal connection to the LUT. The 
illustration summarizes the findings of neurophysiological animal studies from De Groat et al. 
[15] and early functional neuroimaging studies in humans from Blok et al. [16]. During the 
storage phase (A), which normally accounts for most of the day (98%), the detrusor is 
relaxed and the bladder neck closed due to sympathetic tone acting on the bladder body and 
neck. Sympathetic fibres travel along the hypogastric nerve from the sympathetic nuclei in 
the intermediolateral column of the lumbar spinal cord to the LUT and provide adrenergic 
input to beta-receptors on intramural ganglia of the bladder body (→ relaxation) and alpha-
receptors at the bladder neck (→ contraction/closure). Bladder afferents traverse through the 
pelvic nerve and enter the dorsal horn of the sacral spinal cord. At low filling volumes, there 
might be only little afferent activity and weak afferent signals might reach the PAG and 
diencephalic structures (e.g. thalamus), but bladder sensations do usually not reach 
consciousness during this state. With increasing bladder volumes, afferent activity might 
increase, likely due to changes in intravesical pressure and, at some degree of filling, 
bladder sensations will reach consciousness in the form of a first desire to void. From the 
sacral dorsal horn, excitatory collaterals reach the sympathetic nuclei in the lumbar 
intermediolateral column and the sacral frontal horn, where the motor neurons of the external 
urethral sphincter (EUS) are located (Onuf’s nucleus), to facilitate sympathetic input to the 
bladder and bladder neck, and somatic input to the EUS respectively. This supports 
continence during increasing bladder volumes, when voiding has to be postponed. Another 
region thought to be responsible for continence is the pontine L-region (named L-region as it 
is lateral to the other relevant pontine structure named the pontine micturition centre or M-
region or Barrington’s nucleus), which has excitatory input to the EUS motor neurons in 
Onuf’s nucleus and thus facilitates the elevation of the EUS tone. 
If the decision to empty the bladder is made (in the higher brain centres), the periaqueductal 
grey (PAG) activates the pontine micturition centre (PMC) (B). The switch between L-region 
and PMC activation is sometimes conceived in a simplified manner as moving a lever from 
one programme to the other. Only one region can be activated at a time. From the PMC, 
strong inhibitory inputs reach the sympathetic nuclei in the intermediolateral lumbar cord to 
suppress the sympathetic input to bladder body and bladder neck to enable synergic 
micturition. Simultaneously, the PMC has strong excitatory projections to the 
parasympathetic nuclei in the sacral spinal cord that in turn activate the detrusor muscle via 
muscarinic receptors. The parasympathetic fibres travel along the pelvic nerve. In addition to 
the parasympathetic activation, the PMC has excitatory collaterals to inhibitory interneurons 
in the sacral cord that reduce the activity of EUS motor neurons, and thus facilitate EUS 
relaxation and synergic micturition. 
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Table 1-1 Prevalence of different neurogenic lower urinary tract dysfunction (NLUTD) and 
symptoms in multiple sclerosis (MS), Parkinson’s disease (PD), multiple system atrophy (MSA), 
and stroke. 
 MS PD MSA Stroke 
Prevalence of NLUTD 34-99% [17] 27-71% 
[18, 19] 
78-96% [20] 38-94% 
[21, 22] 
Average time interval 
between diagnosis of 
neurological disease 
and onset of urological 
symptoms [years] 
5.9 (4.6-7.8) 
[17] 
5 [23] 2 [23]  
Urinary urgency 63.4% (32-
86%) [17] 
33-68% 
[18, 19] 
63% [24] 70% [21] 
Urinary frequency 54.4% (25-
99%) [17] 
16-71% 
[18, 19] 
45% [24] 59% [21] 
Nocturia  60-86% 
[18, 19] 
74% [24] 76% [21] 
Urinary urgency 
incontinence 
56.3% (19-
80%) [17] 
27% [19] 63% [24] 29% [21] 
Dysuria 34.8% (6-
79.5%) [17] 
30% [23] 69% [23] 6% [21] 
Retention / incomplete 
bladder emptying 
(PVRV > 100 mL) 
35.6% (8.3-
73.8%) [17] 
 52% [24] 48% [21] 
DO 65% (43-
99%) [17] 
45-93% [19] 35-56% 
[23, 24] 
36-82% [21] 
DSD 35% (5-83%) 
[17] 
 47-98% (incl. 
bladder neck 
dyssynergia) 
[23, 24] 
 
Reduced compliance 2-10% [17]  31% [24]  
Detrusor 
hypocontractility 
25% (0-40%) 
[17] 
53% [19] 52-67% 
[20, 23] 
33-40% [21] 
Open bladder neck 
during filling cystometry 
 31% [20] 87% [20]  
Pathologic EUS-EMG  5% [20] 93% [20]  
The listed numbers reflect only gross guide values due to sparse and / or heterogeneous 
data form investigations using different assessment methods. PVRV post void residual 
volume, DO detrusor overactivity, DSD detrusor-sphincter-dyssynergia, EUS-EMG external 
urethral sphincter electromyogram. Table adapted from [25]. 
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Table 1-2 Associations between injury levels and urodynamic findings in patients with spinal 
cord injury (SCI) based on a meta-analysis by Jeong et al. [26] 
 Level of SCI 
p-value* 
 cervical thoracic lumbar sacral 
No. of 
Patients 
259 215 137 46  
DO [%] 65 78 49 22 < 0.001 
DSD [%] 63 72 33 13 < 0.001 
DU [%] 9 9 39 70 < 0.001 
Normal [%] 1 2 2 9 0.002 
Thoracic lesions are indicated to spinal cord level T9 or above, and injuries at the T10 through 
T12 levels are included in lumbar lesions. The combined suprasacral and sacral lesions have 
been excluded from this analysis. 
* Pearson chi-square test 
DO detrusor overactivity. DSD detrusor-sphincter-dyssynergia, DU detrusor underactivity. 
Table adapted from [26]. 
 
Not by accident, renal disease and other urological complications such as 
urosepsis ranged among the most frequent causes of death in SCI patients 
until the mid 1970s whereupon neuro-urological work–up and follow-up 
gradually became established [27-34].  
Nowadays, due to improvements in medical care, including neuro-urological 
management, many patients with neurological disease or trauma and 
NLUTD have increased their life expectancy to a level close to normal [31, 
35-38]. As a consequence, not only the number of elderly individuals with 
NLUTD is increasing but also the time period for which they have to deal 
with their NLUTD. This is further potentiated by the increasing life 
expectancy of the general population and, consequently, age-associated, 
chronic degenerative neurological diseases such as PD [39, 40]. Finally, 
these aspects are also relevant from a uro-oncological view point as, while 
the incidence of bladder malignancies may not be necessarily higher in 
NLUTD compared to the general population, they may occur earlier and with 
a more rapid/aggressive progression. This can, in conjunction with the 
comorbidities related to the neurological disease/lesion, lead to a higher 
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degree of morbidity [41-43]. Thus, it is all the more important to understand 
how to manage NLUTD and associated complications to provide sustainable 
treatment and follow-up strategies. 
 
Table 1-3 Summary of common storage symptoms that might occur due to lower urinary tract 
dysfunction in neurological diseases or lesions in association with their typically related 
urodynamic and clinical findings. Definitions of Symptoms are reproduced from the International 
Continence Society standardisation of terminology in lower urinary tract function [44]. 
Storage symptom 
Most typical urodynamic and clinical 
findings 
(listed are single findings that can also occur in 
combination) 
Typical 
neurological 
lesion site 
Urinary urgency 
Complaint of a sudden 
compelling desire to 
pass urine which is 
difficult to defer. 
- Detrusor overactivity 1, 2 
- Low bladder compliance 1, 2 
1 suprasacral 
2 supraspinal 
Urinary frequency 
(increased daytime 
frequency, pollakisuria) 
Complaint by the patient 
who considers that 
he/she voids too often 
by day. 
- Detrusor overactivity 1, 2 
- Low bladder compliance 1, 2 
- Incomplete bladder emptying / 
elevated post void residual volume 
due to hypocontractile detrusor 3, 4 or 
bladder outlet obstruction 
(anatomical: prostate enlargement, 
urethral stricture; functional: 
detrusor-sphincter-dyssynergia 1, 2) 
1 suprasacral 
2 supraspinal 
3 subsacral / 
lumbosacral 
4 peripheral 
Nocturia 
Complaint that the 
individual has to wake 
at night one or more 
times to void. 
- Detrusor overactivity 1, 2 
- Low bladder compliance 1, 2 
- Incomplete bladder emptying / 
elevated post void residual volume 
due to hypocontractile detrusor 3, 4 or 
bladder outlet obstruction 
(anatomical: prostate enlargement, 
urethral stricture; functional: 
detrusor-sphincter-dyssynergia 1, 2) 
1 suprasacral 
2 supraspinal 
3 subsacral / 
lumbosacral 
4 peripheral 
Urgency urinary 
incontinence 
Complaint of involuntary 
leakage accompanied 
by or immediately 
preceded by urgency. 
- Detrusor overactivity 1, 2 
- Low bladder compliance 1, 2 
1 suprasacral 
2 supraspinal 
Stress urinary 
incontinence 
Complaint of involuntary 
leakage on effort or 
exertion, or on sneezing 
or coughing. 
- Urethral sphincter insufficiency 3, 4 
- Bladder neck incompetence 3, 4 
3 subsacral / 
lumbosacral 
4 peripheral 
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Storage symptom 
Most typical urodynamic and clinical 
findings 
(listed are single findings that can also occur in 
combination) 
Typical 
neurological 
lesion site 
Mixed urinary 
incontinence 
Complaint of involuntary 
leakage associated with 
urgency and also with 
exertion, effort, 
sneezing or coughing. 
- Detrusor overactivity 1, 2 
- Low bladder compliance 1, 2 
       AND 
- Urethral sphincter insufficiency 3, 4 
- Bladder neck incompetence 3, 4 
1 suprasacral 
2 supraspinal 
3 subsacral / 
lumbosacral 
4 peripheral 
Continuous urinary 
incontinence 
Complaint of continuous 
urinary leakage. 
- Open bladder neck and flaccid 
urethral sphincter 3, 4 
        OR 
- Overflow incontinence due to 
bladder outlet obstruction 
(anatomical: prostate enlargement, 
urethral stricture; functional: 
detrusor-sphincter-dyssynergia 1, 2) 
and/or acontractile 3, 4, hyposensitive 
bladder 3, 4 
1 suprasacral 
2 supraspinal 
3 subsacral / 
lumbosacral 
4 peripheral 
Reduced or absent 
bladder sensation 
The individual is aware 
of bladder filling 
but does not feel a 
definite desire to void or 
reports no sensation of 
bladder filling or desire 
to void. 
- Bladder distension during filling 
cystometry is not perceived or only 
at high volumes 1-4 
1 suprasacral 
(only in complete 
spinal cord 
lesions) 
2 supraspinal 
(only in complete 
spinal cord 
lesions) 
3 subsacral / 
lumbosacral 
4 peripheral 
Increased bladder 
sensation 
The individual feels an 
early and persistent 
desire to void. 
- Bladder distension during filling 
cystometry is perceived early, at low 
volumes 1, 2. 
1 suprasacral 
2 supraspinal 
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STORAGE DYSFUNCTION OF THE LOWER URINARY 
TRACT IN NEUROLOGICAL PATIENTS 
DETRUSOR OVERACTIVITY 
One of the most relevant risk factors for developing LUTS and complications 
of lower and upper urinary tract, especially in neurological patients, is 
detrusor overactivity (DO) [7, 14, 45-47]. This term describes a condition of 
involuntary detrusor contractions during the storage phase that result from 
loss or impaired supraspinal inhibitory input to the sacral bladder reflex 
circuitry. This also implicates that DO can occur as a consequence of any 
lesion / disease affecting the suprasacral central nervous system. This 
makes DO one of the most common dysfunctions in neurological patients 
(Table 1-1, Table 1-2). DO can be visualised and diagnosed using filling 
cystometry. This specialized examination provides details on the maximum 
pressure amplitude during DO, the frequency and duration of DO, and the 
volume of DO occurrence, which are relevant parameters for a full 
understanding and characterization of the extent of DO. An increase in 
detrusor pressure during DO will usually cause a sensation of urgency, if 
sensory function is maintained. When pressure levels of DO exceed the sub-
vesical closing pressure, the DO will result in DO incontinence. Moreover, 
DO has been proven to be associated with irreversible morphological 
alterations of the LUT and renal function impairment in the long-term [6-9, 
11, 12]. 
The morphological alterations associated with DO include detrusor 
hypertrophy, trabeculation of the bladder wall, and the development of 
pseudo-diverticula [11]. Renal function impairment associated with DO may 
occur through multiple mechanisms, such as obstruction, excessive 
pressure exposure, vesicoureteral reflux (VUR), and recurrent infections. 
Usually, the terminal distal parts of the ureters pass transversely through the 
bladder wall to their orifices in the trigone [48]. This intramural passage 
provides a flap valve mechanism with compression of the intramural ureter 
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parts during detrusor contraction, preventing VUR during micturition. During 
storage, when the detrusor is relaxed, the intramural ureter is not 
compressed and can thus deliver the urine into the bladder. However, in 
case of detrusor hypertrophy due to chronic DO, the intramural ureter parts 
may become constantly compressed by the hypertrophic detrusor resulting 
in ureteric outflow obstruction, which in the long-term will lead to dilatation of 
the ureters and subsequently also the pelvicaliceal system of the kidneys 
[11]. Such pressure-related ectasia of the UUT is associated with renal 
damage [11, 13]. 
Even prior to the development of detrusor hypertrophy, DO can become 
harmful to renal function if detrusor pressure increases to amplitudes above 
40 cmH2O, pressures that have been demonstrated to be associated with 
upper urinary tract deterioration [7, 8, 49, 50]. However, this pressure 
threshold of 40 cmH2O for UUT damage is deemed controversial due to the 
rather low level of evidence and the clinical observation that intravesical 
storage pressures below 40 cmH2O do not guarantee UUT safety but may 
result in even more severe UUT deterioration if tolerated over a longer 
period of time. Hence, the pressure level of DO alone is certainly not the 
only factor related to UUT deterioration but rather a mixture of pressure 
level, frequency of DO contractions, and duration of pressure elevation 
during single DO contractions [51]. Development of VUR in this context may 
aggravate pressure exposure and transmission to the kidneys but the 
absence of VUR does not prevent renal impairment in DO. 
UUT deterioration due to DO may even be accelerated by recurrent urinary 
tract infections (UTI). Patients with LUTD such as DO are prone to develop 
recurrent UTI [10, 46, 52] and in conditions of altered UUT urodynamics, i.e. 
obstruction and VUR, such infections may reach the upper urinary tract more 
frequently and easily. 
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Table 1-4 Summary of common voiding symptoms that might occur due to lower urinary tract 
dysfunction in neurological diseases or lesions in association with their typically related 
urodynamic and clinical findings. Definitions of Symptoms are reproduced from the International 
Continence Society standardisation of terminology in lower urinary tract function [44]. 
Voiding Symptom 
Most typical urodynamic and clinical 
findings 
(listed are single findings that can also occur 
in combination) 
Typical 
neurological lesion 
site 
Urinary retention 
Inability to pass urine to 
empty the bladder. This 
might occur acute or 
chronically, complete or 
incomplete. 
- Hypo- or acontractile detrusor 
muscle 3, 4 
- Bladder outlet obstruction 
(anatomical: prostate 
enlargement; functional: detrusor-
sphincter-dyssynergia 1, 2) 
1 suprasacral 
2 supraspinal 
3 subsacral / 
lumbosacral 
4 peripheral 
Urinary hesitancy 
An individual describes 
difficulty in initiating 
micturition resulting in a 
delay in the onset of 
voiding after the 
individual is ready to 
pass urine. 
- Bladder outlet obstruction 
(anatomical: prostate 
enlargement, urethral stricture; 
functional: detrusor-sphincter-
dyssynergia 1, 2) 
- Hypocontractile detrusor 3, 4 
1 suprasacral 
2 supraspinal 
3 subsacral / 
lumbosacral 
4 peripheral 
Urinary intermittency 
An individual describes 
urine flow which stops 
and starts, on one or 
more occasions, during 
micturition. 
- Detrusor-sphincter-dyssynergia 1, 2 
- Hypocontractile detrusor 3, 4 
1 suprasacral 
2 supraspinal 
3 subsacral / 
lumbosacral 
4 peripheral 
Slow urinary stream 
Perception of reduced 
urine flow, usually 
compared to previous 
performance or in 
comparison to others. 
- Bladder outlet obstruction 
(anatomical: prostate 
enlargement, urethral stricture; 
functional: detrusor-sphincter-
dyssynergia 1, 2) 
- Hypocontractile detrusor 3, 4 
1 suprasacral 
2 supraspinal 
3 subsacral / 
lumbosacral 
4 peripheral 
 
 
DETRUSOR-SPHINCTER-DYSSYNERGIA 
The development of elevated storage pressures and dysfunctional dynamics 
of the urinary tract due to DO may aggravate with Detrusor-Sphincter-
Dyssynergia (DSD) which is frequently associated with DO specifically in 
neurological patients [53]. 
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DSD is defined as a detrusor contraction concurrent with an involuntary 
contraction of the urethral sphincter and / or periurethral striated muscle 
groups. Occasionally, flow may be prevented altogether [54]. Hence, DSD 
may, on the symptomatic level, limit or prevent urinary incontinence but in 
turn contribute to significant rise of intravesical pressure due to functional 
subvesical outlet obstruction during a detrusor contraction. Such DSD-
related intravesical pressure excesses can increase urgency or pain 
symptoms and, more importantly, potentiate the risks for LUT and UUT 
complications, the latter leading to significant renal damage in the long run 
[55].  
Different types of DSD have been described previously [56-58]: type 1) 
concomitant increase in both detrusor pressure and sphincter EMG activity 
with sudden sphincter relaxation at the peak of the detrusor contraction, type 
2) sporadic contractions of the external urethral sphincter throughout the 
detrusor contraction, and type 3) a crescendo-decrescendo pattern of 
sphincter contraction which results in urethral obstruction throughout the 
entire detrusor contraction. However, the clinical relevance of the different 
types of DSD is controversial as type distinction does not yet have any 
impact on treatment decision or outcome [58, 59]. 
 
 
AUTONOMIC DYSREFLEXIA 
An acute and potentially life-threatening complication associated with DO / 
DSD most commonly observed in SCI patients with lesions above the 
thoracic (Th) level 6 is autonomic dysreflexia (AD) [60, 61]. AD is defined as 
an increase in systolic blood pressure (SBP) of at least 20mmHg from 
baseline [62]. It is based on an sympathetic overreaction due to the loss of 
descending central (brain stem) inhibitory pathways to the sympathetic chain 
causing vasoconstriction below the level of lesion and consequently a blood 
pressure increase [60]. This becomes especially pertinent in SCI lesions 
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above Th6 due to the lack of central modulation on the splanchnic nerves 
that usually emanate below Th5 but innervate the critical mass of blood 
vessels required to cause elevation of the blood pressure [60]. In response 
to excessive hypertension during AD, baroreceptors above the lesion level 
may become activated and induce a vagal-mediated bradycardia. This 
compensatory parasympathetic output above the level of lesion is thought to 
be responsible also for symptoms such as headache, flushing and sweating 
in the head and neck region [60]. However, AD may also occur completely 
asymptomatically, which makes it even more hazardous in daily life. 
In addition to DO / DSD, AD can be triggered by various, often usually 
benign stimuli below the lesion, i.e. bladder and/or bowel distention, urinary 
stones or infection, skin lesions / irritations, wounds, fractures, menstruation 
and sexual intercourse [63]. When AD occurs, it is important and most 
effective to eliminate the trigger stimulus, i.e. emptying the bladder, to 
prevent otherwise rapid progression of AD. 
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RESTORATION OF URINARY BLADDER STORAGE 
FUNCTION 
DO with or without DSD are the main causes of increased storage pressures 
and long-term damage to the UUT and LUT particularly in neurological 
patients [6-10, 12-14, 45, 46, 49]. Hence, to protect the UUT function and 
prevent long-term complications, it is necessary to maintain or restore low-
pressure and unrestricted urinary drainage from the kidneys [64]. Depending 
upon the extent and severity of the neurogenic urinary storage dysfunction, 
this can be achieved using conservative, minimally-invasive, and / or 
surgical treatment options: 
 
 
CONSERVATIVE TREATMENT OPTIONS 
 
NEUROPHYSIOLOGICAL BACKGROUND 
Despite the apparently more obvious cause of LUT storage dysfunction in 
neurological patients based on the impairment of aforementioned multilevel 
neuronal control, it is important to also consider the physiological 
mechanisms occurring within the LUT. This is of particular relevance since 
there are as yet no direct treatments available for most of the neurological 
lesions / diseases causing LUT storage dysfunction. Understanding the 
physiological processes in the LUT also on a receptor and neurotransmitter 
level, however, can help to detect useful targets for pharmacotherapy. 
In previous decades, different receptors, chemical mediators and signal 
transduction pathways within the LUT have been discovered and described 
as being involved in normal and pathological LUT function [65]. Of those, the 
cholinergic system, including muscarinic receptors, is probably the best 
described and longest-known mechanism in the LUT [66, 67]. 
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In order to contract, the detrusor requires an appropriate command, 
delivered by acetylcholine released from parasympathetic postganglionic 
nerve terminals. Acetylcholine binds to the muscarinic receptors on the 
detrusor and activates G-protein-related pathways that lead to smooth 
muscle contraction [68]. Depending on the muscarinic receptor subtype that 
is activated, detrusor contraction is facilitated by (1) inhibition of adenylyl 
cyclase via M2 receptors and subsequent decrease of intracellular cAMP, 
and / or (2) phospholipase c activation via M3 receptors to generate inositol 
triphosphate which then releases Ca2+ from the sarcoplasmic reticulum [68]. 
Since intracellular Ca2+ release is regarded as the main trigger for smooth 
muscle contraction, M3 receptors are regarded as most relevant for the 
initiation of voiding contractions [68]. 
Beyond the detrusor, muscarinic receptors of all subtypes (M1 – M5) have 
been found elsewhere in the LUT [66, 67]: e.g. urothelium, suburothelium, 
afferent nerve fibers, and autonomic postganglionic nerve endings. Their 
exact role and function in these locations is not yet fully established. 
However, there is evidence that muscarinic receptors on the postganglionic 
nerve endings are involved in facilitation (M1) and inhibition (M2, M4) of 
axonal acetylcholine release [67]. In the urothelium and suburothelium, 
activation of muscarinic receptors can lead to release of neurotransmitters 
such as adenosine triphosphate (ATP), that in turn can modulate afferent 
nerve- and smooth muscle activity [69]. 
In the context of DO, both of idiopathic and neurogenic origin, alterations of 
muscarinic receptor expression and sensitivity have been observed and 
seem to contribute to the pathophysiological process of DO: e.g. muscarinic 
receptors in the detrusor tissue of patients with idiopathic detrusor 
overactivity (IDO) and neurogenic detrusor overactivity (NDO) demonstrated 
increased sensitivity to stimulation, compared to healthy controls [70] and 
decreased suburothelial expression [71]. In the animal model, SCI seem to 
alter the muscarinic receptor profile on the postganglionic nerve terminals 
towards upregulation of M3 and downregulation of M1 receptors [72, 73]. 
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The sympathetic counterparts of muscarinic receptors are beta-
adrenoceptors. Their activation, naturally by noradrenaline release from 
postganglionic sympathetic neurons of the hypogastric nerve, can mediate 
relaxation of the detrusor and thus contribute to the restoration of bladder 
storage function. Beta-3-adrenoceptors seem to be the most relevant in this 
context [74] and recent clinical trials have resulted in approval of a beta-3-
adrenoceptor agonist for the treatment of bladder overactivity including DO 
[75, 76] (see paragraph on beta-adrenoceptor agonists below). 
In addition to classical cholinergic/adrenergic mechanisms, there are other 
pathways, neurotransmitters, and receptors that have been described to play 
a role in bladder storage (dys-)function and thus may serve as relevant 
treatment targets [65]: e.g. purinergic system, cannabinoid system, nerve 
growth factor, Rho-kinase pathway, transient receptor potential (TRP) 
channels, prostanoid receptors, potassium channels, and vitamin D3 
receptors. So far, purinergic receptors, TRP channels, and the cannabinoid 
system seem to constitute the most promising targets [65]. 
The purinergic system is based on the principle that ATP is released from 
the urothelium upon stretch and binds to purinergic receptors (P2X) on 
suburothelial sensory nerves which mediate the sensation of bladder filling. 
Increased levels of ATP release or purinergic receptor expression may 
contribute to increased sensitivity, i.e. urinary urgency, or detrusor 
overactivity [65]. In the bladders of patients with NDO, increased levels of 
nerve fibers expressing the purinergic receptor P2X3 have been detected 
[77, 78]. Patients with a clinical response to intravesical vanilloid treatment 
with resiniferatoxin showed decreased P2X3 expression, whereas non-
responders did not [77]. Similar effects were observed in response to 
botulinum neurotoxin A (BoNT/A) intradetrusor injections [79]. In SCI rats, 
which showed higher frequencies of spinal cord field potentials and non-
voiding contractions compared to normal rats, application of P2X3 
antagonists A-317491 and AF353 was demonstrated to reduce both 
parameters [80, 81].  
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TRP cationic ion channels are universal sensors of physical and chemical 
stimuli that are ubiquitous in various tissues of the human body including the 
LUT [82]. Their basic mechanism is to allow cationic (e.g. K+, Ca2+) influx 
upon stimulation, causing secondary reactions dependant on the tissue in 
which the TRP channel is located, e.g. depolarization with elicitation of an 
action potential in neurons. Within the LUT, several TRP channels have 
been detected in various layers (including mucosa and detrusor) and on 
neuronal fibers innervating the LUT. Of such TRP channels, specifically 
TRPV1, TRPV2, TRPV4, TRPM8, and TRPA1 have been attributed to play a 
relevant role in normal and pathological LUT function [65, 82]. As with the 
increased purinergic receptor expression in patients with NDO, TRPV1 
expression was also found to be elevated in NDO patients [83, 84]. Again, 
treatment with resiniferatoxin or BoNT/A intradetrusor injections was able to 
reduce TRPV1 expression in those patients responding also clinically to 
treatment [79, 83, 84] 
Despite their promising effects in human studies, the evidence for 
intravesical treatment with vanilloids such as capsaicin and resiniferatoxin is 
still very limited and adverse events including pelvic pain, facial flush, 
worsening of incontinence, autonomic dysreflexia, urinary tract infection, and 
haematuria are very frequent [85]. Intravesical vanilloids are not approved 
for treatment in LUTD / LUTS and have largely fallen into oblivion, 
particularly after the propagation of BoNT/A intradetrusor injections. 
However, based on their action on specific LUT receptors and afferent 
fibers, vanilloids are still of scientific interest and may undergo a clinical 
revival once more tolerable solvents for their application are developed [85]. 
The cannabinoid system in the LUT involves two G-protein-coupled 
cannabinoid receptors, CB1 and CB2, their endogeneous (e.g. anandamide, 
2-arachidonoylglycerol) and exogeneous (phytocannabinoids, synthetic 
cannabinoids) ligands, and related enzymes for biosynthesis and 
degradation (e.g. fatty acid amid hydrolase, monoacylglycerol lipase) [86]. 
Hence, effects can be elicited directly by stimulation of the cannabinoid 
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receptors or indirectly by inhibiting the degradation enzymes such as fatty 
acid amid hydrolase (FAAH). In SCI rats, treatment with the selective CB2 
agonist O-1966 resulted in improved bladder function recovery which was 
associated with a significant reduction of inflammatory response in the spinal 
cord following injury [87]. In MS patients with NDO, delta-9-
tetrahydrocannabinol alone or in combination with cannabidiol applied as 
oral capsule or spray improved symptoms such as urinary incontinence and 
frequency [88]. However, symptomatic improvements were not reflected 
urodynamically and there were mild but frequent adverse events such as 
UTI, dizzinesss, headache, vomiting, and worsening of dry mouth [65, 88]. 
Although Sativex® is an approved drug, its indication in most countries is 
limited to treatment of refractory spasticity in patients with advanced MS. 
The overall clinical evidence for the use of cannabinoids in the treatment of 
NLUTD is still very limited and trials applying indirect cannabinoid 
stimulation, e.g. use of FAAH inhibitors, for the treatment of NLUTD, are 
lacking. 
Despite the numerous potential treatment targets identified in different 
animal models, of which only few are neurogenic, i.e. SCI or MS, translation 
of findings into humans is a major challenge. Thus, approved 
pharmacotherapy for LUTD / LUTS is still very limited and antimuscarinic 
drugs are still the mainstay of conservative therapy for bladder storage 
dysfunction (see paragraph below). 
 
ANTIMUSCARINIC DRUGS 
In principle, antimuscarinics act as reversible competitive antagonists that 
block the muscarinic receptors on the detrusor myocytes resulting in 
reduced detrusor excitability through acetylcholine release from 
parasympathetic nerve terminals [68]. Assuming urinary urgency and DO are 
the result of premature acetylcholine release from the parasympathetic 
nerves during the storage phase, the available antimuscarinic drugs will shift 
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the dose response curve of acetylcholine to the right, i.e. more acetylcholine 
is necessary to cause the same effect or symptom, resulting in the 
postponement or attenuation of cholinergic stress on the detrusor. Clinically, 
this results in the typical improvements in LUTD / LUTS such as increased 
warning time, larger bladder capacities prior occurrence of urgency and DO, 
and reduced pressure amplitudes of DO [89-95]. This competitive 
antagonism is a dynamic process, the efficacy of which depends inter alia on 
the available concentration of the antimuscarinic drug at the neuromuscular 
junction in relation to the acetylcholine concentration. Thus, high dosages of 
antimuscarinics may cause enough detrusor sedation to result in increased 
post-void residual volume (PVRV) or even urinary retention [93, 96, 97]. 
However, with the clinically applied and approved antimuscarinic dosages, 
this seems to happen rarely – at least in patients with non-neurogenic 
overactive bladder symptoms (OABS) [98, 99]. Nevertheless, 
antimuscarinics still apply a verifiable effect on storage symptoms and DO 
[89, 90, 95], raising the question why they seem to selectively act during the 
storage but not voiding phase. Certainly, antimuscarinics cannot differentiate 
or act differently across both phases and this observation may simply be a 
false conclusion, as many aspects of the pathogenesis of OABS and the 
interplay between muscarinic receptor expression, acetylcholine release and 
antimuscarinic drugs remain unknown. In addition, the treatment effect of 
currently available antimuscarinic drugs for LUTD / LUTS is often little 
greater than placebo [100] and their effect on the detrusor pressure 
amplitude during micturition has never been systematically analysed. This 
would be of relevance for our understanding of antimuscarinic action and the 
lack of voiding symptoms does not per se prove that there is no effect on 
detrusor contractility during voiding at all. Yet, potential relationships 
between antimuscarinic effects during the storage and voiding phase remain 
unclear, e.g. if the reduction in DO or urgency corresponds to a reduction in 
voiding contraction. The explanation that during micturition the expected 
massive neuronal release of acetylcholine cannot be countered by 
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antimuscarinic drugs in the approved dosages [101] appears reasonable in 
view of the competitive antagonistic mechanism of action of antimuscarinic 
drugs but still leaves unclear what happens during the storage phase 
causing urinary urgency and DO that can be alleviated by antimuscarinics. 
As mentioned, some premature neuronal acetylcholine “leakage” that can be 
covered by antimuscarinic drugs at the approved dosages may be involved, 
providing support to the neurogenic hypothesis of OABS [102], but non-
neuronal acetylcholine release and muscarinic receptors on other tissues 
than detrusor may also play a role. 
Recent studies in animals and isolated human bladder tissue provide 
evidence for acetylcholine release from sources other than the 
parasympathetic nerve terminals, i.e. urothelium and suburothelial 
myofibroblasts, and the presence of muscarinic receptors on afferent nerves 
[101, 103]. In addition, it has been demonstrated that antimuscarinic drugs 
can suppress adenosine triphosphate release form the urothelium [101, 
104]. The antagonization of acetylcholine release from non-neuronal sources 
and the modulation of neurotransmitter release at the urothelial and 
suburothelial level by antimuscarinic drugs may influence localized 
autonomous non-micturition contractile activity [105] and afferent activity, 
which in consequence reduces OABS [101]. However, the detailed 
mechanism in humans, especially if there is a direct afferent effect of 
muscarinic drugs, requires further elucidation. 
Although some newer antimuscarinic drugs show some selectivity for the M2 
and / or M3 receptors on the detrusor, all antimuscarinic drugs for LUTD / 
LUTS treatment still bind to other muscarinic receptors elsewhere in the 
body causing, to various extents, adverse events such as dry mouth, 
constipation, blurred vision, somnolence, dizziness, and cognitive 
impairment [106]. The main route of antimuscarinic drug administration is 
oral, through which extended-release compared to immediate-release 
formulations are usually better tolerated and enable a once-daily application. 
Alternative administration routes, such as transdermal and intravesical 
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application, are available and may be an option for reducing some side 
effects [106]. 
The voluminous literature and evidence available for the use of 
antimuscarinic drugs is mainly related to the treatment of OABS which 
occurs per definition only in patients without any neurological etiology for 
their LUTS and for whom these drugs have been mainly developed and 
marketed [90, 95, 107]. However, there is also some evidence for the 
efficacy of antimuscarinic drugs in NDO [89, 91, 108]. In conjunction with the 
relatively good safety profile and tolerability, as well as being a conservative 
treatment strategy, are the reason antimuscarinic drugs also remain first line 
treatment for NDO [64]. Data on the urodynamic effects of antimuscarinics in 
NDO are primarily available for “older” drugs such as oxybutynin, trospium 
chloride, propiverine, and tolterodine and show increases in maximum 
cystometric bladder capacity of about 120 mL and reductions in maximum 
detrusor pressure amplitude of about 28 cmH2O [91, 108]. Data for 
urodynamic effects of newer drugs in NDO such as darifenacin, solifenacin, 
or fesoterodine are scarce. Solifenacin seems to be beneficial but with 
somewhat less impact on maximum cystometric bladder capacity and 
maximum detrusor pressure [109]. 
For some patients with NDO, antimuscarinic drugs are not efficacious at the 
available dosages [108]. This may be related to the fact that current 
antimuscarinics as competitive antagonists cannot resist the likely massive 
cholinergic output from the parasympathetic nerve terminals during full-
blown NDO. Here, some authors suggest the application of higher dosages 
either of the same or as a combination of different antimuscarinic drugs 
[110-114]. However, this is off-label use without sufficient evidence and 
adverse events might be more pronounced, decreasing the benefit / risk 
ratio and patient compliance with this therapy [64, 89]. 
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BETA-ADRENOCEPTOR AGONISTS 
An alternative strategy is combined treatment of an antimuscarinic drug and 
the newer beta-3-agonist mirabegron, aimed at achieving a synergistic effect 
by targeting two different receptors without exceeding approved dosing [115, 
116]. In addition to a small, retrospectively-analysed case series suggesting 
beneficial urodynamic and clinical effects of such combination treatment 
[117], there is a very recently published randomized placebo-controlled trial 
available, concluding that mirabegron monotherapy with 50mg once daily 
improves both urodynamic variables and patient reported outcomes in 
patients with NDO [118]. However, this trial had a very short follow-up period 
of only 4 weeks and the main urodynamic parameters such as maximum 
detrusor pressure and maximum cystometric bladder capacity were not 
significantly improved, raising doubts as to the efficacy of mirabegron in the 
treatment of NDO. More comprehensive data are lacking. Moreover, 
mirabegron may not be a good option in the treatment of patients prone to 
AD due to its sympathomimetic properties, which may cause elevated blood 
pressure and palpitations and potentially lead to more pronounced 
symptoms and blood pressure elevations during AD. 
 
PER- OR TRANSCUTANEOUS NEUROMODULATION 
Neuromodulative therapies aim to modulate neuronal signals in both afferent 
and efferent directions, exerting their effect by fairly slowly-occurring 
alterations of neuronal communication and circuitry. Thus, they must be 
distinguished from neurostimulation aiming at a direct response, i.e. muscle 
contraction, upon stimulation. The exact mechanism of action of 
neuromodulation for LUTD / LUTS remains unknown but it is hypothesized 
that, in the dorsal horn of the sacral spinal cord, bladder afferent activity may 
be inhibited through interneurons activated by somatic sensory pathways 
originating in the external genitalia, perineum, lower limb and muscles of the 
pelvic floor via the pudendal and / or tibial nerve [119, 120]. This inhibitory 
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interaction between larger somatic sensory fibres and small bladder 
afferents (A-delta or unmyelinated C fibres) may operate in a similar way to 
the ‘gate control’ theory of pain [121]. Animal studies suggest that pudendal 
nerve stimulation can elicit two effects [122]: (1) suppression of pelvic nerve 
activity to the detrusor by inhibition of the sacral micturition reflex at either 
the afferent input or the parasysmpathetic pre-ganglionic motor neurons and 
(2) activation of sympathetic neurones running in the hypogastric nerves 
causing inhibition of the parasympathetic efferent motor neurons at the level 
of the pelvic ganglia. 
Based on these hypotheses, the most frequently investigated sites to apply 
per- or transcutaneous neuromodulation for the treatment of LUTD / LUTS 
are the dorsal genital nerve [123] as a terminal branch of the pudendal nerve 
and the tibial nerve [124].  
The approach of using the pudendal and tibial nerve as therapeutic targets 
for NLUTD goes back at least to the publication by Parker M.M. and Rose 
D.K. in 1937, which demonstrated reduced DO in response to pin prick 
stimulation at the glans penis and sole of the foot in complete traumatic SCI 
patients [125]. In the 1970s, initial reports of electrical stimulation of terminal 
branches of the pudendal nerve, mainly using anal or vaginal plugs to 
reduce detrusor (over)activity, were published [126, 127]. Today, clitoral / 
penile, vaginal or rectal electrodes to reach the pudendal nerve or its 
terminal branches are commercially available, but transcutaneous electrical 
nerve stimulation (TENS) for LUTD / LUTS treatment is not limited to the 
genital / rectal area and may also be applied to sacral and suprapubic sites 
using conventional surface electrodes [123]. For percutaneous tibial nerve 
stimulation (PTNS), a 34-gauge needle electrode is inserted approximately 5 
cm cephalad to the medial malleolus and posterior to the tibia with a surface 
electrode on the arch of the foot [120]. In some more recent studies, 
transcutaneous tibial nerve stimulation (TTNS) has been used, which works 
with another surface electrode instead of the needle and thus makes it more 
amenable to individual home-use. 
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Both, TENS and PTNS / TTNS have been demonstrated to be effective on 
urodynamic and bladder diary parameters in patients with NLUTD [123, 
124]. TENS increased maximum cystometric capacity by 4 – 163 mL, 
reduced maximum storage detrusor pressure by 3 – 58 cmH2O, the number 
of bladder emptyings / 24 h by 1 – 3, and the number of incontinence 
episodes / 24 h by 0 – 4 [123]. PTNS / TTNS increased maximum 
cystometric capacity by 49 – 150 mL, reduced maximum storage detrusor 
pressure by 4 – 21 cmH2O, the number of bladder emptyings / 24 h by 3 – 
7, and the number of incontinence episodes / 24 h by 1 – 4 [124]. 
Despite these promising beneficial effects, there are very few long-term 
results [128] and a lack of QoL data. Larger randomized controlled trials are 
needed to provide reliable evidence, which might be, in addition to the 
handling and necessity for regular application of treatment sessions, a 
reason that this kind of therapy is still not very commonly used, despite the 
commercial availability of inexpensive devices and the fact that adverse 
events are almost inexistent. 
 
INTERMITTENT SELF-CATHETERISZATION 
In addition to its obvious utility in emptying the urinary bladder, it is often 
necessary to add intermittent self-catheterization (ISC) to the management 
of bladder storage dysfunction in the neurological patient in order to achieve 
continence. It may even represent the first choice in patients with DO 
incontinence provoked by a reduced functional bladder capacity prior to the 
occurrence of the DO incontinence due to accumulation of residual urine 
volume. Post-void residual volume may in particular increase with therapies 
aiming to restore continence by detrusor sedation to reduce or prevent DO, 
i.e. antimuscarinic drugs, BoNT/A intradetrusor injections and augmentation 
cystoplasty. If such a residual volume becomes too large and the bladder is 
not regularly emptied, symptoms such as urinary urgency and incontinence 
may persist or reoccur due to reduced functional capacity. In such cases, 
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ISC is today’s gold standard for regularly, efficiently, and autonomously 
emptying the bladder. A certain degree of hand function and, in females, 
pelvic and lower limb mobilisation is required to adequately perform ISC and 
these aspects must be considered in the treatment strategy of LUTD in 
neurological patients. 
Since its introduction in 1972 by Lapides [129], catheter models and 
characteristics have significantly improved and today there is a wide 
selection of high-tech catheters available, covering the needs of nearly every 
patient. More recent data and expert panels are in favour of single-use 
catheters with a hydrophilic coating [130, 131]. However, further evidence 
from prospective randomized controlled trials evaluating catheter type 
(hydrophilic vs. uncoated) and catheterization technique (sterile vs. clean vs 
aseptic; single-use vs re-use) in a broader context, including evaluation of 
therapy compliance, QoL, and costs are needed. 
 
OTHER CONSERVATIVE TREATMENT OPTIONS 
There are a few other alternative conservative treatment options available, 
such as pelvic floor muscle training [132] and intravesical electrostimulation 
[133, 134]. In particular pelvic floor muscle training under professional 
guidance is a first line conservative treatment option that should be 
considered if appropriate to improve LUT function. However, the level of 
evidence for these therapies in the treatment of NDO is very limited as 
randomized controlled trials are lacking. Moreover, pelvic floor muscle 
training and intravesical electrostimulation require at least some preserved 
sensory-motor function to be effective and therefore may be suitable only for 
a subset of patients with NDO. 
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MINIMALLY INVASIVE TREATMENT OPTIONS 
 
IMPLANTABLE DEVICES FOR TIBIAL NERVE STIMULATION 
To facilitate tibial nerve stimulation outside the hospital or clinic setting, 
implantable devices are also available [135-138]: Urgent-SQ® (formerly 
Uroplasty then Cogentix Medical, now Laborie, Mississauga, ON, Canada), 
RENOVA® (BlueWind Medical, Herzliya, Israel), and StimGuard® 
implantable miniature device (StimGuard, Pompano Beach, FL, USA). 
These devices consist of a small electromagnetic impulse receiver requiring 
no battery with stimulation electrodes and an external electromagnetic 
impulse generator. The impulse receiver with electrodes is implanted next to 
the tibial nerve, usually above or at the ankle, and the external impulse 
generator is strapped around the ankle during therapy sessions to allow 
wireless transmission of the stimulation signal to the implanted receiver to 
induce stimulation. Despite this smart approach and some decent long-term-
data [135], currently available studies focus on non-neurogenic overactive 
bladder (NNOAB) patients and the level of evidence is generally low due to 
the lack of randomized controlled trials [135-137]. Hence, currently, no 
recommendation or conclusion on the use in neurological patients can be 
made. 
 
SACRAL NEUROMODULATION 
Similar to the principles described for TENS and PTNS / TTNS earlier, sacral 
neuromodulation (SNM) aims to modulate the activity of one of the neural 
pathways affecting the pre-existing activity of another neural pathway, i.e. 
LUT-related afferent and efferent pathways, via spinal interneurons and 
synaptic interaction. Available evidence suggests that both spinal reflexes 
and supraspinal circuits involved in LUT control are modulated in this way 
[139, 140]. 
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Although SNM has been commercially available for more than 20 years, it 
was not initially used for NLUTD as it was believed that intact neuronal 
innervation was a prerequisite for SNM to be effective [141-143]. In contrast 
to per- or transcutaneous neuromodulation, SNM is an implantable therapy 
that delivers constant stimulation to the sacral nerve roots. For the purposes 
of LUTD / LUTS treatment, electrodes are usually placed next to the S3 root 
as it passes through the sacral foramen. 
In a first stage, the quadripolar electrodes (tined lead, Medtronic, 
Minneapolis, Minnesota, USA) are placed in a minimally-invasive fashion by 
puncturing the 3rd sacral (S3) foramen under fluoroscopic guidance and 
implanting the tined lead using the Seldinger technique with a special 
introducer sheath [144, 145]. The procedure can be performed under local 
anaesthesia, which allows for evaluation of sensory responses and the anal 
motor response. However, sensory testing during tined lead placement for 
sacral neuromodulation does not necessarily improve clinical outcomes of 
neuromodulation [146]. Following tined lead placement, which can be 
performed uni- or bilaterally, electrode wires are tunnelled subcutaneously 
and connected to an external stimulator [144, 145]. During a subsequent test 
phase, different neuromodulative settings, i.e. number of active electrodes, 
stimulation frequency, and stimulation strength, can be evaluated with 
respect to treatment efficacy. If an improvement of at least 50% can be 
achieved with a certain parameter setting and the patient is happy to go for 
the full implantation, the permanent neuromodulator (Insterstim or Interstim 
II, Medtronic. Minneapolis, Minnesota, USA) is implanted into the gluteal 
subcutaneous fat tissue [144, 145]. 
To date, a pooled success rate of 68% in the test phase and 92% in the fully 
implanted condition has been described for SNM in the treatment of NLUTD 
[139]. Despite these very promising numbers, the current evidence is based 
on rather small prospective cohort studies and retrospective case series only 
and consequently constitutes an evidence level too low to allow a final 
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conclusion or recommendation [64]. The first randomized controlled trial is 
currently ongoing (NCT02165774) [147]. 
Adverse events seem to be more frequent after complete implantation than 
during the test phase and comprise lead migration (7%), pain at the 
neuromodulator implantation site (5%), infection at the neuromodulator 
implantation site (5%), hypersensitivity to stimulation (4%), infection at the 
lead site (2%), pain at the lead site (1%), lead fracture (1%), migration of the 
neuromodulator (1%), malfunction of the neuromodulator (1%), and others 
(4%) [139]. 
A more recent study using bilateral SNM for treatment of LUTD in patients 
after complete traumatic SCI demonstrated excellent results on bladder, 
bowel and sexual function [148]. NDO in particular could be prevented, 
resulting in normo-capacitive and normo-active bladders in the storage 
phase. This surprisingly advantageous effect was attributed to the early time 
point of implantation, i.e. 3 months after SCI. An early application of SNM 
may at least partly prevent the formation or emergence of pathological reflex 
circuits in the spinal cord below the lesion during the spinal shock phase that 
otherwise results in NDO. Also, detrusor inhibitory effects via the 
sympathetic hypogastric nerve may be activated or facilitated through SNM, 
contributing to a degree of autonomic balance below the lesion that 
otherwise is deranged due to the SCI [148]. However, this potentially 
promising approach has only been described in this publication of 10 cases 
and long-term, multi-center, and randomized controlled data are lacking. 
Very recently, newer devices for SNM have been developed, e.g. Virtis® 
(Nuvectra, Plano, TX, USA) and Axonics Sacal Neuromodulation System 
(Axonics, Irvine, CA, USA), that provide improvements with regard to MR-
compatibility and ability to recharge the implanted neurostimulator. Since 
none of the devices are yet approved for treatment, clinical experience is 
currently still very limited and data for use in NLUTD are lacking. However, 
initial study results appear promising, at least in NNOAB patients, not only 
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with respect to symptom relief but also in terms of cost-effectiveness [149-
151]. 
 
BOTULINUM NEUROTOXIN A INTRADETRUSOR INJECTIONS 
BoNT/A is a highly potent neurotoxin that has been in medical use for 
several decades in the treatment of localized motor dysfunction and muscle 
spasms such as blepharospasm, cervical dystonia, strabism, and hemifacial 
spasm [152]. Beyond motor / movement disorders, treatment of autonomic 
dysfunction such as sialorrhea, hyperhidrosis, and detrusor overactivity 
using BoNT/A injections has been explored. 
The proposed general mechanism of action of BoNT/A is the irreversible 
cleavage of the SNAP-25 protein in the axon terminal of the neuromuscular 
junction. SNAP-25 is a SNARE (soluble N-ethylmaleimide sensitive fusion 
protein attachment receptor protein) that is responsible for the fusion of the 
synaptic vesicles into the synaptic membrane and subsequent release of the 
neurotransmitter, i.e. acetylcholine, from the vesicles into the synaptic cleft 
[152, 153]. The disenabling of SNAP-25 by BoNT/A prevents or reduces 
acetylcholine release upon arrival of an action potential at the axon terminal 
and hence results in a chemo-denervation of the target muscle. Depending 
on the applied dosage, such chemo-denervation can reduce elevated 
muscle tone or spasticity or even paralyse the muscle. Despite the 
permanent cleavage of the SNAP-25 protein, the duration of effect of 
BoNT/A is limited to several weeks or months depending inter alia on the 
type of targeted nerve terminal (somatic vs. autonomic) and applied dosage 
[153-155]. The mechanism presumed to be responsible for the reversibility 
of the neuroparalysis is synaptic sprouting with formation of new 
neuromuscular junctions [153, 154]. 
Due to the large molecular size, i.e. 150 kD for the core toxin alone, BoNT/A 
cannot be absorbed through skin or mucosa and needs to be injected to 
reach the target tissue. Intradetrusor injections can be applied via a flexible 
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or rigid cystoscope [156]. Although several aspects of the injection 
technique, i.e. number of injection sites, volume per injection and injection 
depth are still matter of discussion, the currently approved dosage and 
technique for the treatment of NDO implies a total dose of 200 units 
onabotulinumtoxinA, as 1 mL (~6.7 Units) injections across 30 sites into the 
detrusor [157, 158]. 
There are several different BoNT/A formulations on the market, i.e. 
onabotulinumtoxinA (Botox®), abobotulinumtoxinA (Dysport®), 
incobotulinumtoxinA (Xeomin®) of which currently only onabotulinumtoxinA 
is approved for the treatment of NDO. However, two ongoing Phase-III 
studies using abobotulinumtoxinA in the treatment of NDO (NCT02660138, 
NCT02660359) may lead to approval of abobotulinumtoxinA in the near 
future. 
OnabotulinumtoxinA 200 or 300 units significantly reduced the mean 
frequency of urinary incontinence per week by 11 episodes in patients with 
NDO at 6 weeks after treatment compared to placebo. In the same time, 
maximum cystometric capacity significantly increased on average by 145 mL 
and maximum detrusor pressure decreased on average by 33 cmH2O 
compared to placebo [159]. 
BoNT/A intradetrusor injections are a safe treatment with few adverse 
events that are mostly self-limiting such as haematuria (relative risk 1.7), 
injection site pain, procedure-related urinary tract infection (relative risk 
1.47), and generalized muscle weakness (relative risk 2.59) [155, 159]. 
However, urinary retention (relative risk 5.58) can occur and needs to be 
explained to the patient prior to injection as it may require the use of 
intermittent or indwelling catheters [155, 159]. 
Due to the limited effect duration, repeated treatments are necessary in the 
majority of cases, which seems to be feasible without loss of efficacy [160-
162]. Caution should be taken in regard to multidisciplinary BoNT/A 
treatments to prevent unintended overdosage. It is recommended to not 
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exceed a total dose of 360 units onabotulinumtoxin-A administered in a 3 
month interval [157]. 
Based on the existing high-level evidence, BoNT/A intradetrusor injections 
are recommended as second line treatment for NDO refractory to 
antimuscarinic treatment [64]. Usually, prior antimuscarinic treatment is 
stopped shortly after BoNT/A intradetrusor injections, but may be continued 
as concomitant treatment in selected cases to optimize efficacy if required. 
Antimuscarinic treatment may be restarted once the BoNT/A effects starts to 
fade and symptoms recur to bridge the time until reinjection. 
Similar to antimuscarinic drugs, recent basic research has revealed multiple 
alternative or additional sites and mechanisms of action of BoNT/A within the 
LUT [163]. Such alternative mechanisms include modulation of 
neurotransmitter and -peptide release, receptor trafficking, and neurogenesis 
both on peripheral but probably also at a central level [163].  
Moreover, BoNT/A has been evaluated in applying intraprostatic injections, 
which seem to improve prostate related LUTD / LUTS [164]. This may be 
specifically relevant for male neurological patients who show a prostatic 
component in their LUTD / LUTS but in whom surgical intervention would 
bear increased risk of urinary incontinence [165-167]. 
 
 
SURGICAL TREATMENT OPTIONS 
 
SACRAL DEAFFERENTATION (WITH / WITHOUT SACRAL 
ANTERIOR ROOT STIMULATION) 
Considering NDO as result of an overshooting spinal reflex because of 
impaired or lost inhibitory control from supraspinal centers similar to 
musculoskeletal spasticity, transection of the afferent branch of the reflex arc 
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would result in the disruption of this spinal reflex and consequently abolish 
NDO. Sacral deafferentation is a neurosurgical procedure with the aim of 
transecting the dorsal S2-S5 nerve roots. It requires a laminectomy to 
access the spinal nerve roots and opening of the dura to microsurgically 
separate the ventral from the dorsal roots prior to transection [168]. An 
extradural approach is also possible but implies a higher risk of incomplete 
de-afferentiation and injury of the anterior root due to a less definite 
separation between anterior and posterior root segments compared to the 
intradural approach [169]. Intraoperative urodynamics and cardiovascular 
monitoring allow the functional differentiation between ventral and dorsal 
roots upon electrical stimulation [168]. After this procedure, a form of 
catheterization, i.e. ideally ISC, is required to empty the bladder.  
Complete deafferentation of the S2-S5 roots can be achieved in 73-95% 
[168, 170, 171] resulting in an acontractile, flaccid detrusor and continence 
without further treatment in 83-85% [168, 171]. Moreover, coexisting AD can 
also be abolished with this treatment in about 59-61% [170, 171]. 
The main drawbacks of this treatment are the invasive and irreversible 
character of the procedure with the necessity of performing a laminectomy 
and to irreversibly transect intact nerve tissue resulting in loss of potentially 
preserved sensory function of the pelvis and lower limbs. Moreover, sexual 
function (e.g. reflex erections) and the defecation reflex will be lost. These 
drawbacks are the main reason why few patients are today willing to 
undergo such treatment. 
A possibility for regaining function and to even empty the bladder through 
the urethra without using a catheter is to implant a sacral anterior root 
stimulator (SARS) after sacral deafferentation. A SARS, e.g. Finetech-
Brindley bladder stimulation system, can be implanted in the same 
procedure following sacral deafferentation by placing special electrodes 
bilaterally around the anterior roots S2-S4. By placing each root in a 
separate electrode segment, independent control of pelvic functions is 
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possible, for example S3 stimulation for detrusor contraction and micturition, 
S3 + S4 stimulation for rectal pressure rise and defecation, and S2 
stimulation to induce penile erection [168]. However, adjustments may differ 
on an individual level and, while the efficacy of the SARS for micturition and 
defecation seems to be good, it is less effective for sexual function. 
Although SARS is sometimes referred to as a bladder pacemaker in the 
same manner as the SNM system, both procedures must be clearly 
distinguished. SARS is much more invasive, needs much higher amplitude 
of stimulation above the pain threshold, and thus has a much narrower 
indication, reserved to selected SCI patients. 
 
 
AUGMENTATION CYSTOPLASTY 
Augmentation cystoplasty is a well-established abdominal surgical 
procedure that aims to reduce detrusor contractility and to enlarge bladder 
capacity. Detrusor contractility is reduced by removing part of the detrusor or 
cleaving the detrusor at the dome and thereby interrupting its muscular 
continuity. Bladder capacity is increased by replacing or augmenting the 
bladder with bowel tissue. In addition, augmentation cystoplasty can be 
combined with a continent cutaneous urinary diversion to facilitate ISC via 
an abdominal site, when ISC via the urethra is impossible or difficult [172]. 
Although several types of gastrointestinal tissues have been used for 
augmentation cystoplasty [173], i.e. stomach, ileum, colon, or sigmoid, ileum 
is nowadays the most frequently used tissue, generally due to its slightly 
more advantageous properties with regard to intraoperative handling, 
postoperative complications, and effectiveness [173]. 
Using an augmentation cystoplasty for NDO treatment, reduction of MDP 
from 60 to 15 cmH2O and an increase in MCC of 166–500 mL can be 
achieved, contributing to continence rates of 69–88% [174-178]. In addition, 
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augmentation cystoplasty has been described as reducing VUR [179]. 
Patients with concomitant neurogenic sphincter insufficiency may require a 
complementary, anti-stress urinary incontinence (SUI) procedure, e.g. 
aponeurotic sling or artificial sphincter to achieve continence. 
Augmentation cystoplasty requires some hospitalisation time (2-4 weeks) but 
has a rather low mortality rate of 0–3.2% [173]. However, there are several 
moderate to severe complications that can occur in the short and long term 
[174-176, 178, 180]: urinary stones (6–21%), recurrent symptomatic UTI 
(20%) including recurrent pyelonephritis (1.5–11%), ileus (1.9–11.7%), 
chronic diarrhoea (7–18.6%), perforation (0.75–4%), and fistulas (0.4–1.3%). 
In addition, metabolic complications can occur due to altered absorption / 
reabsorption of metabolic products in the augmented bladder and in the 
shortened gastrointestinal tract. Thus, type and severity of metabolic 
complications largely depend on the type and length of the resected 
gastrointestinal tissue. Metabolic complications include: hypochloremic 
acidosis, lipid malabsorption, vitamin B12 deficiency and bile acid deficiency 
[181]. Patients with a catheterizable cutaneous derivation might experience 
additional complications regarding the urinary stoma [182-184]: stomal 
stenosis (6–15%), channel leakage (9%), false passage (6%), and stomal 
prolapse (5%). 
Nevertheless, patient satisfaction is usually high [180], as most patients 
already suffered for a considerable time period from severe DO and usually 
had several failed treatment attempts before being considered for 
augmentation cystoplasty. However, only patients able and willing to perform 
ISC should be considered for this kind of treatment, as otherwise the patient 
is not gaining much from this kind of invasive therapy. 
 
CYSTECTOMY WITH URINARY DIVERSION 
If none of the aforementioned treatment options can sufficiently reduce NDO 
and / or significant structural alterations have already occurred, it may 
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become necessary to remove the entire bladder as a last resort. It is thus the 
most definite form of NDO treatment and requires the formation of a urinary 
diversion that can be constructed to be continent or incontinent. 
Operative and postoperative risks and complications are similar to those of 
the augmentation cystoplasty. However, complete cystectomy and creation 
of a urinary diversion is usually more complex and time-consuming and 
requires the re-implantation of the ureters, which implies the risk of ureteral 
stenosis. 
For a continent urinary diversion, different forms of pouches and neo-
bladders made of detubularised bowel segments are available and can be 
selected depending on the patient’s needs and physical preconditions and 
the surgeon’s expertise [185, 186]. Again, it is important to consider the 
patient’s abilities and preferences with regard to emptying the new pouch or 
bladder in advance. 
For an incontinent urinary diversion, which is usually somewhat less 
complex and less prone to complications than a continent diversion, the 
ureters are connected to a short, detached ileum segment that is then 
diverted through the abdominal wall outwards and connected to the skin 
[187]. This form of urinary diversion is also called ileal conduit or Bricker 
diversion, named after Eugene M. Bricker who described this procedure for 
the first time [187].  
As the urine is now continuously and directly draining outwards, a urine bag 
has to be placed on the stoma site to collect the draining urine. 
Such an intervention certainly interferes with the body image of most 
patients, but in addition to a high probability of UUT protection from elevated 
pressures, it offers the possibility to independently manage urinary drainage 
with less expenditure of supplies and time compared to other treatment 
strategies that require regular catheterisation, medical treatment 
(antimuscarinc drugs, BoNT/A intradetrusor injections) and follow-up 
(urodynamic investigation).  
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However, changes in kidney function and morphology, stenosis of the 
ureteroileal and ileocutaneous junction, and bowel dysfunction are known 
postoperative complications [188, 189]. 
 
 
ALTERNATIVE TREATMENT OPTIONS FOR SELECTED 
PATIENTS 
In principle, the reduction of elevated storage pressures in the LUT and 
protection of UUT can be achieved by diminishing outflow resistance to a 
minimum in order to guarantee sufficient urine outflow from the bladder prior 
to the onset of elevated pressures. However, it has to be considered that the 
two treatment options (a and b) mentioned below do not actually restore or 
maintain a low pressure reservoir but rather aim at continuous low pressure 
drainage, leaving the restoration of the native bladder as a reservoir 
unconsidered, which may work for selected patients but is also one of the 
main drawbacks of these treatment strategies contributing to their 
associated complications in short- and long-term. 
a) Insertion of an indwelling catheter either transurethrally or suprapubically 
and left on permanent drainage would help to reduce storage pressures 
and post void residual urine by direct continuous low pressure drainage. 
However, indwelling catheters are associated with several complications 
such as recurrent or chronic UTI, stone formation, urethral erosion 
(mainly with transurethral catheters), increased risk of bladder cancer 
and reduction of sperm quality and motility and are hence not generally 
recommended [64, 190-192] but may be an option for selected patients 
not able to perform ISC and who are not suitable for more invasive 
therapies such as urinary diversion. Nevertheless, an indwelling catheter 
itself does not treat DO and associated complications such as AD will 
persist and become evident each time the catheter occludes [193]. 
Moreover, constant urinary drainage required here to avoid elevated 
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storage pressures may lead to significant loss of capacity over time and 
consecutive urinary leakage transurethrally and / or alongside the 
catheter [194]. 
b) Transurethral sphincterotomy plus further subvesical desobstruction if 
required (e.g. resection of prostate and / or bladder neck tissue), 
implantation of a urethral stent, or BoNT/A intrasphincteric injections (off-
label use) are options for reducing outflow resistance to enable low 
pressure urine drainage from the LUT. Although there are several cohort 
studies reporting promising results for each technique, i.e. reduction of 
maximum detrusor pressure and PVRV as well as lower incidence of 
hydronephrosis and AD [53], there are specific complications such as 
the necessity for repeated procedures due to urethral scarring, bladder 
neck obstruction, inefficient urodynamic improvement, stent migration / 
erosion and stone formation. In addition, there are only very few 
randomized controlled trials available with inconclusive urodynamic data 
and a lack of QoL data, hampering clear recommendations [64, 195] and 
official approval for the use of BoNT/A in this context. Moreover, the 
mentioned techniques based on their principle of lowering outflow 
resistance will not reduce DO but lead to increased urinary incontinence 
and are thus mainly applicable to male patients who can wear a condom 
catheter to collect the urine. 
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RESTORATION OF URETHRAL URINE STORAGE 
FUNCTION 
Urinary incontinence has a devastating impact on QoL as it demonstrates 
loss of bodily control in its most inconvenient and unpleasant way, make 
LUT care the most challenging issue in the patient’s daily life, and can itself 
drive patients into depression [196-198]. Furthermore, urinary incontinence 
can negatively affect the skin due to frequent contact with urine and / or the 
necessity to wear pads or diapers which facilitates the development of 
wounds / ulcerations and dermal infections [199-201].  
Despite the frequent association of NDO with urinary incontinence [202], 
adequate treatment of NDO alone may be either insufficient to prevent 
urinary incontinence or even evoke urinary incontinence. 
Sometimes, behavioural aspects have to be considered and augmented, as 
even the best NDO treatment is not meant to create a low pressure and 
continent urinary reservoir that needs to be emptied just once daily. In this 
regard, the patient’s expectations and post-treatment responsibilities have to 
be clearly discussed. Behavioral treatments such as timed voiding / 
catheterization or adaption of fluid intake may help to prevent urinary 
incontinence in patients with impaired bladder sensibility or increased 
evening fluid intake, respectively [203]. 
Nevertheless, patients with an insufficient closing mechanism at the bladder 
neck and / or external urethral sphincter due to a lack or impairment of 
neurogenic innervation of these structures will most likely suffer from 
neurogenic SUI. In such cases, the main treatment principle is to increase 
outlet resistance. Hence, prior to application of such treatments, it is 
absolutely mandatory that NDO is either absent or at least adequately 
treated to prevent high pressure conditions and consequently a risk of renal 
damage. 
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Four different types of surgical interventions can be distinguished: (1) 
bladder neck / urethral reconstruction, (2) injectables (e.g. bulking agents), 
(3) suspensions (e.g. Burch, suburethral tapes and slings), and (4) 
prostheses (e.g. artificial urinary sphincter). 
 
 
BLADDER NECK / URETHRAL RECONSTRUCTION 
Urethral lengthening in the form of an intravesical extension of the urethra 
using a bladder wall flap creates a valvular closure of the urethra with 
increasing filling of the bladder [204-208]. The original technique described 
by Young-Dees-Leadbetter was modified in recent decades by different 
urological surgeons mainly in pediatric patients with bladder extrophy [204, 
209-212]. These techniques provide continence rates of 50-94% [204, 205, 
209, 213, 214]. However, such bladder neck / urethral reconstructions 
require regular ISC to empty the bladder and often prior or simultaneous 
bladder augmentation to secure low pressure storage [215]. Compared to 
the artificial urinary sphincter (AUS), continence rates seems to be similar 
but with a significantly lower reoperation rate [216]. 
 
 
INJECTABLES 
Injectables can consist of different materials (e.g. autologous fat, collagen, 
silicon, carbon, Teflon®, poly-acrylamide hydrogel) and are injected 
transurethrally below the bladder neck to create a sub-mucous cushion / 
bulking of the urethra that cause obstruction to withhold the urine. Despite 
some recent promising findings [217, 218], the current literature does not 
provide sufficient evidence for this kind of therapy [219] and long-term 
Chapter 1 
39 
results in patients with neurogenic sphincter deficiency seem to be rather 
poor [220]. 
 
 
SUSPENSIONS 
Suspension therapies aim to restore or to improve urethral and / or bladder 
neck position and support, thereby enhancing the bladder neck or 
sphincteric closing mechanism. These are established treatment methods 
for female SUI [221, 222] and have recently been introduced also for male 
SUI [223, 224]. Alongside traditional techniques such as Burch 
colposuspension, there are several different forms and materials of slings 
and tapes available. In patients with NLUTD, the use of autologous rectus 
abdominis fascia slings in a pediatric or adolescent population with or 
without simultaneous augmentation cystoplasty has been reported most 
commonly, demonstrating excellent results and low complication rates [225-
235]. Synthetic tapes also seem to be suitable and effective for neurogenic 
SUI [236-238], except where a tight sling is necessary to provide adequate 
continence as there is a marked increase in the erosion risk. 
 
 
PROSTHESES 
Prostheses for neurogenic SUI treatment comprise implantable devices that 
cause adjustable mechanical obstruction or closure of the urethra and / or 
bladder neck. Autologous prostheses for sphincter augmentation have also 
been successfully explored using gracilis myoplasty around the bladder neck 
or urethra [239-242]. The use of autologous tissue around the urethra and 
bladder neck may reduce the risk of infection and erosion compared to 
artificial implants, especially in conditions where increased tension needs to 
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be applied and ISC is performed. Nevertheless, an implanted pulse 
generator is required to stimulate the gracilis prosthesis to obtain contraction 
and urethral closure, respectively. Data on this procedure are scarce and, 
due to the rather sophisticated surgical approach, this approach is not 
widely-used. 
Regarding artificial prostheses, two options are available, the AUS (e.g. 
AMS 800®, ZSI 375®) and the inflatable para-urethral balloons (ACT® / 
ProACT®). 
Currently, the most widely-used AUS model (AMS 800®, formerly American 
Medical Systems, now Boston Scientific, Marlborough, MA, USA) consists of 
3 major components, the inflatable cuff, the pump, and the pressure-
regulating balloon. All three components are implanted and connected via 
special flexible but non-colliding tubes, allowing hydraulic function of the 
sphincter. The inflatable cuff is placed around the bulbar urethra (in men) or 
bladder neck (in men after prostatectomy and women or in some neurogenic 
indications) and connected to a control pump that is placed in the scrotum 
(in men) or labium majus (in women). The balloon is placed in the 
subperitoneal space lateral to the bladder. Activating the pump deflates the 
cuff by pumping water from the cuff into the balloon, from where it flows back 
into the cuff due to the hydraulic gradient between balloon and cuff. The re-
closing of the cuff takes 2–4 minutes during which the patients can empty 
the bladder via spontaneous voiding or via ISC. ISC may be performed even 
with a closed AUS but the risk of urethral injuries may increase. The AUS is 
suitable for both men and women. Due to its efficacy, the AUS is today’s 
gold standard in the therapy of SUI [224]. Patients with neurogenic SUI, in 
whom the natural sphincter is insufficiently working due to damage of its 
neuronal control, also have greatly benefited from this therapy [243]. The 
success rate (proportion of continent patients) in patients with neurogenic 
SUI lies between 23% and 91% (mean 73%) [244-251].  
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Frequent complications for this procedure are erosion, infection, and 
mechanical / device-related failure that cause a re-operation rate for 
revisions and / or explantations of 16% to 80% [244, 245, 247-250]. 
Murphy et al. compared treatment outcomes between patients with 
neurogenic SUI and patients with non-neurogenic SUI [246]. According to 
this study, patients with neurogenic SUI tend to have complications more 
frequently that were not related to mechanical or device-related failure [246]. 
Bersch et al. reported very promising long-term results of a modified 
AMS800 system in patients with neurogenic SUI [252]. This modified system 
has the advantage that it works without the pump and is thus less 
susceptible to device-related defects and less costly [252]. Instead of the 
pump, a subcutaneous port is implanted that enables postoperative 
adjustments of the cuff-pressure. This system also seems to have some 
advantage with regard to the risk of pump-erosion in wheelchair-bound 
female patients [252]. In addition, cuff pressure can be adjusted at any later 
time point via the subcutaneous port. Using cuff only AUS implantation in 
conjunction with an augmentation cystoplasty seems to be another 
alternative with very few AUS specific complications [253]. 
Inflatable paraurethral balloons are a relatively new minimally invasive 
technique that offers the advantage of postoperative adaption of the balloon 
size and consequently the degree of urethral obstruction [254, 255]. The 
balloons are placed bilaterally to the urethra at the bladder neck (in women) 
or at the membranous urethra (in men). Each balloon has a port that is 
placed into the ipsilateral scrotum or labium majus. The inflation is 
performed during follow-up visits with saline via the port of each balloon. 
Depending on the volume, the balloons cause a functional obstruction that 
should keep the urine within the bladder during situations of increased 
abdominal pressure. First time exploration of using this prosthesis in 
neurogenic SUI is part of this thesis. 
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PURPOSE, RESEARCH QUESTIONS, AND OUTLINE OF 
THIS THESIS 
Despite the many above-mentioned therapies already in use clinically, many 
questions remain regarding their technical applicability, mechanism of 
action, and long-term outcomes. Hence, the purpose of this thesis is to 
contribute further insights into treatments of LUTD / LUTS in patients with a 
neurological disease / lesion as the underlying cause of their LUTD / LUTS. 
Since BoNT/A intradetrusor injections had such a seminal impact on the 
treatment of LUTD / LUTS over the last two decades and set off many new 
research projects and considerations on LUT neurophysiology, we placed a 
specific focus on this treatment. 
 
The following specific research questions are addressed in this thesis: 
1) What are the current therapeutic principles of LUTS in male neurological 
patients? 
2) How does the onabotulinumtoxinA solution spread within and potentially 
also beyond the bladder wall after intradetrusor injections for LUTS 
treatment? 
3) Can low dose treatment with onabotulinumtoxinA intradetrusor injections 
in MS patients effectively treat LUTS while sufficient voluntary micturition is 
maintained? 
4) Does onabotulinumtoxinA cause any distant systemic effects on cardiac 
function following intradetrusor injections? 
5) What is the evidence for and efficacy of further treatment options using 
BoNT/A for the therapy of male LUTS? 
6) Is the adjustable continence therapy device an effective and sustainable 
treatment option for SUI due to neurogenic sphincter insufficiency? 
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The findings of the corresponding studies addressing the above mentioned 
research questions are critically discussed in chapter 8. Since the LUTD 
discussed in this thesis are a direct consequence of neurological trauma or 
disease which are currently neither curable nor reversible, patients with 
NLUTD require life-long, specialized neuro-urological care and follow-up. 
This thesis elucidates relevant aspects of treatment strategies for such care 
and follow-up. It also underlines the importance of multidisciplinary 
interaction between neurologists, rehabilitation physicians and urologists. In 
addition, translational research aspects are addressed and elaborated. 
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ABSTRACT 
Purpose of review: Urinary incontinence in male neurological patients is a 
very frequent problem but treatment remains challenging. Thus, we 
summarize and highlight the latest developments in the management of 
urinary incontinence in this specific patient population. 
 
Recent findings: Intermittent self-catheterization, antimuscarinics, 
intradetrusor injections with onabotulinumtoxinA, augmentation cystoplasty, 
urinary diversion, and artificial urinary sphincter are the cornerstones of the 
armamentarium for treating neurogenic urinary incontinence. However, with 
the exception of onabotulinumtoxinA intradetrusor injections, level of 
evidence is often low and male-specific outcomes are virtually not available. 
Alternative conservative and / or minimally invasive procedures such as 
neuromodulation techniques and suburethral suspension devices provide 
promising data with apparently good safety and tolerability but still 
insufficient evidence lacking randomized control trials. 
 
Summary: Standard options for treatment of urinary incontinence in 
neurological patients remain largely unchanged. Alternative treatment 
options, especially of conservative or minimally invasive character, have the 
potential to further broaden the therapeutic spectrum. 
While a higher level of evidence is needed to assess the potential of such 
therapeutic approaches, randomized controlled trials in the male 
neurological population present a challenge. To truly advance treatment of 
urinary continence in male neurological patients, well-designed, multicenter 
studies are warranted. 
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INTRODUCTION 
Urinary incontinence in neurological patients is a very frequent [1] and 
debilitating condition resulting from the profound alterations of LUT control 
and function caused by the neurological disorder. It should be implicitly 
considered that in neurological patients LUTS such as urgency may be 
reduced or absent because of sensory deficits, and that urinary incontinence 
is often the ‘only’ apparent symptom of relevant LUTD requiring further 
specialized investigation [2]. 
Therefore, it is of utmost importance not only to appropriately differentiate 
between the different types of urinary incontinence but also to understand 
the underlying neurological cause as it significantly influences the choice of 
treatment. Urinary incontinence related to NDO requires a completely 
different management than urinary incontinence related to isolated 
neurogenic sphincter insufficiency. Neglect of this principle may result not 
only in insufficient and inaccurate treatment but also in significant harm of 
the patient. 
The scope of this article is to review the management of urinary incontinence 
in male neurological patients. However, data specifically considering the 
male neurological population is very rare so that we took into account 
neurological patients in general and referred to male-specific data whenever 
possible. 
 
MANAGEMENT OPTIONS FOR URINARY INCONTINENCE IN 
MALE NEUROLOGICAL PATIENTS 
As therapeutic principles in male neurological patients largely depend on the 
underlying cause of urinary incontinence, that is, mainly NDO and / or 
neurogenic sphincter insufficiency, the current armamentarium focuses on 
treating either cause or both in mixed forms. However, prior to the appliance 
of any form of subvesical obstruction with the intention to treat neurogenic 
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SUI, that is, suburethral slings, adjustable continence devices, and AUS, it is 
mandatory to first adequately treat DO or reduced bladder compliance as 
otherwise increased storage pressures can jeopardize UUT function. 
An often-underestimated or neglected problem in neurological patients is 
concomitant problems with defecation that can interfere with LUT function 
and should be addressed before or concomitantly with any medical or 
surgical urinary incontinence therapy. 
 
Behavioral therapy and pelvic floor exercises 
Although specific studies on behavioral treatment (aiming to adapt drinking 
and voiding habits) in male neurological urinary incontinence are lacking, it 
should be part of the first-line treatment. 
Behavioral regimens have to be adapted to the individual abilities and needs 
of the patients and suit best for patients in whom voiding function is intact 
and urinary incontinence is mainly due to impaired bladder sensation, 
cognitive, or motor deficits. However, in such cases, caregivers need to 
provide additional support. 
Pelvic floor muscle training (PFMT) has been mainly explored within MS 
populations with predominantly female patients [3]. In men, PFMT is 
primarily used to treat postprostatectomy SUI. Nevertheless, PFMT has 
been shown to be beneficial in the treatment of both, stress and urgency 
urinary incontinence [4]. However, to be successful, voluntary pelvic floor 
sensorimotor control must be at least partly intact which can be a limiting 
factor in many neurological patients. 
 
Catheters 
ISC can improve urinary incontinence and is the gold standard in the 
management of neurogenic voiding dysfunction due to DSD or underactive / 
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acontractile detrusor. Although newer data and expert panels are in favor of 
single-use hydrophilic catheters in an aseptic or clean manner [5-8], the level 
of evidence is still low resulting in an ongoing debate on the optimal 
technique (sterile vs. clean vs. aseptic; single-use vs. reuse) and catheter 
type (hydrophilic vs. noncoated catheters) regarding the rate of UTI, urethral 
lesions, cost-effectiveness, and health-related QoL (HRQoL) [9-13]. 
Recent articles focused on the impact of ISC on HRQoL [14], patient’s 
adherence to ISC [15], and preferences regarding catheter design [13, 16] 
including male-specific data [17, 18]. 
Indwelling catheters can be effective in treating urinary incontinence and 
especially suprapubic catheters might be an option for highly selected 
populations, such as tetraplegic patients [19]. However, indwelling catheters 
are not recommended for routine long-term treatment because of the 
associated complications such as acute and chronic UTI, stone formation, 
urinary leakage / incontinence, erosion of meatus and urethra, fistula 
formation, reduction in bladder capacity, and compliance (with continuous 
drainage) [20-22]. 
Condom catheters [23] or other external appliances such as drip collectors 
can help to control urinary incontinence and make it socially more 
acceptable. 
 
Drugs 
The first-line drug treatment for NDO and subsequent urinary incontinence 
are antimuscarinics, that is, oxybutynin, trospium chloride, tolterodine, 
solifenacin, darifenacin, propiverine, and fesoterodine. Efficacy and safety of 
antimuscarinics are well described for the non-neurogenic overactive 
bladder population [24, 25] but less conclusive for patients with NDO 
because of a limited and very heterogeneous body of studies [26]. 
Nevertheless, antimuscarinics were demonstrated to significantly improve 
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patient-reported and urodynamic outcome compared with placebo in the 
NDO population [26]. However, a significant improvement of urinary 
incontinence could not be demonstrated [26]. The current results are mainly 
based on data from SCI or MS populations and conclusions cannot be 
readily extended to other neurological diseases, such as stroke or PD. 
Furthermore, effects on bladder compliance, UUT function, and HRQoL 
were usually not assessed and long-term data of antimuscarinics in 
neurological patients are very limited [26, 27]. 
Although some large clinical trials could demonstrate statistically significant 
efficacy differences between several antimuscarinics, such differences seem 
to remain rather marginal from a clinical viewpoint and could not be 
demonstrated for the NDO population [26, 28]. Differences in the safety and 
tolerability profiles seem to be more relevant and should be considered 
when choosing an antimuscarinic drug for a specific patient, especially 
considering central nervous side-effects [28, 29]. 
Dose-escalating mono or combination therapy can be an option for NDO 
patients, requiring higher doses as urodynamic parameters could be 
significantly improved compared with standard dose treatment [27, 30]; 
however, high-evidence level studies are lacking. 
A recent, but rather small, study comparing the immediate and extended 
release forms of propiverine for NDO demonstrated better continence rates 
using the extended release form [31]. Transdermal or intravesical 
antimuscarinic applications are alternative options that may help to increase 
bioavalability and reduce adverse events due to the circumvention of the 
intestinal first pass metabolism [32], but clinical data for the use in adult 
NDO patients are still very limited. 
Other drugs, such as phosphodiesterase inhibitors or beta-adrenergic 
receptor agonists, seem to become future alternatives [33, 34] but have not 
yet been investigated for the treatment of urinary incontinence in 
neurological patients. 
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External neuromodulation 
Of the different potential treatment modalities available, tibial nerve 
stimulation either percutaneously (PTNS) or transcutaneously (TTNS) seems 
to be the currently most promising and investigated method. However, the 
mainstay of available data are from non-neurogenic overactive bladder 
patients [35, 36], but some recent studies also provided data from 
neurological patients, that is, MS and PD [37-44]. However, randomized 
controlled trials (RCT) are lacking for PTNS and TTNS in the neurological 
population, and there are currently no long-term data or systematic data on 
HRQoL available. Nevertheless, the benefits of PTNS and TTNS are clearly 
the almost inexistent adverse events and the non-invasiveness that allows 
performance of diagnostic measures, such as repeated magnetic resonance 
imaging (MRI) or home-based therapy (for TTNS). 
 
Intradetrusor injections with botulinum toxin 
On the basis of the results of the two recent Phase III studies [45, 46], 
intradetrusor injections using onabotulinumtoxinA received Food and Drug 
Administration approval in 2011 for the treatment of urinary incontinence due 
to NDO in adults who have an inadequate response to or are intolerant of 
antimuscarinics. Intradetrusor injections with BoNT/A have been 
demonstrated to be safe, well tolerated and to significantly improve 
urodynamic parameters [47, 48], reduce LUTS [47], and improve QoL [49, 
50]. Daily urinary incontinence episodes can be reduced by 63% [47]. These 
effects seem to occur regardless of concomitant antimuscarinics or 
neurological disorder, that is, MS or SCI [51]. However, data on the use of 
BoNT/A intradetrusor injections in neurological patients other than SCI and 
MS are scarce but there may be an indication [52]. 
Injections require a cystoscopic (rigid or flexible) intervention that needs to 
be repeated every 6–9 months [53]. The procedure can be performed in 
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local anesthesia in most NDO patients. There is, however, still controversy 
about the best technique. 
Long-term data confirm the efficacy of onabotulinumtoxinA beyond multiple 
intradetrusor injections [54, 55], and cost-effectiveness seems to be superior 
to best supportive care [56]. If the durability of onabotulinumtoxinA is greater 
than 5 months, intradetrusor injections seem to be more cost-effective in the 
treatment of refractory NDO than augmentation cystoplasty [57]. 
 
Permanent neuromodulation with implanted electrodes 
Initially, considered as unsuitable for the treatment of LUT dysfunction in 
neurological patients due to the impaired neuronal innervation, SNM has yet 
been demonstrated to be a promising treatment option for NDO [58, 59]. 
However, there is a lack of RCTs, and it is unclear which neurological patient 
is most suitable for SNM [58]. 
Remarkably, early bilateral SNM during the phase of spinal shock phase 
could prevent NDO and subsequent urinary incontinence in complete SCI 
patients [60]. However, long-term results are pending and the exact 
mechanism of action is not well understood [61]. Nevertheless, as the 
method is generally appealing because of its minimally invasive and fully 
reversible technique, well designed and adequately powered studies are 
highly warranted. 
 
Sacral deafferentation with or without anterior root stimulator 
This technique, also known as posterior rhizotomy, has to be strictly 
distinguished from the aforementioned SNM as sacral deafferentation is a 
specialized surgical intervention that aims to abolish NDO by transection of 
the afferent part of the sacral reflex arc and is not reversible. Although highly 
effective with up to 83% continence rates [62], if complete transection of the 
sacral roots S2-S5 can be achieved, it is preserved for a highly selected and 
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well informed group of SCI patients who accept the inevitable and 
permanent loss of any potentially preserved sensation of the pelvis and 
lower limbs and sexual function (e.g., reflex erections) [63]. In combination 
with a sacral anterior root stimulator (Finetech-Brindley bladder stimulation 
system) patients can regain control of micturition and even improve erectile 
and defecation function. An additional benefit is that sacral deafferentation 
can effectively abolish AD. 
However, this procedure is nowadays less frequently performed because of 
effective but less-invasive alternatives, such as onabotulinumtoxinA 
intradetrusor injections. Thus, new data are scarce. One current 
retrospective study is available reporting continence rates of 23% 15 years 
after sacral deafferentation and anterior root stimulator implantation but also 
84 cases of complications requiring surgical intervention among 137 patients 
[64]. 
 
Augmentation cystoplasty 
Although there are no RCT, augmentation cystoplasty is a recommended 
and established treatment option for intractable urinary incontinence due to 
NDO but requires major abdominal surgery with interposition of an intestinal 
segment (usually ileum) into the bladder and / or partial replacement of 
bladder by an intestinal substitute, and should be preserved for patients in 
whom conservative or less invasive treatment options failed to achieve an 
adequate level of continence [65, 66]. Importantly, this treatment should only 
be offered to patients who are able and willing to perform ISC. Augmentation 
cystoplasty can be combined with a continent catheterizable cutaneous 
urinary diversion to facilitate ISC in patients with limited dexterity. Recent 
long-term data confirm previous data on efficacy demonstrating sustained 
improvements in both, urodynamic parameters and symptoms [67-70]. 
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A less-invasive version of bladder augmentation is detrusor myectomy 
(autoaugmentation) with lower surgical burden and complication rates, but 
efficacy seems to be inferior to augmentation cystoplasty [71-73]. 
 
Urinary diversion 
In highly selected patients cystectomy with urinary diversion becomes 
necessary. Cystectomy in contrast to augmentation cystoplasty requires the 
reimplantation of the ureters, which basically implies the risk of ureteral 
stenosis. 
For continent urinary diversion different techniques have been described [74, 
75]. Regular ISC is required subsequently and specific complications include 
stomal stenosis, channel leakage, false passage, and stomal prolapse [75, 
76]. However, there is less alteration of body appearance than with 
incontinent diversion that is usually indicated if ISC is impossible or patient 
compliance is inadequate. 
A recent case series in MS patients with advanced refractory NDO 
demonstrated an effective treatment of LUTD and associated problems with 
an improvement in HRQoL following incontinent urinary diversion [77]. 
However, the complication rate was high (55%) and the authors consider 
urinary diversion as an effective but rather last resort treatment option for 
neurogenic urinary incontinence. 
 
Bulking agents 
Although bulking agents have been mainly used for the treatment of SUI in 
women, there are also studies in men with rather discouraging results, 
especially in the long term [78, 79]. RCT are lacking and from the available 
data, bulking agents cannot be considered a durable treatment especially for 
more severe forms of SUI, which may be the reason that there are no 
current data in adult male neurological patients. 
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Suspension therapy 
Suburethral slings or tapes become more and more popular for the 
treatment of male SUI as a minimally invasive option, and different types 
have been introduced with success rates of 54–80% [80]. In male patients 
with neurogenic SUI mainly autologous fascia slings, often in combination 
with bladder augmentation, have been investigated predominantly in 
pediatric populations but also in adults, demonstrating favorable results and 
low complication rates [81-83]. Synthetic tapes are up-to-date rarely 
investigated in male neurological patients. Currently, only one small study 
presents promising data from a mixed adult and pediatric male neurological 
population treated with the AdVance sling [84]. RCT and data on long-term 
follow-up are lacking.  
 
Implants for stress urinary incontinence 
Adjustable periurethral balloons might be an option in highly selected 
patients, but there is only one study in a mixed population of patients with 
neurogenic SUI demonstrating rather fair results [85]. 
The AUS is the gold standard for the treatment of SUI and has also been 
investigated in the adult male neurological population demonstrating a high 
efficacy of 23–100% (mean 70%) continent patients [83]. However, frequent 
complications are erosion, infection, and mechanical / device-related failure 
that cause a reoperation rate for revisions and / or explantations of 7–100% 
[83]. Comparing complication rates between neurogenic and non-neurogenic 
patients revealed that patients with neurogenic SUI tend to have more 
frequently complications that were not related to mechanical or device-
related failure [86]. 
A recent study suggested a less costly and less fragile alternative for SCI 
patients replacing the pump with a subcutaneous port to adjust cuff pressure 
also postoperatively and to omit the necessity to repetitively activate the 
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pump [87]. The two most recent studies report on long-term outcomes, 
demonstrating persistent efficacy in 74% of patients up to 10 years [88], and 
on the feasibility to implant the AUS using the daVinci robot [89]. 
However, RCT are actually lacking and the best site for cuff placement in 
male neurological patients is still a matter of debate. In male neurological 
patients, assessment of the ejaculatory status can be relevant as AUS 
placement at the bladder neck level may allow patients to achieve antegrade 
ejaculation [83]. 
 
CONCLUSION 
Management of urinary incontinence in male neurological patients is 
challenging and will usually require a combination of different treatment 
options. Although the therapeutic armamentarium has been increased during 
the last decades providing new possibilities for clinicians and patients, the 
level of evidence is often low. Moreover, current findings are mainly from MS 
and SCI patients without gender-specific outcomes limiting generalization of 
the results. 
The established cornerstones of neurogenic urinary incontinence therapy, 
such as ISC, antimuscarinics, intradetrusor onabotulinumtoxinA injections, 
augmentation cystoplasty, urinary diversion, and AUS, have not substantially 
changed. There is a clear interest in conservative and further minimally 
invasive therapeutic options, such as neuromodulation, either applied from 
external or via implantable devices, and suburethral suspension systems. 
Recent data are promising but further research is urgently needed. RCT for 
assessing efficacy and safety of different therapies for urinary incontinence 
in male neurological patients are a challenge and well-designed multicenter 
studies are highly warranted. 
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ABSTRACT 
Objectives: Although BoNT/A intradetrusor injections are a recommended 
therapy for NDO, refractory to antimuscarinic drugs, a standardisation of 
injection technique is missing. Furthermore, some basic questions are still 
unanswered, as where the toxin solution exactly spreads after injection. 
Therefore, we investigated the distribution of the toxin solution after injection 
into the bladder wall, using MRI. 
 
Methods: Six patients with NDO were recruited. Three of six patients 
received 300 U of onabotulinumtoxinA + contrast agent distributed over 30 
injection sites (group 1). The other three patients received 300 U of 
onabotulinumtoxinA + contrast agent distributed over 10 injection sites 
(group 2). Immediately after injection, MRI of the pelvis was performed. The 
volume of the detrusor and the total volume of contrast medium inside and 
outside the bladder wall were calculated. 
 
Results: In all patients, a small volume (mean 17.6%) was found at the 
lateral aspects of the bladder dome in the extra peritoneal fat tissue, 
whereas 82.4% of the injected volume reached the target area (detrusor). In 
both groups there was a similar distribution of the contrast medium in the 
target area. A mean of 33.3 and 25.3% of the total detrusor volume was 
covered in group 1 and 2, respectively. Six weeks after injection, five of six 
patients were continent and showed no DO in the urodynamic follow-up. No 
systemic side effects were observed. 
 
Conclusions: Our results provide morphological arguments that the 
currently used injection techniques are appropriate and safe. 
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INTRODUCTION 
BoNT/A injections into the detrusor muscle are a recommended therapy for 
NDO, when antimuscarinic drug therapy failed or is not tolerated [1-4]. 
BoNT/A injections have been successfully used to treat NDO worldwide and 
further indications and therapy options are currently explored [5-8]. The toxin 
is injected into the detrusor muscle via a cystoscopic approach, either 
flexible or rigid. The injection needle, which can be of different length and 
diameter, is stabbed into the bladder wall, followed by the injection of the 
toxin and the retraction of the needle. This is usually performed at multiple 
sites of the bladder wall, depending on the technique and amount of toxin, 
chosen for therapy [3, 9]. Target structure of the toxin is the detrusor muscle, 
as its main mechanism of action is at the neuromuscular junction [10, 11]. 
However, detrusor thickness is variable and depends on several factors 
such as gender, age, bladder filling volume and the presence of neurogenic 
lesion or obstruction [12, 13]. Although injection is performed under 
cystoscopic guidance, injection depth can only be estimated by the surgeon. 
Therefore, it remains difficult to estimate exactly in which layer the toxin is 
injected and where it spreads out. The sole visual control could be a bulging 
of the bladder wall after injection. If a big transparent bleb forms, the 
injection was probably superficial in the mucosa, if a slight bulging of bladder 
wall tissue can be observed the injection was probably in the detrusor layer. 
But very often, no bulging can be observed at all and it remains a very 
insecure sign of a correct injection. 
Although the injection of BoNT/A is frequently used to treat NDO, no 
standardisation of technique exists [9, 14, 15]. There are repeatedly reports 
of treatment failures, even in those patients, who formerly showed an 
excellent treatment response to BoNT/A [16-18]. Not all treatment failures 
can be explained properly and one reason for this might be a variation in the 
amount of toxin that reaches its target area. 
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Therefore, it was our purpose to investigate for the first time, the distribution 
of the toxin solution after injection into the bladder wall, using MRI. Since we 
previously investigated the use of two different injection schemes (10 vs. 30 
injection sites), which showed similar clinical results [14], we were also 
interested to observe the morphological outcome of both injection schemes. 
Due to our long term experience with the use of BoNT/A in the treatment of 
NDO and our favourable results in those years [19, 20], we expected most of 
the toxin to be found in the detrusor. Nevertheless we also expected some 
toxin outside the detrusor, as perforation cannot be completely excluded 
using the cystoscopic approach. As a secondary outcome measure we 
evaluated the urodynamical data before and after BoNT/A injection to be 
able to correlate the clinical outcome with the morphological evaluation of 
the toxin distribution. 
 
MATERIALS AND METHODS 
After approval of the local ethics committee, a patient sample was recruited 
in the neuro-urological out-patient clinic of the SCI centre at the Balgrist 
University Hospital. 
Inclusion criteria were: urodynamically proven NDO, failure to treatment with 
antimuscarinic drugs, minimum age of 18. 
Exclusion criteria: allergy to BoNT/A or to MRI contrast agents, any existing 
malignancy in the bladder or urethra, UTI, pregnancy, breastfeeding, 
incapability or unwillingness to perform ISC, coagulation disorders or intake 
of anticoagulant drugs, impaired renal function, myasthenia gravis, 
pacemaker, Lambert–Eaton syndrome, medication with aminoglycosides (or 
other drugs with impact upon neuromuscular transmission), any 
ferromagnetic metal implants or compounds in or at the body. 
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Prior to inclusion, all patients were informed about the character of the study, 
both verbally and in writing and each patient had to provide written informed 
consent. 
Pre-treatment evaluation consisted in physical examination, medical history, 
cystomanometry, blood chemistry, urine sediment and culture. Infections 
were treated according to germ resistance before examination or injection 
and all patients received antibiotic prophylaxis for 3 days, starting 1 day 
before injection and ending 1 day after injection. 
Local anaesthesia using electromotive drug administration of 2% lidocain 
was applied in patient 2 because of preserved bladder sensibility due to an 
incomplete SCI (Table 3-1) [21]. 
The BoNT/A injections were performed at the bladder base and dome in a 
standardised manner by the same surgeon in all patients, using a rigid 
cystoscope (19 or 22 Fr) and a 22 G (=0.7 mm) needle with a length of 8 
mm. Not the full needle length was inserted into the bladder wall during 
injection. Instead, the needle was retracted up to half its length, depending 
on the injection angle. The used BoNT/A compound in this study was 
BOTOX® (Allergan AG, Lachen, Switzerland). 
The first group (group 1) of patients received 300 U of BOTOX®, distributed 
over 30 injection sites each 1 ml BoNT/A solution [3]. A second group (group 
2) received 300 U of BOTOX®, distributed over ten injection sites each 1 ml 
BoNT/A solution [14]. For group 1, 300 U of BOTOX® were diluted in 27 ml 
0.9% saline + 3 ml gadopentate. For group 2, 300 U of BOTOX® were 
diluted in 9 ml 0.9% saline + 1 ml gadopentate. The paramagnetic MRI 
contrast agent gadopentate (Magnevist®, Schering AG, Berlin, Germany) 
was mixed into the BoNT/A solutions to detect the distribution of the 
injections in the following magnetic resonance (MR)-scans, which were 
performed in a 1.5 T Avanto Siemens Magnetom. Prior to scanning, the 
bladder of all patients was emptied and filled with 200 ml 0.9% saline to 
achieve a standardised filling during MR scanning. 
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A T1 fast low angle shot (FLASH) 3D with fat saturation was used in the MR 
evaluation including the following specifications: TR: 4 ms, TE: 1.7 ms, 
flipangle: 12°, matrix: 256 x 256, FOV: 200 mm, slice thickness: 2.9 mm, 
NEX (Acquisitions): 2. 
Using the freehand tool of the MR-software, the following regions of interest 
(ROIs) were selected: (1) the area of contrast agent within the detrusor 
muscle, (2) the area of contrast agent outside the detrusor and (3) the whole 
detrusor itself. Once a ROI was defined, the software automatically 
calculated the area in square millimetres. The 3D acquisition technique 
enabled the generation of volume data by multiplying the previously 
measured ROIs of each slice with the slice thickness. The distribution of 
gadopentate after injection was calculated and evaluated by two different 
radiologists who were blinded to the injection protocol. A urodynamic control 
visit was scheduled for each patient 3 months after injection and the 
urodynamic outcome measures were compared with those before BoNT/A 
injection. 
 
RESULTS 
Six patients with spinal cord injury and subsequent NDO could be included 
(Table 3-1). All injections could be performed without any clinically evident 
adverse events and none of the patients felt discomfort or pain. Only in 
patient 6, the injection procedure itself was difficult because of an increased 
spasticity of the lower limb. No systemic side effects were observed in any 
patient directly after the injection or during follow-up. Bleeding from the 
injection sites was minimal and stopped shortly after retracting the needle. 
The average delay between the end of the BoNT/A injection and the start of 
the first MR-sequence was 17.5 min, ranging from 10 to 32 min. Mean 
examination time in the MR-scanner was 25 min, ranging from 17 to 42 min. 
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In none of the patients, contrast agent could be detected intraperitoneal, 
which would be highly suspicious for a penetration into the peritoneum. 
Furthermore, no contrast agent was found in other organs like the rectum or 
pelvic muscles. In all six patients, fractions of the contrast agent could be 
detected outside the bladder wall, located in the perivesical fat, mainly at the 
lateral aspects of the bladder dome either on one or both sides. In one 
patient, contrast agent was also found beyond the bladder base, in another 
patient beyond the middle part of the bladder dome. The average spreading 
distance of contrast agent from the outer margin of the detrusor was 16 mm. 
The mean total detrusor volume of all subjects was 156.4 cm3. The mean 
contrast enhanced detrusor volume of all subjects was 46.3 cm3 (29.3% of 
the mean total detrusor volume). The mean amount of contrast enhanced 
volume outside the detrusor was 8.7 cm3 (17.6% of the mean total contrast 
enhanced volume). Accordingly, 82.4% of contrast agent was found within 
the detrusor (Table 3-1). 
In group 1, the mean total detrusor volume was 199 cm3. The mean volume 
of detrusor, found to be contrast enhanced, was 62.8 cm3 (33.3% of the 
mean total detrusor volume in group 1). The mean amount of contrast 
enhanced volume outside the detrusor was 10.7 cm3 (14.3% of the mean 
total contrast enhanced volume). Accordingly, 85.7% of contrast agent was 
found within the detrusor (Table 3-1). 
In group 2, the mean total detrusor volume was 113.7 cm3. The mean 
volume of detrusor, found to be contrast enhanced, was 29.9 cm3 (25.3% of 
the mean total detrusor volume in group 2). The mean amount of contrast 
enhanced volume outside the detrusor was 6.6 cm3 (20.8% of the mean total 
contrast enhanced volume). Accordingly, 79.2% of contrast agent was found 
within the detrusor (Table 3-1). 
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Table 3-1 Patients characteristics, urodynamic parameters before and after treatment, and the 
results of the magnet resonance imaging analysis of all six patients 
 P 1 P 3 P 5 P2 P 4 P 6 
Age 34 34 41 82 67 18 
Sex male male male female male female 
Level of SCI Th11 Th6 Th6 Th7 Th10 Th10 
ASIA impairment scale A A A C A A 
Urodynamic parameters 
before treatment 
      
Max. bladder capacity [ml] 217 300 222 217 200 249 
Max. Detrusor pressure 
[cmH2O] 
69 46 41 37 48 27 
Incontinence / Urine leak yes yes yes yes yes yes 
Treatment       
Units of Botox® 300 300 300 300 300 300 
No. injection sites 30 30 30 10 10 10 
Urodynamic parameters 
after treatment 
      
Max. bladder capacity [ml] 381 500 500 186 500 440 
Max. Detrusor pressure 
[cmH2O] 
57 10 8 36 11 10 
Incontinence / Urine leak no no no yes no no 
MR imaging analysis       
Volume detrusor [cm3] 217.16 253.95 126.02 64.55 198.3 78.27 
Volume contrast medium 
(total) [cm3] 
101.53 61.2 57.74 14.51 56.57 38.53 
Volume contrast medium 
inside detrusor [cm3] 
85.6 52.97 49.76 11.52 54.08 24.11 
Volume contrast medium 
outside detrusor [cm3] 
15.93 8.23 7.98 2.99 2.49 14.42 
P patient, SCI spinal cord injury, ASIA American Spinal Injury Association, MR magnetic 
resonance, Th thoracic spine 
 
In five of six patients, the BoNT/A injections showed to be effective. Before 
treatment, all six patients had NDO in their urodynamic examination. The 
average volume at which the first DO could be observed was 234.2 ml. The 
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maximum detrusor pressure was on average 44.7 cmH2O. Five of six 
patients had urinary incontinence (Table 3-1). 
After the BoNT/A injections, four of six patients had no DO up to 500 ml and 
were continent. In patient 1 bladder capacity at least increased from 217 to 
381 ml and the maximum detrusor pressure decreased from 69 to 57 cmH2O 
(Table 3-1). Patient 2 showed no improvement in the follow-up cystometry, 
although he reported improvement. This patient had the lowest percentage 
of detrusor volume covered by the contrast agent (Table 3-1). 
Due to the spastic limb contractions in patient 6, shifts in the penetration 
depth of the needle might have incidentally occurred. When analysing this 
patient’s data we found that nearly 40% of the applied contrast agent was 
located beyond the detrusor (Table 3-1). 
All patients would agree to a second injection, when the effect of the last 
injection fades. 
 
 
Figure 3-1 An exemplary coronal slice of the magnet resonance imaging of the lower pelvis, 
showing the urinary bladder in the middle of the image. The contrast agent, appearing in 
white, can be found for the most part within the detrusor (a) and to some extent outside the 
detrusor in the perivesical fat tissue (b) (the areas were encircled in red for better visibility) 
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DISCUSSION 
The aim of this study was to investigate the distribution of the BoNT/A 
solution, after injection into the bladder wall. Our data show, that using the 
previously described and most widely used injection technique with 30 or 10 
injection sites [3, 14], most of the applied volume spreads inside the 
detrusor. Only small amounts were found outside the detrusor, almost 
exclusively in the fat tissue at the lateral aspects of the bladder dome. 
That 82.4% (average of all 6 subjects) of the injected BoNT/A-gadopentate 
solution were detected inside the detrusor, met our expectations. In regard 
with the clinical improvement of the patients, these results show that the 
used techniques are accurate and efficient. 
Due to the fact, that contrast agent could be detected outside the detrusor, it 
has to be assumed that the injection needle perforated the detrusor during 
some of the injections. This is probably not uncommon following detrusor 
injections via a cystoscopic approach, as the surgeon can only estimate the 
relation of needle length to detrusor thickness. These two factors, e.g. 
needle length and detrusor thickness, are most crucial in regard to injection 
depth. One can now assume that the surgeon could choose the needle 
length according to the detrusor thickness, which can be measured using 
ultrasound at a defined filling level [12]. This measurement, however, might 
not be very reliable during cystoscopic BoNT/A injection, as filling volumes 
and therefore detrusor thickness is likely to change during cystoscopy due to 
diuresis and more likely due to the regular use of flushing and draining of 
saline. Additionally, detrusor thickness might not be the same throughout the 
bladder, although investigated by Kuzmic [22], who found per individual the 
same detrusor thickness in all parts of the bladder wall. This is probably true 
for healthy subjects but might be completely different for patients with NDO. 
Perforation might not be the only mechanism contributing to the extravesical 
amount of contrast medium. A diffusion of the BoNT/A-gadopentate solution 
outside the bladder cannot be excluded in principle. Although one would 
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expect a more homogeneous and broader extravesical accumulation of the 
contrast medium and not only at certain areas as shown in Figure 3-1. 
The amount of the injected BoNT/A-gadopentate solution found outside of 
the bladder wall in the present study seemed to be low enough, not to cause 
any systemic side effects or to compromise the effect of the toxin on the 
bladder. Most of the intradetrusor contrast agent was found in the bladder 
base and dome, since this are the locations we injected. When descriptively 
comparing the two different treatment modalities (30 vs. 10 injection sites) 
there was a similar amount of contrast agent found in the target area (85.7 
vs. 79.2%) and a similar percentage coverage of detrusor volume with the 
contrast agent (33.3 vs. 25.3%). Although both groups cannot be compared 
statistically due to the small sample size, this finding can still be seen in 
agreement with the study from Karsenty et al. [14], who found no difference 
in clinical efficacy and safety using 10 compared to 30 injection sites with the 
same amount of BoNT/A. 
In general, it remains still unclear, how much detrusor tissue should be 
covered to gain the best dosage / effect ratio of BoNT/A. One would assume 
that a distribution of BoNT/A covering most of the detrusor body might cause 
the greatest effect. In the present study an average of only about 30% 
(mean of all patients) of detrusor muscle was covered with contrast agent. 
Nevertheless, a sufficient effect of the BoNT/A treatment could be observed, 
which is well comparable with the success rates reported in former studies 
[6, 7]. Therefore, it might not be necessary to cover the whole detrusor with 
BoNT/A, to achieve good clinical results. 
An exact explanation why 30% detrusor coverage with BoNT/A are sufficient 
enough to produce the reported clinically significant improvements cannot be 
given with this study. A possible reason eventually underlying these results 
might be areas of detrusor tissue, which are more important for detrusor 
contraction and increase of local reflex activity than other areas after SCI 
[23]. Treatment of those areas with BoNT/A might be sufficient enough to 
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reduce detrusor contractions in NDO patients, regardless of the total amount 
of detrusor area covered. Experimental studies in neonate and SCI rats 
showed that spontaneous contractile activity originated in the urothelium-
suburothelium near the bladder dome [23, 24]. This spontaneous activity, 
unlike activity in normal adult rat bladders, is highly organised, i.e. starting at 
the dome, followed by the bladder body further contracting towards the 
bladder outlet. These organised contractions resulted in high amplitudes 
(10–20 cmH2O). Increased expression of gap junctions seems to play a role 
in this coordinated contraction in neonate and SCI bladders, which gives the 
impression, that the bladder works partially like a “functional syncytium” [24]. 
In addition, BoNT/A is not only inhibiting the efferent pathway by preventing 
neuronal acetylcholine release but also modulating the afferent pathway due 
to its effect on receptors and neurotransmitter release from the urothelium 
and suburothelium, which probably adds to the efficacy of the toxin in the 
treatment of DO [25-27]. 
Disruption of such organised synergic contractions and of the urothelial and 
suburothelial para- and autocrine signalling by an area of 30% of the total 
detrusor, due to intradetrusor injection of BoNT/A at and around the bladder 
dome might not completely abolish detrusor contractions (Table 3-1), but 
prevent complete and / or large amplitude contractions arising from the 
bladder dome. This is probably sufficient enough to prevent incontinence 
and cause satisfying clinical results. Interestingly, two studies mainly using 
injections at the bladder base reported a significant lower rate of complete 
continent patients with NDO compared to other studies injecting BoNT/A in 
base and dome [7, 28, 29]. 
Further investigations are necessary to evaluate the degree of detrusor 
coverage with BoNT/A compared with the clinical outcome. Presumably 
there is an optimal ratio between the amount and the degree of distribution 
of BoNT/A inside the detrusor and the clinical outcome, which is worth to be 
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discovered. Using MRI in conjunction with contrast enhanced BoNT/A 
solution, might be a very useful tool to perform this investigation. 
There are, however, limitations of the used investigation method. First 
limitation is that during the injection procedure there might be some volume 
leaking out of the injection site into the bladder lumen. We consider this 
volume as extremely low, as the needle diameter is very small and most 
injection sites will clot shortly after removing the needle, which is in 
accordance with the experience of Schulte–Baukloh, who investigated toxin 
back flow from the injection site using a dye. He found, although not 
specifically quantified, that none to extremely little dye / toxin is flowing back 
from the injection sites [30]. Quantification of a dye (e.g. methylene blue) in 
the bladder irrigation fluid requires at least a photometric device, which was 
not readily available in our clinic. The group around Helmut Madersbacher 
and Gustav Kiss from the University of Innsbruck very recently performed 
such a photometric evaluation and found out that only 1.96–19.2 U (median 
5.5 U) of 170–400 U BoNT/A are lost due to back flow after injection 
(personal communication, annual meeting of the German Urological 
Association in Stuttgart, 24–27 Sep 2008). 
Second limitation might be measurement errors. Although most borders 
could be clearly distinguished, extravesical fluid may not have perfectly 
smooth borders. Manual determination of the region of interest introduces an 
additional small error. These errors were minimised by having two senior 
radiologists experienced in quantitative assessments of MR images 
performing the evaluations in consensus. The remaining error is small in 
comparison to the measured volumes. 
Third limitation is the number of six patients, which is too small to receive 
data for reliable statistics, but besides monetary constraints (expensive MRI-
examinations) the focus of this study was to demonstrate morphological 
aspects of the injection technique for the first time. The used MRI technique 
is well suited to demonstrate the morphologic situation after injecting the 
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detrusor, but a short delay between injection and obtaining the pictures is 
mandatory because of fast diffusion and venous backflow of the contrast 
agent. 
At least, it has to be considered that we cannot demonstrate the localisation 
of the BoNT/A itself, but only the localisation of the contrast agent. Although 
BoNT/A is not residing just at the injection site [31], it probably diffuses much 
slower and less far as gadopentate, due to the higher molecular weight of 
150 kDa compared to the 835 Da of gadopentate. In our study (with a mean 
delay of 17.5 min after injection) renal excretion of contrast agent could 
already be seen in all patients. 
 
CONCLUSION 
Using the previously described injection techniques, a mean of 82.4% of the 
injected BoNT/A-gadopentate solution can be found within the detrusor. 
However, a perforation with the needle tip and injection into the perivesical 
tissue could not be prevented. Treatment with 10 or 30 injection sites seem 
similar regarding the distribution of contrast agent in or outside the detrusor. 
In consideration of the clinical improvements of the patients, our results 
provide further arguments that the currently used injection techniques are 
appropriate and safe. Further studies are necessary to explore the optimal 
ratio between the amount and the degree of dissemination of BoNT/A inside 
the detrusor and the clinical outcome. 
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ABSTRACT 
Purpose: Patients with MS often experience OABS. High dose BoNT/A 
intradetrusor treatment is effective but often results in urinary retention and 
urinary diversion via a catheter. In this pilot study we evaluated whether only 
100 units onabotulinumtoxinA would significantly decrease OABS in patients 
with MS without impairing pre-treatment voluntary voiding. 
 
Materials and Methods: Included in our study were 12 patients with MS 
who had OABS such as urgency, frequency and / or urgency incontinence. 
The treatment effect was evaluated using data on 3 consecutive visits, that 
is before, and a mean ± SD of 46.2 ± 11.9 and 101 ± 21 days after 
intradetrusor injection of 100 units Botox®, including the results of 
cystometry and uroflowmetry at visits 1 and 2, and uroflowmetry alone at 
visit 3. Patients completed a 3-day voiding diary for all 3 visits. 
 
Results: Maximum bladder capacity significantly increased and maximum 
detrusor pressure decreased. Daytime and nighttime frequency, urgency 
and pad use significantly decreased. PVRV significantly increased initially 
but decreased until 12 weeks. Median time to re-injection due to recurrent 
overactive bladder symptoms was 8 months. 
 
Conclusions: Overactive bladder treatment in patients with MS using 100 
units OnabotulinumtoxinA intradetrusor injections seems to be effective and 
safe. Despite slightly impaired detrusor contractility most patients still voided 
voluntarily without symptoms. Thus, 100 units OnabotulinumtoxinA may be a 
reasonable treatment option for OABS in patients with MS who still void 
voluntarily. 
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INTRODUCTION 
LUTD is common in patients with MS and can severely impair QoL in 
addition to the restrictions already experienced due to the neurological 
disease [1-4]. Of the patients 10% are already affected by detrusor and 
sphincter disorders at the initial MS diagnosis [1]. Initial symptoms of LUTD 
are often irritative, such as urgency and frequency, but incontinence or 
urinary retention also occurs often [1]. In the MS course the prevalence and 
severity of these symptoms inevitably increase and up to 75% of patients 
with MS experience bladder problems during the disease course [3-5]. A 
point is commonly reached at which patients with MS do not tolerate first line 
antimuscarinic treatment or find the effects insufficient to treat OABS and 
second line treatment becomes necessary [6]. 
BoNT/A is an effective second line treatment for OABS in neurogenic cases. 
Most often a dose of 300 units is chosen when using OnabotulinumtoxinA for 
intradetrusor injection [7]. However, patients with MS often present with 
initial PVRV and treating them with 300 units OnabotulinumtoxinA may 
probably result in high PVRV or urinary retention, requiring ISC or an 
indwelling catheter [1, 6-8]. This is often not satisfactory in patients with MS 
who are still ambulatory and voluntarily empty most of the bladder capacity. 
Recently 100 units OnabotulinumtoxinA were noted to effectively alleviate 
OABS in non-neurogenic cases without causing urinary retention or a 
significant increase in PVRV [9, 10]. To our knowledge there is as yet no 
proof that 300 units OnabotulinumtoxinA are needed to efficiently treat 
OABS in MS cases. Drug treatment usually starts with a low dose that can 
be increased as needed, rather than with a high dose. 
The aims of our study were to (1) investigate whether intradetrusor injections 
of only 100 units OnabotulinumtoxinA would sufficiently treat OABS in 
patients with MS and 2) observe whether 100 units OnabotulinumtoxinA 
would prevent urinary retention and, thus, provide the possibility of avoiding 
or decreasing the frequency of de novo ISC. We hypothesized that 100 units 
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OnabotulinumtoxinA would alleviate OABS in our MS population but 
efficient, symptom-free voluntary voiding would still be possible. 
 
MATERIALS AND METHODS 
After receiving approval from the local ethics committee we recruited 
patients with MS who consulted our neuro-urology department for treatment 
of LUTS. Study inclusion criteria were a proven diagnosis of MS; OABS with 
or without incontinence, as documented by 3-day voiding diary, with at least 
3 urgency episodes in 3 days that were refractory to at least 2 antimuscarinic 
agents, each ingested for 1 month; treatment naïve status to BoNT/A before 
the first consultation at our department; preserved voluntary voiding or 
voluntary voiding as the only way of bladder emptying; ability and willingness 
to perform ISC; and written informed consent. Study exclusion criteria were 
neurological diseases other than MS, MS relapse 6 months before or during 
the evaluation period, previous LUT surgery or malignancy and previous 
BoNT/A treatment. 
 
 
Figure 4-1 Study course 
 
All patients had to complete 5 visits, including initial urodynamic evaluation 
at visit 1, blood and urine test before BoNT/A intradetrusor injection at visit 2, 
Botox® intradetrusor injection at visit 3, post-treatment urodynamic 
evaluation 6 to 7 weeks after injection at visit 4 and uroflowmetry follow-up 
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12 to 14 weeks after injection at visit 5 (Figure 4-1). At visits 1, 4 and 5 a 3-
day voiding diary was completed (Figure 4-1). 
BoNT/A intradetrusor injection at visit 3 was done with a 19Fr or 22Fr rigid 
cystoscope and a 22 gauge 0.7 mm needle 8 mm long. Only half of the 
needle was inserted. Each patient received 100 units OnabotulinumtoxinA 
diluted in 10 ml 0.9% saline and distributed over 10 injection sites at 1 ml 
each. Local anesthesia of the bladder mucosa was achieved with 50 ml 2% 
lidocaine / 8.4% bicarbonate solution instilled into the bladder for 10 minutes 
before injection. 
Evaluated outcome parameters were maximum detrusor pressure (pDetmax), 
maximum cystometric capacity (MCC), bladder volume at first desire to void 
(FDV) on video cystometry at visits 1 and 4; voided volume, maximum flow 
rate (Qmax), PVRV on uroflowmetry at visits 1, 4 and 5; daytime and 
nighttime frequency, incontinence episodes, urgency episodes and number 
of pads used on voiding diary at visits 1, 4 and 5. All outcome parameters 
were defined according to the International Continence Society 
standardization of terminology [11]. 
We also assessed the extended disability symptom scale (EDSS) in all 
patients to provide information on individual impairment (Table 4-1) [12]. The 
EDSS range is 0.0—normal neurological examination to 10.0—death from 
MS and it quantifies the disability in 8 functional systems. Procedure pain 
and patient satisfaction were evaluated using 2 visual analogue scales 
(VAS) with a range of 1—no pain or complete dissatisfaction to 10—worst 
pain or maximum satisfaction. 
Patients were eligible for re-injection on demand but not before 3 months 
after the previous injection. The reinjection appointment was scheduled by 
patients when OABS recurred. 
Video cystometry outcome parameters were statistically compared between 
visits 1 and 4 using the nonparametric Wilcoxon signed ranks test with α = 
0.05. Uroflowmetry and voiding diary outcome parameters were statistically 
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compared among visits 1, 4 and 5 using the nonparametric Wilcoxon signed 
ranks test but due to multiple comparisons α = 0.025. 
 
Table 4-1 Patient demographics 
Patient No. - Gender Age [years] at BoNT/A 
injection 
Age [years] at MS 
diagnosis 
EDSS 
1 - F 43 35 3.0 
2 - F 58 41 3.0 
3 - F 60 45 4.5 
4 - F 39 27 5.5 
5 - F 50 20 6.0 
6 - F 62 29 6.0 
7 - F 51 34 7.5 
8 - M 50 33 6.0 
9 - F 43 37 4.5 
10 - F 65 35 3.0 
11 - F 59 52 6.0 
12 - F 38 21 4.5 
Mean ±SD 51.5 ±9.3 34.1 ±9.3 5.0 ±1.5 
BoNT/A botulinum neurotoxin A, EDSS extended disability symptom scale, MS multiple 
sclerosis 
 
RESULTS 
One man and 11 women with a mean ± SD age of 50.7 ± 10 years met all 
study inclusion and exclusion criteria, and were evaluated (Table 4-1). Mean 
time between visits 3 and 4 was 44.1 ± 10.6 days and between visits 3 and 5 
it was 113.8 ± 61.4 days. Before visit 2 no patient performed ISC. 
All patients showed OABS on 3-day voiding diary at visit 1, although some 
had normal video cystometry results. No patient had VUR before or after 
treatment. DO with incontinence was observed on cystometry in 7 patients 
before and in 3 after Botox® application. 
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Mean MCC significantly increased in 9 patients from 352.6 ml at visit 1 to 
538.8 ml at visit 4 (p = 0.008). The remaining 3 patients already had an initial 
MCC of about 600 ml. However, comparison of all 12 MCCs between visits 1 
and 4 revealed a significant increase (p = 0.034, Figure 4-2). Mean volume 
at FDV increased significantly from 340.3 ± 233 ml at visit 1 to 453.1 ± 200 
ml at visit 4 (p = 0.05). In all patients Pdetmax decreased significantly from a 
mean of 38.0 cmH2O at visit 1 to 16.3 cmH2O at visit 4 (p = 0.004, Figure 
4-3A). 
 
Figure 4-2 Volume at FDV and MCC at visits 1 (open bars) and 4 (light gray bars), and 
voided volume and PVRV at visits 1, 4 and 5 (dark gray bars) in all patients. Box plots 
indicate minimum, 25% percentile, median, 75% percentile and maximum. Pound sign 
indicates p = 0.05. Asterisk indicates p = 0.034. Plus sign indicates p = 0.003. 
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Voiding diary data showed a significant decrease in frequency, urgency 
episodes and pad use from visits 1 to 4 (Table 4-2, Figure 4-4). This 
significant decrease was sustained up to visit 5 (Table 4-2, Figure 4-4). We 
noted a significant decrease in nocturia from visits 1 to 4 (Table 4-2, Figure 
4-4). However, this significant decrease was not sustained up to visit 5, 
although mean nighttime frequency was still lower at visit 5 than at visit 1 
(Table 4-2). The mean number of incontinence episodes decreased 
continuously from visits 1 to 5 but we noted no significant difference between 
visits in the number of incontinence episodes (Table 4-2, Figure 4-4). 
We found no significant differences between visits in voided volume and 
Qmax, although each parameter seem to slightly decrease from visits 1 to 5 
(Table 4-2, Figure 4-2, and Figure 4-3B). PVRV significantly increased from 
visits 1 to 4 (Table 4-2, Figure 4-2). However, until visit 5 PVRV decreased 
back toward baseline values and we noted no significant difference between 
visits 1 and 5 (Table 4-2, Figure 4-2). 
 
 
Figure 4-3 A, Pdet max during filling cystometry in all patients at visits 1 and 4. B, Qmax 
during uroflowmetry in all patients at visits 1, 4 and 5. ml/s, ml per second. Box plots indicate 
minimum, 25% percentile, median, 75% percentile and maximum. § indicates p = 0.004 
 
After visit 3 ISC was needed only in 2 patients once to twice daily on 
demand. One patient needed a suprapubic catheter. The need for ISC was 
based on symptoms, eg persistent OABS or recurrent UTI, and not related to 
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a certain PVRV. The mean incidence of symptomatic UTI was 1.0 ± 1.1 at 12 
months before BoNT/A injection and 1.1 ± 1.4 between BoNT/A injection and 
re-injection. Other adverse events were mild self-limited hematuria in 6 
patients and mild self-limited injection site pain in 8. The mean VAS pain 
score in those cases was 2.8 ± 1.9 points. 
The mean VAS satisfaction score in all patients was 7.3 ± 2.1. Ten of 12 
patients agreed to be treated with BoNT/A again. Of those 10 patients 1 was 
lost to further follow-up and 9 required re-injection after a mean of 11 ± 6.1 
months (median 8, range 5 to 22). The 2 patients who did not agree to re-
injection were not satisfied with the treatment outcome, although 1 showed 
significant improvement in the urodynamic and voiding diary parameters. 
 
Table 4-2 Three-day voiding diary and uroflowmetry results in 12 patients at visits 1, 4, and 5. 
  
Visit 1  
[mean 
±SD] 
Visit 4  
[mean 
±SD] 
p Value vs 
Visit 1* 
Visit 5  
[mean 
±SD] 
p Value 
vs Visit 
1* 
No. voids 
Daytime 
11.4 
±3.5 
7.1 
±2.1 
p = 0.002 
8.5 
±2.6 
p = 
0.004 
Nighttime 
2.4 
±1.4 
1.3 
±1.2 
p = 0.005 
1.9 
±2.0 
p = 
0.107 
No. 
episodes 
/ day 
Inconti-
nence 
3.8 
±5.1 
1.9 
±3.2 
p = 0.041 
1.0 
±1.4 
p = 
0.214 
Urgency 
9.1 
±5.7 
2.8 
±3.8 
p = 0.013 
4.4 
±5.2 
p = 
0.008 
No. pads 
/ day 
 
1.9 
±09 
0.8 
±0.8 
p = 0.020 
0.7 
±0.9 
p = 
0.011 
Uroflow-
metry 
Voided 
vol. (mL) 
337.4 
±256.5 
330.8 
±186.2 
p = 0.875 
221.3 
±132.4 
p = 
0.239 
Qmax 
(mL/s) 
27.9 
±21.0 
23.1 
±13.2 
p = 0.530 
18.7 
±13.5 
p = 
0.055 
PVRV 
(mL)  
98.3 
±77.6 
222.1 
±113.2 
p = 0.003 
135.2 
±94.8 
p = 
0.328 
PVRV post void residual volume, *α = 0.025 
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DISCUSSION 
Our study showed significant improvement in all cystometric and voiding 
diary parameters except incontinence episodes after intradetrusor injection 
of only 100 units OnabotulinumtoxinA. Currently only 2 studies are available 
of the effect of BoNT/A intradetrusor injections in a pure MS population and 
each describes the effect of 300 units [6, 13]. Direct comparison of the 
studies by Schulte- Baukloh [13] and Kalsi [6] with our study remains difficult 
and no direct conclusion can be drawn about which dose is more effective. 
However, somewhat similar results were observed in cystometric parameters 
at 4 to 6-week follow-up, and for voiding diaries at 4 to 6 and 12 to 16-week 
follow-up. Nevertheless, decreased daytime and nighttime frequency, 
incontinence and urgency appear more pronounced and persistent in the 
study by Kalsi [6] than in our series. Moreover, in our study the mean 
number of urgency episodes, and mean daytime and nighttime frequency 
showed a tendency to increase again after 12-week follow-up, although 
urgency episodes and daytime frequency remained significantly decreased 
compared to before treatment. Our follow-up was only until 12 weeks after 
treatment and the median interval after which patients requested re-injection 
was 8 months. This shows that from the patient viewpoint the effect of 100 
units OnabotulinumtoxinA lasted for a period comparable to that in the study 
by Kalsi [6]. 
Our results show that intradetrusor injections of 100 units 
OnabotulinumtoxinA alleviated OABS significantly in our MS population. 
However, 100 units OnabotulinumtoxinA do not preserve initial detrusor 
contractility and cannot generally prevent the need for de novo ISC or even 
urinary diversion via a catheter. PVRV increased significantly, and mean 
Qmax and voided volume decreased, although not significantly. BoNT/A 
intradetrusor injections may most often cause a higher incidence of de novo 
ISC and increased PVRV in patients with neurogenic OABS but not or only 
rarely in those with NNOAB presumably due to the already neurologically 
compromised process of bladder emptying, e.g. DSD, in the neurogenic 
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OABS population [6]. However, that observation may be biased or 
influenced by the use or omission of a certain PVRV threshold at which to 
start ISC as well as the potential difference of those thresholds among 
studies. A recent study using 200 units OnabotulinumtoxinA in patients with 
NNOAB showed quite a high number with de novo ISC with a PVRV 
threshold requiring ISC at 200 ml regardless of symptoms [14]. Thus, using 
or not using a PVRV threshold for ISC and its level can significantly 
influence the study outcome. In our series we did not use a fixed PVRV 
threshold for ISC but rather focused on symptomatology. 
To our knowledge there is yet no evidence-based consensus of PVRV 
threshold use, although experts on this topic from the United Kingdom 
seems to be ahead [15]. The suggested United Kingdom consensus of a 100 
ml PVRV cutoff for ISC regardless of symptoms is straightforward and 
seems to be reasonable treatment since full functional bladder capacity is 
available in the storage phase due to complete bladder emptying by ISC 
[15]. Also, all patients in whom BoNT/A intradetrusor treatment is planned 
should be encouraged to learn ISC since increased PVRV or even urinary 
retention are known risk factors [7, 14, 16]. However, ISC done at least 4 to 
6 times daily only because of a certain PVRV is not evidence-based and can 
be discussed critically. Moreover, it may not meet the individual expectations 
and needs of a patient with OAB. 
In regard to this issue daily practice may legitimately differ from the protocol 
in prospective studies. To our knowledge no current study provides enough 
evidence to establish a certain PVRV threshold. A recent literature review 
stated that PVRV greater than 300 ml may be considered to favor UTI 
development [1]. Another group noted in a series of patients with stroke that 
PVRV greater than 150 ml seems to be an independent risk factor for UTI 
[17]. None of our patients had PVRV greater than 200 ml at 12-week follow-
up or an increased incidence of UTI. Only 1 patient, who was 1 of the 2 
requiring ISC twice daily, had a PVRV of 350 ml. 
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Figure 4-4 Three-day VD results in all patients at visits 1 (open bars), 4 (light gray bars) and 
5 (dark gray bars) regarding daytime (§ indicates p = 0.002 and # indicates p = 0.004) and 
nighttime (§ indicates p = 0.005) frequency, incontinence, urgency (§ indicates p = 0.013 and 
# indicates p = 0.008) and pad use (§ indicates p = 0.02 and # indicates p = 0.011). Box plots 
indicate minimum, 25% percentile, median, 75% percentile and maximum of 3-day averages. 
 
When OABS are satisfactorily treated, no recurrent UTI develops, no VUR is 
present and patients can still sufficiently empty the bladder without 
symptoms, it may be justified to omit or decrease the frequency of ISC. 
However, regular follow-up investigations remain mandatory since the 
consequences of sustained high PVRV on the UUT in this population have 
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not yet been specifically assessed. In this context α-receptor-antagonists 
may be an option to decrease outflow resistance and, thus, PVRV in these 
patients. In our study 100 units OnabotulinumtoxinA intradetrusor injections 
enabled most patients to omit or at least decrease ISC to a minimum without 
symptoms. 
Since OABS development and severity can be quite heterogeneous in the 
MS population [1], a more rational approach would be to first start at a low 
dose and increase the dose during the treatment course according to 
symptoms and the treatment effect, as it is usually done with most other 
forms of drug therapy. 
Potential limitations of this study are 1) our small number of patients, which 
is probably the cause of the high SD in some outcome parameters and the 
subsequent lack of significance, e.g. incontinence episodes, and 2) 
uroflowmetry and voiding diary follow-up was only up to 12 weeks, limiting 
information on the real duration of efficacy. Nevertheless, our pilot study 
presents promising first results of a different approach to OABS treatment in 
patients with MS and BoNT/A use in this context. 
 
CONCLUSIONS 
100 units OnabotulinumtoxinA seemed to be effective and safe for OABS in 
our MS study group due to significantly decreased urgency episodes, 
daytime and nighttime frequency, pad use and Pdetmax, and significantly 
increased MCC. However, initial detrusor contractility was not maintained 
since PVRV increased significantly and Qmax decreased. Nevertheless, most 
patients were able to remain on voluntary voiding without symptoms. The 
median time to when patients requested re-injection due to OABS relapse 
was 8 months. Results favour a treatment approach starting with a low 
BoNT/A dose with the possibility of increasing the dose, when applicable. 
This may be a reasonable OABS treatment in patients with MS who still void 
voluntarily.  
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ABSTRACT 
OnabotulinumtoxinA intradetrusor injections are considered a highly effective 
localized therapy for refractory DO. However, despite evidence for distant 
systemic effects of onabotulinumtoxinA, little is known on potential systemic 
side effects following intradetrusor injections. Given that onabotulinumtoxinA 
is a highly potent toxin this is an important safety issue specifically with 
regard to repeat injections and parallel treatments with BoNT/A. Hence, it 
was the purpose of this prospective study to investigate, using heart rate 
variability (HRV) analysis, whether onabotulinumtoxinA causes systemic 
effects on cardiac function following intradetrusor injections. 
Patients with NDO and age-matched healthy controls were recruited. 
Concomitant medication and diseases affecting the cardio-vascular system 
were exclusion criteria. A 3-channel resting electrocardiogram (ECG) was 
recorded in supine position for 15 min during four consecutive visits: 1) two 
weeks prior onabotulinumtoxinA intradetrusor injections, 2) 10min prior 
injections, 3) 30 min after injections, and 4) 6 weeks after injections. NDO 
patients received intradetrusor injections (300 units Botox®) between visits 2 
and 3. The control group had no intervention. 
Short-term (5 min) HRV analysis included assessment of frequency and time 
domain parameters. Statistical analysis was performed using ANOVA with 
repeated measures and the t-test. Due to multiple comparisons, α was 
corrected to 0.0125 (Bonferroni method). 
Twelve healthy volunteers (5♀, 7♂; 46 ± 12 years old) and 12 NDO patients 
(5♀, 7♂; 46± 13 years old) completed all measurements. Comparing both 
groups, resting heart rate was significantly higher in the patients group at 
visit 4 only. No further significant differences in time and frequency domain 
parameters were discovered. 
Within the NDO group, standard deviation of the normal to normal intervals 
(SDNN) in the ECG demonstrated a significant decrease (1.70 to 1.53ms, 
p=0.003) from visit 3 to 4, whereas the total power (TP) significantly 
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increased (3.05 to 3.29 ms2, p = 0.009) from visit 2 to 3. This increase 
subsided until visit 4. 
Study limitations: single treatment investigation under resting conditions 
only. 
In conclusion, onabotulinumtoxinA intradetrusor injections do not seem to 
affect resting state cardiac function. Short-term changes such as total power 
might rather result from natural cardio-vascular responses to the procedure 
itself (e.g. discomfort, stress). Further detailed investigations also under 
physical stress and repeated injections are necessary to fully exclude 
systemic cardiac side effects of onabotulinumtoxinA intradetrusor injections.  
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INTRODUCTION 
DO is a urodynamic finding that can be the underlying cause of bothersome 
LUTS such as urinary urgency and / or incontinence. Furthermore, DO may 
cause irreversible alterations to morphology and function of the urinary tract, 
including in its worst case renal failure [1]. First line treatment of DO is 
usually with antimuscarinics and just recently also a β3 adrenergic receptor 
agonist has been approved for this indication [1]. 
However, antimuscarinics and / or β3 adrenergic receptor agonists might not 
be sufficient to adequately reduce DO. In such cases, a second line 
treatment option is onabotulinumtoxinA intradetrusor injections [1]. The 
efficacy of onabotulinumtoxinA intradetrusor injections has been proven 
previously and the safety profile seems to be beneficial [2, 3]. However, 
most studies reporting on safety concentrated on adverse events related to 
the injection procedure itself, i.e. UTI, bleeding, pain, or the local effects on 
the bladder, i.e. urinary retention. Distant effects after intradetrusor injections 
have not yet been reported or investigated systematically [4]. 
However, there is evidence that BoNT/A causes effects related but not 
necessarily limited to its action on cholinergic nerve terminals elsewhere in 
the body than at the site of injection [5, 6]. One important neuromuscular 
structure that might be affected by distant effects following injection of 
BoNT/A is the heart [7-11]. By blocking acetylcholine release form the 
autonomic nerve terminals, BoNT/A can affect 1) parasympathetic control on 
the sinoatrial and atrioventricular node of the heart through the vagal nerve 
[12] and 2) the preganglionic sympathetic innervation of the heart [11, 13]. 
Both, sympathetic and parasympathetic influence on the heart can be 
assessed using HRV analysis. During normal sinus rhythm, the heart rate 
physiologically varies from beat to beat as a result of the dynamic interplay 
between the multiple physiologic mechanisms that regulate the 
instantaneous heart rate [14]. HRV reflects the ability of the cardio-vascular 
system to rapidly adapt to changing needs in response to a broad range of 
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internal and external stimuli and conditions and thus, is a measure of cardiac 
and overall health [15]. A reduced HRV has been associated with a poor 
prognosis of cardio-vascular disease, an increased risk of incident 
myocardial infarction, cardiovascular mortality, and death from other causes 
in the general population [16]. 
Considering that onabotulinumtoxinA is a highly potent neurotoxin and that 
leakage into the circulation cannot be prevented or excluded during 
intradetrusor injections, it was the purpose of this study to investigate the 
potential effects of onabotulinumtoxinA on cardiac function after 
intradetrusor injections using HRV assessment. 
From the anticholinergic mechanism of onabotulinumtoxinA and previous 
findings [7, 9, 10, 12, 17, 18], we would expect a reduced HRV following 
interdetrusor injection. 
 
SUBJECTS AND METHODS 
This is a prospective, controlled, single center study. The study was 
performed according to the declaration of Helsinki, approved by the local 
ethics committee and registered at https://www.clinicaltrials.gov (NCT 
identifier: NCT01337024). All subjects provided written informed consent 
prior to study inclusion. 
 
Subjects 
Patients with NDO eligible for treatment with onabotulinumtoxinA 
intradetrusor injections and age matched (±5 years) healthy controls were 
recruited. 
Inclusion criteria for patients: age ≥ 18 years, urodynamically proven NDO 
refractory to antimuscarinic treatment. Inclusion criteria for healthy subjects: 
age ≥ 18 years, good physical and mental health. 
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Table 5-1 Demographic data of patients with neurogenic detrusor overactivity and age-matched 
healthy control subjects. 
Patient / Subject 
No. – Gender – Age 
[years] 
Neurological 
lesion / disease 
ASIA impairment 
scale / level of 
lesion 
Duration of 
lesion / disease 
[years] 
1 – M – 36 Spinal cord inury A / Th5 18 
2 – M – 39 Spinal cord inury A / Th6 17 
3 – F – 43 Multiple sclerosis - 21 
4 – M – 43 Spinal cord inury A / Th5 4 
5 – M – 38 Spinal cord inury A / Th6 8 
6 – F – 71 Spinal cord inury A / Th3 24 
7 – M – 51 Spinal cord inury C / Th4 7 
8 – F – 47 Spinal cord inury C / L4 3 
9 – M – 63 Spinal cord inury D / C1 3 
10 – F – 58 Multiple sclerosis - 33 
11 – F – 38 Spinal cord inury A / L2 27 
12 – M – 22 Meningomyelocele  22 
    
Healthy controls    
1 – M – 35 None - - 
2 – M – 34 None - - 
3 – F – 48 None - - 
4 – M – 48 None - - 
5 – F – 41 None - - 
6 – M – 67 None - - 
7 – M – 51 None - - 
8 – F – 50 None - - 
9 – M – 62 None - - 
10 – M – 54 None - - 
11 – F – 36 None - - 
12 – F – 27 None - - 
ASIA American Spinal Injury Association, C cervical, L lumbar, Th thoracic 
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Exclusion criteria: pregnancy or lactation, any diseases of the cardiovascular 
system (e.g. cardiac arrhythmia, myocardial infarction, surgery), as well as 
cardiac pacemaker and medication with impact to cardiac function (e.g. 
beta-blockers, antiarrhythmic drugs), and medication influencing thyroid 
function; use of antimuscarinic therapy within 10 days prior to the first 
measurement; previous BoNT/A treatment within the last 12 months prior to 
the first measurement. 
Additional exclusion criteria for healthy subjects only: any current health 
problem or concomitant medication. 
 
Electrocardiogram (ECG) recordings 
The measurements were performed in a quiet separate examination room at 
constant room temperature and each subject / patient had a 30 – 35 min rest 
period to adjust to environment and setting. All subjects / patients were 
instructed to avoid caffeine, smoking, and meals at least 2 h before 
measurements. 
Just prior to each measurement, subjects / patients were instructed to refrain 
from closing their eyes, moving or talking, or to intentionally control 
breathing. 
Subsequently, a 3-channel resting ECG was recorded in a comfortable 
supine position with empty bladder for 15 minutes during four consecutive 
visits: 1) 2 weeks prior to onabotulinumtoxinA intradetrusor injections, 2) 10 
min prior to injections, 3) 30 min after injections, and 4) 6 weeks after 
injections. 
To reduce a confounding effect of pain from the onabotulinumtoxinA 
injection procedure on the HRV measurement, all patients rated their pain 
level on a VAS before and after injection treatment. Only when the post-
injection pain VAS score reached the baseline value, the post-injection ECG 
was recorded. 
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The healthy control group had their ECG recordings at identical time 
intervals. The recordings of each subject / patient were performed at the 
same day times as the initial recording (visit 1). 
 
Table 5-2 Heart rate variability outcome parameters (mean ±SD) from all 4 consecutive visits of 
both groups, patients undergoing onabotulinumtoxinA (onaBTA) intradetrusor injections for 
treatment of neurogenic detrusor overactivity (n = 12) and age-matched healthy controls (HC, n 
= 12). All HRV parameters were generated from 5-minutes time intervals and, except resting 
heart rate (rHR), log10 transformed. The p-values result from a t-test analysis between both 
groups. Due to multiple comparisons α was corrected to 0.0125 for all values (Bonferroni 
method). 
  
rHR 
[bpm] 
VLF 
[ms2] 
LF 
[ms2] 
HF 
[ms2] 
LF/HF 
TP 
[ms2] 
RMSS
D 
[ms] 
SDNN 
[ms] 
V
is
it
 1
 
ona-BTA 
71 
±15 
2.46  
±0.4 
2.50  
±0.4 
2.29  
±0.6 
1.13  
±0.2 
2.96  
±0.4 
1.45  
±0.4 
1.59  
±0.3 
HC 
65 
±10 
2.55  
±0.4 
2.37  
±0.4 
2.32  
±0.4 
1.03  
±0.1 
2.95  
±0.4 
1.39  
±0.3 
1.53  
±0.2 
p value 0.203 0.608 0.413 0.876 0.16 0.974 0.707 0.584 
V
is
it
 2
 
ona-BTA 
73 
±17 
2.66  
±0.3 
2.51  
±0.5 
2.27  
±0.6 
1.15  
±0.2 
3.05  
±0.4 
1.49  
±0.4 
1.65  
±0.2 
HC 
62 
±9 
2.56  
±0.3 
2.54  
±0.4 
2.33  
±0.5 
1.12  
±0.2 
3.00  
±0.3 
1.41  
±0.2 
1.57  
±0.2 
p value 0.062 0.489 0.857 0.808 0.79 0.769 0.552 0.316 
V
is
it
 3
 
ona-BTA 
69 
±14 
2.90  
±0.4 
2.77  
±0.4 
2.51  
±0.6 
1.13  
±0.2 
3.29  
±0.3 
1.57  
±0.3 
1.70  
±0.1 
HC 
60 
±8 
2.61  
±0.3 
2.49  
±0.4 
2.42  
±0.5 
1.04  
±0.2 
3.05  
±0.3 
1.53  
±0.3 
1.64  
±0.2 
p value 0.074 0.053 0.131 0.674 0.247 0.046 0.795 0.454 
V
is
it
 4
 
ona-BTA 
73 
±10 
2.63  
±0.4 
2.42  
±0.5 
2.12  
±0.7 
1.18  
±0.2 
3.04  
±0.4 
1.32  
±0.3 
1.53  
±0.2 
HC 
61 
±9 
2.80  
±0.4 
2.55  
±0.5 
2.46  
±0.5 
1.05  
±0.2 
3.22  
±0.4 
1.51  
±0.3 
1.62  
±0.2 
p value 0.004 0.312 0.575 0.181 0.073 0.257 0.134 0.278 
HC healthy controls, HF high frequency, LF low frequency, LF/HF low frequency / high 
frequency ratio, onaBTA onabotulinumtoxinA, rHR resting heart rate, RMSSD Root Mean 
Square of the Successive Differences, SDNN standard deviation of the NN intervals, TP total 
power, VLF very low frequency. 
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OnabotulinumtoxinA intradetrusor injections 
All included patients with NDO received 300 units onabotulinumtoxinA 
(Botox®) diluted in 30 mL saline and injected at 30 different sites sparing the 
trigone using a rigid or flexible cystoscope as described previously [19]. 
Local intravesical anesthesia was applied with 60 mL buffered lidocaine 
solution (30 mL of 2% lidocaine and 30 mL of 8.4% sodium bicarbonate) 
instilled 15 – 20 minutes prior to onabotulinumtoxinA injection. 
 
HRV analysis 
From the 15 minutes ECG recording, the middle 5 minutes were used for 
HRV analysis which was performed using SOLEASY™(Alea Solutions, 
Zürich, Switzerland) as follows: a) detection of r-waves in the ECG, b) 
calculation of the RR intervals and generation of discrete event series 
(DES), c) calculation of power spectra from DES d) calculation of the integral 
of very low frequency (VLF), low frequency (LF) and high frequency (HF) 
ranges. From these frequency domain parameters the total power (TP = VLF 
+ LF + HF) and the LF/HF ratio were calculated. 
For the time domain analysis, the mean heart rate at rest (rHR), the standard 
deviation of the normal to normal (NN or RR, i.e. interval between two R 
peaks) intervals (SDNN), and the root mean square of the sum of 
differences between adjacent NN intervals (RMSSD) were calculated. 
For more details and background on HRV previous publications elsewhere 
are recommended [14, 15, 20]. 
 
Outcome measures 
The primary outcome parameter was TP, as a general indicator for both, 
sympathetic and parasympathetic autonomic nervous system activity on the 
heart. 
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Secondary outcome parameters were VLF, LF, HF, LF/HF, rHR, RMSSD, 
and SDNN. 
 
 
Figure 5-1 Total power (TP, in ms2) during the four consecutive visits for the control (blue 
bars) and the neurogenic detrusor overactivity (NDO, grey bars) group. In the NDO group, 
there was a significant (*p = 0.009) increase in TP from visit 2 to 3 and significant (#p = 
0.003) decrease from visit 3 to 4. 
 
 
Statistical analysis 
All data, except rHR, were log10 transformed. Statistical analysis was 
performed using IBM SPSS Statistics 17.0 and ANOVA with repeated 
measures to analyse differences within each group, i.e. between visits, and 
the t-test to analyse differences between both groups. Due to multiple 
comparisons, α was corrected to 0.0125 (Bonferroni method). All values are 
presented as mean ± standard deviation (SD).  
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RESULTS 
Twelve patients with NDO (46 ± 13 years old; 5 females, 7 males) and 12 
healthy subjects (46 ± 12 years old; 5 females, 7males) were included and 
completed all investigations (Table 5-1). The cause of NDO was SCI (n = 9), 
MS (n = 2), and spina bifida (n= 1) (Table 5-1). 
 
 
Figure 5-2 Root mean square of the successive differences (RMSSD, in ms) and standard 
deviation of NN intervals (SDNN, in ms) during the four consecutive visits for the control (blue 
bars) and the neurogenic detrusor overactivity (NDO, grey bars) group. In the NDO group, 
SDNN decreased significantly (#p = 0.003) from visit 3 to 4. 
 
HRV parameters 
Within the control group there were no significant changes of any HRV 
parameter throughout the four visits. 
Within the NDO patient group there was a significant increase (p= 0.009) in 
TP from visit 2 to 3 and a significant decrease (p=0.003) from visit 3 to 4 
(Table 5-2, Figure 5-1). The SDNN parameter decreased significantly 
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(p=0.003) from visit 3 to 4 (Table 5-2, Figure 5-2). There were no further 
significant changes of HRV parameters throughout the four visits. 
Comparing both groups during all visits revealed a significant difference 
(p=0.004) in rHR at visit 4 (Table 5-2, Figure 5-3). There were no further 
significant differences of HRV parameters between groups (Table 5-2, 
Figure 5-2, Figure 5-4, Figure 5-5). 
 
DISCUSSION 
The main findings of this study are a temporary increase of TP and decrease 
of SDNN following onabotulinumtoxinA whereas rHR demonstrated a 
generally higher level in patients than in healthy controls. All other HRV 
parameters, i.e. VLF, LF, HF, LF/HF, RMSSD, did not show differences 
between visits, i.e. before vs after onabotulinumtoxinA injections, or groups. 
Considering previous findings from studies on the effect of botulinum toxin 
on the cardiac autonomic function [7, 10, 17, 18, 21-23], effects seem to be 
predominantly HRV depressive, i.e. decrease in coefficient of variation of 
heart rate [7], R-R interval variation [21], RMSSD [10, 18, 23], TP [10], and 
SDNN [10, 17, 18], and / or parasympatholytic [12, 24], i.e. increase in rHR 
[10, 18, 22, 23] and decrease of parasympathetic related test outcomes such 
as 30:15 ratio [17, 22], E/I ratio [10, 17, 22], and Valsalva ratio [17, 22]. In 
line with that, animal studies in dogs demonstrated a significant reduction 
and even elimination of parasympathetic related bradycardia and atrial 
fibrillation, respectively, following BoNT/A injections into pericardial fat pads 
[11, 13]. An attenuation of parasympathetic modulation on the heart has also 
been described in studies on the autonomic cardiac effects of botulism, 
reporting significant declines of parasympathetic test parameters that lasted 
longer than in sympathetic tests [17], elevated rHR, and LF/HF ratio [22]. 
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Figure 5-3 Resting heart rate (rHT, in bpm) during the four consecutive visits for the control 
(blue bars) and the neurogenic detrusor overactivity (NDO, grey bars) group. Comparing the 
control versus the NDO group, there was a significant difference (#p = 0.004) in rHR at visit 4. 
 
However, there is also a study reporting significant bradycardia after high 
dose intravenous BoNT/A application in different animals, i.e. mice, rats, 
rabbits, and dogs, with electrocardiogram alterations across all species 
indicating conduction defects, i.e. prolongation of the P-R, QRS, and Q-T 
intervals. In dogs, bilateral vagotomy and / or atropine could not prevent the 
bradycardia and ECG changes [9]. In addition, bradycardia and ECG 
changes were also observed in the isolated animal hearts, suggesting on the 
one hand that those effects are independent from respiratory related 
conditions and on the other hand that botulinum toxin A seems to act on 
local cardiac conducting structures such as artrioventricular junction, His 
bundle, and Purkinje fibers [9]. 
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Figure 5-4 Low frequency spectrum (LF, in ms2) and high frequency spectrum (HF, in ms2) 
during the four consecutive visits for the control (blue bars) and the neurogenic detrusor 
overactivity (NDO, grey bars) group. 
 
In our study we could not observe such HRV reductive and / or 
parasympatholytic effects as described previously, despite investigating 
resting conditions only under which vagal tone prevails and variations in 
heart rate are largely dependent on vagal modulation [20] which would then 
be specifically susceptible to attenuation by BoNT/A. 
In contrary, the observed temporary increase in TP from visit 2 to 3 in the 
patient / onabotulinumtoxinA group would rather indicate an increase in HRV 
since TP constitutes from the sum of the frequency domain parameters VLF, 
LF, and HF and reflects the overall autonomic activity on the heart including 
sympathetic (main contributor to the LF component) as well as 
parasympathetic (main contributor to the HF component) cardiac modulation 
[14, 15]. In this context it is noteworthy that, although not significantly, the 
mean values of VLF, LF, and HF increased from visit 2 to 3 in the patient 
group suggesting a rather uniform than a single component driven change of 
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TP. In their sum, such insignificant changes of all frequency domain 
parameters might contribute to the eventually statistically significant outcome 
of TP. In addition, TP values were not different between patient and control 
group and compared to normative values from subjects of the same age 
group [25] the TP values of our patients fluctuated within a normative range. 
Hence, attributing this temporary change in TP to an effect of 
onabotulinumtoxinA appears rather unlikely. 
A confounding factor that can affect HRV and might contribute to the 
observed transient TP changes shortly after onabotulinumtoxinA injections is 
the use of the lidocaine based local anesthesia prior to the injections. 
However, lidocaine causes very different and quite opposite changes of HRV 
than isolated TP increase [26, 27], making an effect of lidocaine in this 
context unlikely. 
The significant decrease in SDNN could be related to the 
onabotulinumtoxinA treatment. However, looking at the values, significance 
mainly results form a preceding SDNN increase until visit 3 that returns just 
below baseline value at visit 1 without significant difference to the baseline 
value. 
The significant difference between groups in rHR at visit 4 results most 
probably from the continuously higher rHR in the patient group compared to 
the healthy control group which nearly became already significant at visit 2. 
Slight rHR decrease in the control group and slight rHR increase in the 
patient group at visit 4 were sufficient to cause the statistical significance 
whereas each group demonstrated a quite stable rHR throughout all visits. 
Since most patients suffered from SCI, the higher rHR in the patient group 
might be a consequence of the altered autonomic nervous system function 
in such patients [28]. 
In summary, we did not find relevant HRV changes related to 
onabotulinumtoxinA intradetrusor injections neither within the treated patient 
group nor in comparison with the untreated age-matched healthy control 
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group. To the best of our knowledge, this is the first study on the relationship 
of onabotulinumtoxinA intradetrusor injections and autonomic cardiac 
control. There are some studies that investigated the effect of BoNT/A on 
cardiac autonomic function using HRV before and after injections for the 
treatment of cervical dystonia [7, 8, 10, 29, 30], spastic hemiplegia [31], and 
other dystonic conditions [8, 10]. However, the results are conflicting on 
weather BoNT/A injections have an effect on autonomic cardiovascular 
function [7, 8, 10] or not [29-31]. Comparison amongst studies remains very 
difficult and needs to be done with caution due to the different injection 
doses, injection sites, BoNT/A formulations, and primary HRV endpoints 
used. Moreover, time point of HRV assessment in relation to BoNT/A 
injections as well as the course of treatment, i.e. single primary treatment vs. 
chronic repeated treatment might be additional and essential factors 
influencing study outcome. Post treatment measurements followed mainly 
within 10 days to 6 weeks after BoNT/A injections. 
In our study we re-assessed the patients 6 weeks after onabotulinumtoxinA 
injections since this is the usual interval within which onabotulinumtoxinA is 
expected to show full efficacy on the detrusor. However, an earlier 
occurrence of transient effects might be missed whereas 30 min after 
onabotulinumtoxinA (visit 3) might be too early to observe any 
onabotulinumtoxinA related effects [8, 32]. Regarding the treatment course, 
our patients had previous onabotulinumtoxinA treatments but not within 12 
months prior to the first HRV measurement. Nevertheless, we cannot fully 
exclude a sustained onabotulinumtoxinA effect on autonomic cardiac control 
from previous injections. In this context it is noteworthy that in two of three 
studies, that demonstrated effects of BoNT/A on HRV, only treatment naive 
patients were included (in the third study, patient status was not indicated) 
[7, 8] although short-term (14–45 days) re-injections were necessary to 
record significant effects. This might suggest on the one hand a dose 
dependent effect of BoNT/A on cardiac autonomic control and on the other 
hand that patients with repeat BoNT/A injections might no longer show acute 
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effects on HRV potentially due to an already altered baseline. In contrary, 
Nebe et al. investigated treatment naive patients only as well but did not find 
any BoNT/A effect on HRV [29]. Moreover, in our patient group, potential 
chronic adaptations of the cardiac autonomic control due to previously 
repeated onabotulinumtoxinA injections must be subtle enough not to result 
in any difference compared to the healthy control group. 
Despite using a quite high dosage of 300 units onabotulinumtoxinA 
compared to the studies indicating BoNT/A effects on HRV (20–130 units 
onabotulinumtoxinA or 500 units abobotulinumtoxinA), we could not confirm 
effects of onabotulinumtoxinA on HRV which is in line with the most recent 
study on this topic using 600 units of incobotulinumtoxinA for treatment of 
spastic hemiplegia in stroke survivors without significant post treatment 
effects on HRV [31]. A possible explanation could be a less extensive 
spread of onabotulinumtoxinA after intradetrusor injections compared to 
injections into striated muscle as suggested by a pilot study of Schnitzler et 
al. using single fiber electromyography to assess the neuromuscular jitter as 
sign of distant neuromuscular effects in 21 patients after 300 units 
onabotulinumtoxinA intradetrusor injections for NDO [33]. 
In view of the rather sparse body of literature in contrast to the many 
unclarified aspects on distant effects of BoNT/A after injection treatments 
further investigations on this topic are indicated to improve the knowledge 
and patient safety regarding side effects of one of the most potent 
neurotoxins, that is frequently used in neurorehabilitation. 
Limitations of the study are: A) Focus on resting state HRV investigations 
only. Assessment of cardiovascular parameters under functional tasks such 
as tilt or exercise might have revealed different results. B) Investigation of 
single treatment only. No conclusions possible on the effect of repeated 
injections which might have altered the outcome of HRV measurements, 
specifically if performed at short intervals, i.e. ≤3 months. C) Post-treatment 
assessment of onabotulinumtoxinA effects on HRV at only two time points. 
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Figure 5-5 Low frequency/high frequency (LF/HF) ratio and very low frequency spectrum (VLF, 
in ms2) during the four consecutive visits for the control (blue bars) and the neurogenic detrusor 
overactivity (NDO, grey bars) group. 
 
In conclusion, this is the first study assessing the effects of 
onabotulinumtoxinA intradetrusor injections on autonomic cardiac function 
including 4 visits (two before and two after treatment) to control for natural 
fluctuations in HRV and using a healthy control group. 
Our findings indicate that onabotulinumtoxinA intradetrusor injections (300 
units Botox®) do not affect the resting autonomic nervous system control of 
cardiac function. This is highly relevant in regard to treatment of DO in 
patients with altered autonomic cardiac control and might influence the 
choice of treatment in regard to alternative treatments with systemic side 
effects on the heart [34]. Studies including HRV measurements under 
physical stress and after repeated onabotulinumtoxinA intradetrusor 
injections are desirable future tasks.  
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ABSTRACT 
Purpose of review: LUTS related to benign prostatic hyperplasia (BPH) 
affects a large number of male patients from 45 years onward, increasing 
with age. Routine medical treatment is mainly limited to plant extracts, a-
blockers, and 5-areductase inhibitors. Although all types of drug have a 
proven efficacy, they often do not sufficiently treat all aspects of LUTS 
related to BPH. Thus, there is a need for alternatives. Intraprostatic 
injections with BoNT/A seem to be a promising alternative. The purpose of 
this review is to summarize the most recent findings from basic science and 
clinical studies in relation to BoNT/A application in BPH-related LUTS, 
thereby providing insight into the putative mechanism of action, the rationale 
for the use of BoNT/A in BPH-related LUTS, and the clinical outcomes. 
 
Recent findings: There is some evidence that BoNT/A intraprostatic 
injections affect both, the static and dynamic component of BPH-related 
LUTS by reducing the prostate volume and by downregulation of α-1A-
adrenoreceptors. Clinical trials demonstrated an easy and minimally invasive 
intraprostatic application of BoNT/A with a favourable safety profile. Efficacy 
seems to be good with significant improvements for several months in 
symptoms, urinary flow rate and reduction in postvoid residual, prostate 
volume, and also prostate-specific antigen in some studies. 
 
Summary: BoNT/A seems to be a promising alternative in the treatment of 
BPH-related LUTS with a good tolerance and safety profile. However, the 
level of evidence is still low and further randomized controlled studies are 
mandatory.   
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INTRODUCTION 
BoNT/A, long been used by neurologists for the treatment of focal spasticity 
of striated skeletal muscles, has been introduced into the field of urology in 
1988 for the treatment of Detrusor- Sphincter-Dyssynergia [1]. In 2000, the 
first BoNT/A application in the smooth detrusor muscle in patients with NDO 
was described [2], followed in 2003 by the first results on the injection of 
BoNT/A into the prostate gland for the treatment of benign prostate 
hyperplasia (BPH) [3]. 
BoNT/A is a 150-kDa molecule, consisting of a heavy and a light chain. The 
known mechanism of action on striated skeletal muscles is the inhibition of 
acetylcholine release at motoric axon terminals [4, 5]. Thus, it causes a 
flaccid muscle paralysis, which is however of limited duration (months) due 
to resprouting of the axon terminals. Therefore, regular reinjection becomes 
necessary [4]. 
Basic research on the mechanism of action of BoNT/A in the human and 
animal urinary bladder rapidly provided evidence of additional BoNT/A 
effects, including modulation of urothelial and suburothelial receptor 
expression and neurotransmitter release [6]. 
Recent research on BoNT/A injections into the prostate revealed further 
mechanisms of action of BoNT/A and reported promising results for the 
therapy of LUTS due to BPH (LUTS / BPH). 
This review summarizes and highlights the most recent findings in basic and 
clinical research on the use of BoNT/A for LUTS / BPH. 
 
BASIC SCIENCE AND PROPOSED MECHANISM OF ACTION 
BPH-related LUTS are commonly characterized by a static component 
related to prostate overgrowth, and by a dynamic component related to an 
increase in bladder neck / prostatic / urethral smooth muscle cells (SMC) 
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contractile tone. Current pharmacological treatment options target each 
component separately. Indeed, 5-α-reductase inhibitors (5-ARI) cause 
prostate tissue shrinkage, thereby targeting the static component, while 
prostatic / urethral SMC relaxation is achieved by α-1-adrenergic receptor 
blockers. 
Prostatic SMC tone is mainly controlled by sympathetic innervation while 
prostate size is under both sympathetic and parasympathetic innervation 
influences [7]. As BoNT/A could act on both sympathetic and 
parasympathetic innervation [8], it makes sense to investigate the use of 
BoNT/A to impact both static and dynamic components of LUTS / BPH. 
However, preclinical studies supporting such effects are scarce.  
 
Effects of botulinum neurotoxin type A on the static component of 
benign prostatic hyperplasia-related lower urinary tract symptoms 
Most of the animal studies have provided evidence that intraprostatic 
BoNT/A toxin injections induce prostate size reduction in animals [9-13]. 
Silva et al. [13] performed intraprostatic injections of saline or 10 units 
onabotulinumtoxinA in adult male Wistar rats, and reported a significant 30% 
lower prostate weight 1 week after intraprostatic onabotulinumtoxinA 
injections compared to vehicle injections. Nishiyama et al. [12] also reported 
a significant lower prostate weight of, respectively, 36 and 22% at 1 and 4 
weeks after intraprostatic injection of a newly purified neurotoxin issued from 
BoNT/A (when compared to saline injection). 
The main concern with these preclinical data is the fact that they were 
conducted in normal rats. To date, the only published work performed in an 
experimental model of BPH in dogs does not report any significant effect of 
BoNT/A on prostate weight [14]. Nevertheless, these results need to be 
interpreted cautiously since they were obtained from only two animals in 
each experimental group. 
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Therefore, there is a need for more preclinical data to better investigate the 
effects of intraprostatic BoNT/A on prostate size in an experimental model of 
BPH. 
 
Mechanisms of action of botulinum neurotoxin type A on the 
static component of benign prostatic hyperplasia-related lower 
urinary tract symptoms 
The best characterized mechanism of action of BoNT/A induced reduction of 
prostate volume is the promotion of apoptosis that has been described in 
both humans [15] and animals [9, 10, 12-14]. 
Silva et al. [13] reported that apoptosis rate is clearly enhanced in adult rat 
prostate 1 week following 10 units intraprostatic onabotulinumtoxinA 
injection. Interestingly, this study showed that parasympathetic denervation 
may not participate to this proapoptotic effect while sympathetic innervation 
restoration by phenylephrine reduced apoptosis rate by 60%. Prostate 
atrophy [9, 11, 12, 14, 16] and decreased proliferation rate [9] have also 
been identified in rat and dog prostates treated with BoNT/A. Indeed, using a 
purified BoNT/A, Nishiyama et al. [12] observed histologically a partial 
atrophy of the prostate gland 1 week following intraprostatic injection in rats. 
Such an atrophy characterized by acini dilation and epithelial cells flattening 
was generalized to all parts of the prostate 4 weeks following injection. 
However, in human prostate, no sign of prostate atrophy could be identified 
following intraprostatic BoNT/A injection [15]. 
It is therefore likely that intraprostatic BoNT/A-induced prostate tissue 
shrinkage involves the enhancement of apoptosis rate. However, the 
possible involvement of decreased proliferation rate and/or tissue atrophy in 
the beneficial effects of intraprostatic BoNT/A still need to be confirmed in 
human BPH tissue. 
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Table 6-1 Injection techniques and protocols of different studies on intraprostatic botulinum 
toxin A injections for benign prostatic hyperplasia-related lower urinary tract symptoms 
Study 
Injection 
route / 
guidance 
tool 
Needle 
size 
No. of 
injections 
Dose [units] 
/ product / 
dilution 
[units/ml] 
Anaes-
thesia 
Antibiotic 
prophylaxis 
Maria et 
al. 2003 
[3] 
Trans-
perineal / 
TRUS 
22 G, 
9 cm 
2 
(1 per lobe à 2 
ml) 
200 / Botox® 
/ 50 
none n/a 
Chuang 
et al. 2005 
[15] 
Trans-
perineal / 
TRUS 
21 G, 
20 cm 
2 
(1 per lobe à 2 
ml) 
100 / Botox® 
/ 25 
i.v. 
sedation 
with 50 
mg 
propofol 
Cafazolin 1 
g i.v. 
perioperativ
e 
Kuo 2005 
[17] 
Trans-
urethral / 
cystoscope 
23 G 10 
200 / Botox® 
/ 10 
Light i.v. 
general 
anaesthe
sia 
7 days post 
treatment 
antibiotic 
prophylaxis 
Chuang 
et al. 2006 
[18] 
Trans-
perineal / 
TRUS 
21 G, 
15 or 20 
cm 
2 for PV < 30 ml 
(1 per lobe à 2 
ml), 
4 for PV > 30 ml 
(2 per lobe à 2 
ml) 
100 for PV < 
30 ml, 200 for 
PV > 30 ml / 
Botox® / 25 
i.v. 
sedation 
for first 
20 cases 
only, 
none 
thereafter 
n/a 
Park et al. 
2006 [19] 
Trans-
perineal / 
TRUS 
22 G, 
15 cm 
2 
(1 per lobe) 
100 for PV < 
30 ml, 200 for 
PV between 
30-80 ml, 300 
for PV > 80 
ml / Botox® / 
25 for PV < 
30 ml, 33.3 
for PV > 30 
ml 
none n/a 
Silva et 
al. 2008 
[20] 
Transrectal / 
TRUS 
21 G, 
20 cm 
4 
(2 per lobe à 2 
ml) 
200 / Botox® 
/ 25 
none 
ciprofloxacin 
500 mg bid 
for 7 days 
post 
treatment 
Brisinda 
et al. 2009 
[21] 
Trans-
perineal / 
TRUS 
22 G, 
9 cm 
2 
(1 per lobe à 2 
ml) 
200 / Botox® 
/ 50 
none n/a 
Kuo et 
Liu 2009 
[22] 
Trans-
perineal / 
TRUS 
n.a. 
2-3 
(1 per lobe + 1 
additional in 
median lobe if 
applicable) 
200-600 / 
Botox® / n/a 
Local or 
light i.v. 
general 
anaesthe
sia 
Ciproxin 1 g 
daily for 3 
days 
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Study 
Injection 
route / 
guidance 
tool 
Needle 
size 
No. of 
injections 
Dose [units] 
/ product / 
dilution 
[units/ml] 
Anaes-
thesia 
Antibiotic 
prophylaxis 
Silva et 
al. 2009 
[23] 
Transrectal / 
TRUS 
21 G, 
20 cm 
4 
(2 per lobe à 2 
ml) 
200 / Botox® 
/ 25 
none 
ciprofloxacin 
500 mg bid 
for 7 days 
post 
treatment 
Nikoobak
ht et al. 
2010 [24] 
Trans-
perineal / 
TRUS 
20 G 
2 for PV < 30 ml 
(1 per lobe à 2 
ml), 
4 for PV > 30 ml 
(2 per lobe à 2 
ml) 
300 for PV < 
30 ml, 600 for 
PV > 30 ml / 
Dysport® / 75 
local 
Cefazoline 
1g i.v. 
pretreatment 
and 
ciprofloxacin 
500 mg bid 
for 7 days 
post 
treatment 
b.i.d. (lat. bis in die) twice daily, n/a not available, PV prostate volume, TRUS transrectal ultrasound. 
 
Effects of botulinum neurotoxin type A on the dynamic component of 
benign prostatic hyperplasia-related lower urinary tract symptoms 
Lin et al. [11] reported the consequences of intraprostatic BoNT/A injections 
on prostatic / urethral SMC tone. In dogs, while intraprostatic injection of 100 
units onabotulinumtoxinA did not have any effect, 200 units reduced both in-
vitro prostate strips contractile responses to KCl, phenylephrine and 
electrostimulation, and in-vivo urethral pressor responses to i.v. 
norepinephrine [11]. It is to be noted that these experiments have been 
performed in dogs without prostate enlargement and that the effects of 
intraprostatic BoNT/A on prostatic / urethral SMC reactivity in an 
experimental model of BPH has not been reported to date. 
 
Mechanisms of action of botulinum neurotoxin type A on the dynamic 
component of benign prostatic hyperplasia-related lower urinary tract 
symptoms 
It has been reported that intraprostatic onabotulinumtoxinA down regulates 
the expression of α-1A-adrenoreceptor within rat prostate [9]. Since an 
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overall nine-fold increase in α-1A-adrenoreceptor has been observed in BPH 
compared with normal prostate [25], and α-1A-adrenoreceptors antagonists 
are successfully used to relieve prostatic / urethral obstruction associated 
with increased SMC contractile tone in BPH, the downregulation of prostatic 
α-1A-adrenoreceptors expression following intraprostatic BoNT/A injection 
[9] represents a strong rationale for using such a treatment for symptomatic 
BPH. This is further supported by Lin et al. [11] who demonstrated that, in 
dogs, intraprostatic 200 units onabotulinumtoxinA injection reduced the 
contractile activity of the prostate when observed 1 month after injection. In 
this study, it was suggested that two mechanisms could be responsible for 
such an effect: an impaired release of norepinephrine from adrenergic 
nerves and an impaired contractile machinery of stromal SMC. Prostate 
SMC vacuolization was observed and constitute a plausible explanation for 
the in-vitro decreased contractile response of prostate tissue to KCl. 
However, it is still needed to determine whether this effect lasts over time or 
constitutes an irreversible cellular toxic effect. Interestingly, it has also been 
demonstrated that the cleavage of SNAP-25 (a component of the SNARE 
complex) by BoNT/A light chain increased outwards potassium currents 
channels in oesophageal SMC [26]. This effect would tend to hyperpolarize 
the membrane and thereby decrease smooth muscle tone, since potassium 
channels constitute an important component of SMC contractile machinery. 
Studies are however needed to identify such an effect in prostate SMC.  
 
 FINDINGS FROM CLINICAL STUDIES: FROM TECHNIQUE TO 
INDICATIONS 
In patients, intraprostatic BoNT/A injections exert beneficial effects on BPH-
related bladder dysfunction that are linked to prostatic urethral obstruction 
relief [reduction of the International Prostate Symptom Score (IPSS) voiding 
symptoms component], but also to bladder dysfunction by itself (reduction of 
IPSS storage symptoms component). Indeed, the decrease in storage 
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symptoms component of IPSS accounts for 20–55% of total IPSS reduction 
following intraprostatic BoNT/A injection [19, 27]. 
Three formulations of BoNT/A are currently commercially available, namely 
Botox® (Allergan, Irvine, California, USA), Dysport® (Ipsen, Paris, France), 
and Xeomin® (Merz, Frankfurt am Main, Germany). They mainly differ in 
their envelope proteins covering the BoNT/A molecule and in the application 
dosage. None of them is yet licensed for the treatment of LUTS or BPH. 
Thus, application of BoNT/A for LUTS / BPH remains off-label use. 
 
Technique and dosage 
In most studies a transperineal injection route with transrectal ultrasound 
guidance has been described (Table 6-1), but transrectal and transurethral 
application routes have been also used [17, 23, 24]. Usually a 20– 22G 
needle is used to perform one to two injections per lobe either without or 
under local or light general anaesthesia. A total of 200U Botox® in different 
dilutions are most frequently used, although there is no rationale for this, as 
dose finding studies are still missing. 
 
Efficacy 
The most frequently used outcome parameters to evaluate the efficacy of 
BoNT/A intraprostatic injections on LUTS / BPH are the IPSS or the 
American Urological Association Symptom Index (AUA-SI) (Table 6-2), QoL-
Index (QoL-I), Qmax, prostate volume, PVRV and serum levels of prostate-
specific antigen (PSA) (Table 6-2). 
The first and still only RCT on the efficacy of BoNT/A for LUTS / BPH was 
published by Maria et al. in 2003 [3]. This trial investigated 30 50–80-year-
old patients with moderate to severe BPH symptoms (Table 6-3). Patients 
were either injected with 200 units onabotulinumtoxinA or saline. AUA-SI, 
Qmax, prostate volume, serum PSA level, and PVRV were evaluated at 
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baseline, 1, 2, 6, and 12 months after injection with unblinding after 2 
months [3]. BoNT/A injections demonstrated significant improvements in all 
study parameters at 1 and 2 months post-treatment (65% improvement in 
AUA-SI and 51% decrease of serum PSA) (Table 6-2). In contrast, placebo 
did not show any differences to baseline, which is remarkable as placebo 
usually shows some effect that can reach up to 30% in randomized 
controlled trials using a-blockers for BPH [28, 29]. Follow-up at 6 and 12 
months demonstrated persistent efficacy up to 12 months in all parameters 
(Table 6-2). This study represents the starting point of human studies. 
Similar results in a similar study population were reported by Brisinda et al. 
in 2009 [21] (Table 6-3). In a prospective open-label study, 77 patients 
received 200 units onabotulinumtoxinA. At 1 and 2 months AUA-SI, Qmax, 
prostate volume, serum PSA level, and PVRV were significantly improved. 
Retreatments with 200 units were possible, if patients reported no 
improvements. After the first treatment 71% of patients reported significant 
improvements. The results remained stable up to 30 months [21]. However, 
43 reinjections were performed during that time. 
In 2006, Chuang et al. [18] reported on the effect of a prostate size-related 
onabotulinumtoxinA dosing (100 units for <30 ml and 200 units for >30 ml) in 
41 BPH-patients who failed treatment with 5-ARI and / or a-blocker, (Table 
6-1, Table 6-3). Significant improvements were observed in IPSS, QoL-I, 
Qmax, and prostate volume up to 12 months with slightly greater changes of 
parameters in the 200 units group [18] (Table 6-2). This later observation 
might be due to the fact that 200 units were used in larger prostates, which 
provides a larger impact area and a larger margin for improvements. PVRV 
showed significant improvements only at 3 months in the 100 units group 
and at 1, 2, and 3 months in the 200 units group [18]. 
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Table 6-2 Efficacy results of different studies on intraprostatic botulinum neurotoxin A 
injections for benign prostatic hyperplasia-related lower urinary tract symptoms 
S
tu
d
y
 
Time 
after 
BoNT/A 
injection 
[months] 
No. of 
patients 
improved / 
treated 
IPSS / 
AUA-SI: 
BL ➔ FU 
(p-value) 
Qmax 
[ml/s]: 
BL ➔ FU 
(p-value) 
PVRV 
[ml]: 
BL ➔ FU 
(p-value) 
PV [ml]: 
BL ➔ FU 
(p-value) 
QoL-I: 
BL ➔ FU 
(p-value) 
Serum 
PSA 
[ng/ml]: 
BL ➔ FU 
(p-value) 
M
a
ri
a
 e
t 
a
l.
 2
0
0
3
 [
3
] 
1 11 / 15 23.2 ➔ 
10.6 
(0.00001) 
8.1 ➔ 
14.9 
(0.00001) 
126.3 ➔ 
49.6 
(0.00001) 
52.6 ➔ 
23.8 
(0.00001) 
n/a 3.7 ➔ 2.1 
(0.00006) 
2 13 / 15 23.2 ➔ 
8.0 
(0.00001) 
8.1 ➔ 
15.4 
(0.00001) 
126.3 ➔ 
21.0 
(0.00001) 
52.6 ➔ 
16.8 
(0.00001) 
n/a 3.7 ➔ 1.8 
(0.00001) 
6 17 / 19 23.2 ➔ 
9.1 
8.1 ➔ 
14.6 
126.3 ➔ 
24.2 
52.6 ➔ 
21.0 
n/a 3.7 ➔ 2.1 
12 17 / 19 23.2 ➔ 
8.9 
8.1 ➔ 
15.0 
126.3 ➔ 
24.0 
52.6 ➔ 
20.5 
n/a 3.7 ➔ 2.3 
C
h
u
a
n
g
 e
t 
a
l.
 2
0
0
5
 [
1
5
] 
1 16 / 16 18.8 ➔ 
8.9 
(0.0001) 
7.3 ➔ 
11.8 
(0.0001) 
67.7 ➔ 
25.1 
19.6 ➔ 
17.0 
(0.0014) 
3.8 ➔ 2.1 
(0.0001) 
0.8 ➔ 
0.72 
3 16 / 16 18.8 ➔ 
7.9 
(< 0.05) 
7.3 ➔ 
11.9 
(< 0.05) 
67.7 ➔ 
27.3 
19.6 ➔ 
16.7 
(< 0.05) 
3.8 ➔ 1.9 
(< 0.05) 
n/a 
6 16 / 16 18.8 ➔ 
7.4 
(< 0.05) 
7.3 ➔ 
12.5 
(< 0.05) 
67.7 ➔ 
26.4 
19.6 ➔ 
16.9 
(< 0.05) 
3.8 ➔ 1.8 
(< 0.05) 
n/a 
10 16 / 16 18.8 ➔ 
9.0 
(< 0.05) 
7.3 ➔ 
12.6 
(< 0.05) 
67.7 ➔ 
26.8 
19.6 ➔ 
16.4 
(< 0.05) 
3.8 ➔ 2.1 
(< 0.05) 
n/a 
K
u
o
 2
0
0
5
 [
1
7
] 3 7 / 10 n/a 7.6 ➔ 9.9 
(0.02) 
243.0 ➔ 
53.9 
(0.002) 
65.5 ➔ 
45.9 
(0.001) 
n/a n/a 
6 10 / 10 n/a 7.6 ➔ 
11.6 
(0.05) 
243.0 ➔ 
36.8 
(0.005) 
65.5 ➔ 
49.6 
(0.009) 
n/a n/a 
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S
tu
d
y
 
Time 
after 
BoNT/A 
injection 
[months] 
No. of 
patients 
improved / 
treated 
IPSS / 
AUA-SI: 
BL ➔ FU 
(p-value) 
Qmax 
[ml/s]: 
BL ➔ FU 
(p-value) 
PVRV 
[ml]: 
BL ➔ FU 
(p-value) 
PV [ml]: 
BL ➔ FU 
(p-value) 
QoL-I: 
BL ➔ FU 
(p-value) 
Serum 
PSA 
[ng/ml]: 
BL ➔ FU 
(p-value) 
C
h
u
a
n
g
 e
t 
a
l.
 2
0
0
6
 [
1
8
] 
1a 31 / 41 18.7 ➔ 
9.8 (0.001) 
19.3 ➔ 
9.5 
(0.001) 
7.9 ➔ 
12.0 
(0.001) 
7.0 ➔ 
10.3 
(0.001) 
64.1 ➔ 
35.7 
(0.3) 
161.7 ➔ 
45.2 
(0.02) 
21.1 ➔ 
18.0 
(0.001) 
54.3 ➔ 
46.3 
(0.001) 
3.9 ➔ 2.1 
(0.001) 
4.1 ➔ 2.0 
(0.001) 
n/a 
3a n/a 18.7 ➔ 
8.1 
(< 0.05) 
19.3 ➔ 
8.3 
(< 0.05) 
7.9 ➔ 
12.7 
(< 0.05) 
7.0 ➔ 9.8 
(< 0.05) 
64.1 ➔ 
24.1 
(< 0.05) 
161.7 ➔ 
37.6 
(< 0.05) 
21.1 ➔ 
18.0 
(< 0.05) 
54.3 ➔ 
45.0 
(< 0.05) 
3.9 ➔ 2.0 
(< 0.05) 
4.1 ➔ 2.2 
(< 0.05) 
n/a 
6a n/a 18.7 ➔ 
7.3 
(< 0.05) 
19.3 ➔ 
5.2 
(< 0.05) 
7.9 ➔ 
12.7 
(< 0.05) 
7.0 ➔ 
11.9 
(< 0.05) 
64.1 ➔ 
38.5 
161.7 ➔ 
45.5 
(< 0.05) 
21.1 ➔ 
17.5 
(< 0.05) 
54.3 ➔ 
45.3 
(< 0.05) 
3.9 ➔ 1.4 
(< 0.05) 
4.1 ➔ 1.8 
(< 0.05) 
n/a 
12a n/a 18.7 ➔ 
9.0 
(< 0.05) 
19.3 ➔ 
8.3 
(< 0.05) 
7.9 ➔ 
13.4 
(< 0.05) 
7.0 ➔ 
11.1 
(< 0.05) 
64.1 ➔ 
40.0 
161.7 ➔ 
93.6 
21.1 ➔ 
17.0 
(< 0.05) 
54.3 ➔ 
47.2 
(< 0.05) 
3.9 ➔ 1.8 
(< 0.05) 
4.1 ➔ 2.4 
(< 0.05) 
n/a 
P
a
rk
 e
t 
a
l.
 2
0
0
6
 [
1
9
] 
1b 18 / 26 
21 / 26 
24.2 ➔ 
18.5 
(0.001) 
24.3 ➔ 
17.5 
(0.001) 
9.1 ➔ 
10.1 
10.2 ➔ 
11.4 
108.1 ➔ 
82.2 
137.4 ➔ 
95.5 
47.9 ➔ 
44.1 
(0.001) 
46.6 ➔ 
42.4 
(0.009) 
4.6 ➔ 3.4 
5.0 ➔ 3.3 
n/a 
3 39 / 52 24.3 ➔ 
16.9 
9.6 ➔ 
11.1 
122.7 ➔ 
80.7 
47.2 ➔ 
41.0 
4.8 ➔ 3.2 n/a 
6c 21 / 23 24.0 ➔ 
14.7 
7.4 ➔ 9.4 108.7 ➔ 
59.4 
47.5 ➔ 
40.8 
4.7 ➔ 3.0 n/a 
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S
tu
d
y
 
Time 
after 
BoNT/A 
injection 
[months] 
No. of 
patients 
improved / 
treated 
IPSS / 
AUA-SI: 
BL ➔ FU 
(p-value) 
Qmax 
[ml/s]: 
BL ➔ FU 
(p-value) 
PVRV 
[ml]: 
BL ➔ FU 
(p-value) 
PV [ml]: 
BL ➔ FU 
(p-value) 
QoL-I: 
BL ➔ FU 
(p-value) 
Serum 
PSA 
[ng/ml]: 
BL ➔ FU 
(p-value) 
S
il
v
a
 e
t 
a
l.
 2
0
0
8
 [
2
0
] 1 16 / 21 n/a retention 
➔ 9.0 
retention 
➔ 80.0 
70.0 ➔ 
57.0 
(0.006) 
n/a 6.0 ➔ 5.8 
3 17 / 21 n/a retention 
➔ 10.3 
retention 
➔ 92.0 
70.0 ➔ 
47.0 
(< 0.05) 
n/a 6.0 ➔ 5.0 
(0.04) 
6c 9 / 10 n/a retention 
➔ 11.4 
retention 
➔ 66 
59.0 ➔ 
50.0 (0.02) 
n/a 6.5 ➔ 6.3 
B
ri
s
in
d
a
 e
t 
a
l.
 2
0
0
9
 [
2
1
] 
1 41 / 77 24.1 ➔ 
12.6 
(0.00001) 
8.6 ➔ 
13.1 (0.01) 
92.1 ➔ 
80.3 (0.01) 
54.1 ➔ 
47.2 
n/a 6.2 ➔ 4.8 
(0.03) 
2 55 / 77 24.1 ➔ 
8.7 
(0.00001) 
8.6 ➔ 
16.5 
(0.00001) 
92.1 ➔ 
40.6 
(0.002) 
54.1 ➔ 
30.9 
(0.00001) 
n/a 6.2 ➔ 3.0 
(0.00001) 
6 n/a / 77 24.1 ➔ 
10.4 
8.6 ➔ 
13.2 
92.1 ➔ 
34.3 
54.1 ➔ 
24.3 
n/a 6.2 ➔ 3.6 
12 n/a / 77 24.1 ➔ 
14.0 
8.6 ➔ 
11.4 
92.1 ➔ 
64.7 
54.1 ➔ 
32.0 
n/a 6.2 ➔ 4.1 
18 n/a / 77 24.1 ➔ 
9.2 
8.6 ➔ 
16.0 
92.1 ➔ 
30.0 
54.1 ➔ 
24.2 
n/a 6.2 ➔ 2.9 
24 n/a / 77 24.1 ➔ 
10.1 
8.6 ➔ 
15.0 
92.1 ➔ 
32.0 
54.1 ➔ 
27.1 
n/a 6.2 ➔ 2.6 
30 n/a / 77 24.1 ➔ 
11.1 
8.6 ➔ 
14.5 
92.1 ➔ 
27.1 
54.1 ➔ 
26.9 
n/a 6.2 ➔ 3.1 
K
u
o
 e
t 
L
iu
 2
0
0
9
 [
2
2
] 
6d n/a 16.5 ➔ 
11.1 
(< 0.05) 
18.2 ➔ 
9.2 
(< 0.05) 
9.4 ➔ 
10.5 
8.4 ➔ 
10.2 
(< 0.05) 
65.3 ➔ 
85.7 
92.7 ➔ 
102.2 
83.4 ➔ 
81.6 
89.7 ➔ 
79.8 
(< 0.05) 
3.57 ➔ 
2.93  
(< 0.05) 
4.11 ➔ 
2.22 
(< 0.05) 
5.74 ➔ 
3.89 
5.94 ➔ 
5.80 
12d n/a 16.5 ➔ 
9.4 
(< 0.05) 
18.2 ➔ 
8.9 
(< 0.05) 
9.4 ➔ 
10.7 
8.4 ➔ 
10.7 
(< 0.05) 
65.3 ➔ 
68.5 
92.7 ➔ 
113.7 
83.4 ➔ 
76.6 (< 
0.05) 
89.7 ➔ 
76.8 
(< 0.05) 
3.57 ➔ 
2.53 
4.11 ➔ 
2.04 
5.74 ➔ 
4.14 
5.94 ➔ 
3.87 
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Time 
after 
BoNT/A 
injection 
[months] 
No. of 
patients 
improved / 
treated 
IPSS / 
AUA-SI: 
BL ➔ FU 
(p-value) 
Qmax 
[ml/s]: 
BL ➔ FU 
(p-value) 
PVRV 
[ml]: 
BL ➔ FU 
(p-value) 
PV [ml]: 
BL ➔ FU 
(p-value) 
QoL-I: 
BL ➔ FU 
(p-value) 
Serum 
PSA 
[ng/ml]: 
BL ➔ FU 
(p-value) 
S
il
v
a
 e
t 
a
l.
 2
0
0
9
 [
2
3
] 
1 11 / 11 n/a retention 
➔ 11.3 
retention 
➔ 73.0 
82.2 ➔ 
68.7 
n/a 6.7 ➔ 6.6 
3 11 / 11 12.3 11.3 ➔ 
12.0 
73.0 ➔ 
82.0 
82.2 ➔ 
59.1 
3.3 6.7 ➔ 5.1 
6 11 / 11 12.3 ➔ 
10.0 
11.3 ➔ 
12.3 
73.0 ➔ 
55.0 
82.2 ➔ 
49.0 
3.3 ➔ 2.4 6.7 ➔ 5.1 
12 11 / 11 12.3 ➔ 
10.8 
11.3 ➔ 
11.4 
73.0 ➔ 
64.0 
82.2 ➔ 
63.8 
3.3 ➔ 3.0 6.7 ➔ 5.4 
18 11 / 11 12.3 ➔ 
11.3 
11.3 ➔ 
10.5 
73.0 ➔ 
58.0 
82.2 ➔ 
73.0 
3.3 ➔ 3.2 6.7 ➔ 5.9 
N
ik
o
o
b
a
k
h
t 
e
t 
a
l.
 2
0
1
0
 [
2
4
] 
1e n/a 16.2 ➔ 
9.9 
(0.004) 
19.7 ➔ 
10.2 
(< 0.001) 
6.5 ➔ 
12.7 
(0.005) 
6.3 ➔ 
12.6 
37.2 ➔ 
21.1 
50.7 ➔ 
25.0 
(< 0.001) 
 3.2 ➔ 2.3 
3.6 ➔ 2.4 
(< 0.001) 
 
6e n/a 16.2 ➔ 
9.0 
(0.001) 
19.7 ➔ 
7.8 
(< 0.001) 
6.5 ➔ 
14.2 
(0.001) 
6.3 ➔ 
13.6 
(< 0.001) 
37.2 ➔ 
20.5 
50.7 ➔ 
10.7 
(< 0.001) 
27.3 ➔ 
21.6 
(0.001) 
46.6 ➔ 
28.8 
(< 0.001) 
3.2 ➔ 1.8 
(0.001) 
3.6 ➔ 1.9 
(< 0.001) 
1.9 ➔ 1.4 
2.8 ➔ 1.8 
(0.036) 
12e n/a 16.2 ➔ 
9.1 
(0.003) 
19.7 ➔ 
8.4 
(< 0.001) 
6.5 ➔ 
13.2 
(0.002) 
6.3 ➔ 
14.0 
(< 0.001) 
37.2 ➔ 
16.1 
50.7 ➔ 
16.3 
(< 0.001) 
 3.2 ➔ 2.0 
(0.005) 
3.6 ➔ 1.9 
(< 0.001) 
 
AUA-SI American Urological Association Symptom Index, BL baseline, BoNT/A botulinum neurotoxin type A, 
FU follow-up, IPSS International Prostate Symptom Score, Qmax, maximum urinary flow rate, n/a not available, 
PSA prostate-specific antigen, PVRV postvoid residual volume, QoL-I quality of life index. P values indicate 
significance level in comparison to baseline values. 
a Outcome parameters are indicated for 100 (upper values) and 200 (lower values) units Botox® separately. 
b Outcome parameters are indicated for the BoNT/A group (upper values) and the BoNT/Aþa-blockers group 
(lower values) separately. 
c The indicated mean baseline values represent only those patients who participated in this follow-up. 
d Outcome parameters are indicated for the combined medication group (upper values) and the BoNT/A group 
(lower values) separately. 
e Outcome parameters are indicated for the group with prostate volume <30 ml (upper values) and the group 
with prostate volume >30 ml (lower values) separately. 
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The first results using Dysport on LUTS / BPH were recently reported by 
Nikoobakht et al. [24] in a prospective open-label study. A population of 72 
males was included using similar inclusion criteria as Maria et al. (Table 
6-3). Follow-up was 12 months with intermediate evaluation at 1 and 6 
months. IPSS, Qol-I, PVRV, and Qmax were evaluated at each follow-up visit. 
Serum PSA, prostate volume, urine analysis, and urine culture were 
evaluated at 6 months only [24]. All parameters significantly improved from 1 
up to 12 months in the whole study population with a magnitude of effect that 
is comparable to the one observed by Maria et al. (Table 6-2). Like Chuang 
et al. [18], Nikoobakht et al. [24] treated different prostate sizes with different 
dosages of BoNT/A (Table 6-1). Subgroup analysis showed again 
differences in the outcome analysis in means that BoNT/A was more 
efficient in patients with larger prostates regarding the reduction in prostate 
volume, PSA, and PVRV and the increase in Qmax (Table 6-2) [18, 24]. 
 
Special indications 
Several studies already investigated the use of BoNT/A for LUTS / BPH in 
special indications, like especially small or large prostates, poor surgical 
candidates, and as add-on treatment to α-blocker and 5-ARI. The findings 
are summarized below. 
 
Small prostates 
In a small population (n=16), Chuang et al. [15] reported the efficacy of 100 
units onabotulinumtoxinA as a second-line treatment following α-blocker 
therapy in patients with small prostate volumes (<30 ml) and a Qmax less 
than 12 ml/s (Table 6-3). IPSS, Qmax, prostate volume, and QoL-I were 
significantly improved from 1 up to 10 months (Table 6-2). Mean PVRV was 
markedly reduced but standard deviations were probably too large to reveal 
any significance. 
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Table 6-3 General characteristics of different studies on intraprostatic botulinum neurotoxin A 
injections for benign prostatic hyperplasia-related lower urinary tract symptoms 
Study 
No. of 
patients 
Mean age 
[years] ±SD 
(range) 
Patient characteristics / 
Inclusion criteria 
Control 
group or 
comparison 
group 
LoE 
Maria et 
al. 2003 
[3] 
30 
68.8 ±4.4 
(50-80) 
AUA-SI > 8, Qmax < 15 ml/s, 
voiding volume > 150 ml, 
enlarged PV on DRE 
placebo 1b 
Chuang 
et al. 2005 
[15] 
16 
66.3 ±2.8 
(n.a.) 
PV < 30 ml, Qmax < 12 ml/s, 
inadequate response to alpha-
blocker therapy for > 1 month 
none 3 
Kuo 2005 
[17] 
10 
75.2 ±9.7 
(48-92) 
Acute or chronic urinary 
retention, severely difficult 
urination, large PVRV, failure 
of treatment with finasteride 
and alpha-blocker for > 1 year, 
poor surgical candidates 
none 3 
Chuang 
et al. 2006 
[18] 
41 
69.1 ±7.1 
(n.a.) 
IPSS of ≥ 8, Qmax < 12 ml/s, 
inadequate response or failure 
to tolerate alpha-blockers 
and/or 5-ARI. All had a benign 
DRE and a PSA level of < 4 
ng/ml, or a PSA level of 4–10 
ng/ml but with a biopsy that 
showed no malignancy 
none 3 
Park et al. 
2006 [19] 
52 
66.4 ±8.3 
(45-84) 
Urinary obstruction symptoms 
as determined by the IPSS 
and an enlarged prostate 
gland on digital rectal 
examination. All patients were 
treated with an alpha-blocker 
with or without a 5-ARI at least 
one month before this study. 
BoNT/A + 
alpha-blockers 
3 
Silva et 
al. 2008 
[20] 
21 
80.0 ±2.0 
(65–92) 
High risk patients not suitable 
for prostate surgery, history of 
indwelling catheter for > 3 
months due to urinary 
retention refractory to alpha-
blocker. At time of inclusion 
none of patients was taking 5-
ARI or alpha-blocker. 
none 3 
Brisinda 
et al. 2009 
[21] 
77 
67.9 ±3.6 
(n/a) 
AUA-SI > 8, Qmax < 15 ml/s, 
minimum voided volume > 
150ml, enlarged prostate 
gland on DRE 
none 3 
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Study 
No. of 
patients 
Mean age 
[years] ±SD 
(range) 
Patient characteristics / 
Inclusion criteria 
Control 
group or 
comparison 
group 
LoE 
Kuo et 
Liu 2009 
[22] 
60 
74.9 ±8.3 
(n/a) 
IPSS > 8, combined 5-ARI and 
alpha-blocker treatment at full 
doses > 12months with 
symptom progression 
(occurrence of acute urinary 
retention or increased IPSS by 
> 4) or unsatisfactory 
therapeutic outcome 
(persistent difficult urination 
with either Qmax <12ml/s 
and/or PVRV > 100ml) 
Combined 
medical 
treatment (5-
ARI + alpha-
blocker) 
3 
Silva et 
al. 2009 
[23] 
11 
81.7 ±2.6 
(61-92) 
High risk patients not suitable 
for prostate surgery, history of 
indwelling catheter for > 3 
months due to urinary 
retention refractory to alpha-
blocker. At time of inclusion 
none of patients was taking 5-
ARI or alpha-blocker. 
none 3 
Nikoobak
ht et al. 
2010 [24] 
72 
63.5 ±8.5 
(49-80) 
Enlarged PV in DRE, serum 
PSA < 4ng/ml, IPSS > 8, Qmax 
< 12ml/s, and normal renal 
function tests. For serum PSA 
between 4 and 
10ng/ml, free PSA was 
measured and the patient was 
included if free PSA was within 
the normal range (i.e. 0.02–0.5 
ng/ml) 
none 3 
5-ARI 5-a-reductase inhibitor, AUA-SI American Urological Association Symptom Index, BoNT/A, 
botulinum neurotoxin type A; DRE, digital rectal examination, IPSS International Prostate Symptom 
Score, LoE level of evidence, QMAX maximum urinary flow rate; n/a, not available, PSA prostate-
specific antigen, PVRV postvoid residual volume. 
 
Poor surgical candidates for benign prostatic hyperplasia surgery 
Kuo [17] treated 10 patients with 200 units onabotulinumtoxinA who had 
severe obstruction but were poor candidates for surgery due to co-
morbidities (Table 6-3). Results were rated excellent, if spontaneous voiding 
occurred in patients with urinary retention or if patients had improvements in 
voiding pressure, Qmax, and PVRV of more than 25% from baseline values. 
At 6 months, eight of 10 patients had excellent results and two patients 
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showed improvement. Follow-up at 3 and 6 months demonstrated significant 
improvements in Qmax, PVRV, and prostate volume (Table 6-2). 
In a similar population of 21 males (poor surgical candidates with urinary 
retention and indwelling catheters), Silva et al. [20] reported 2008 about the 
short-term results of intraprostatic injections of 200 units 
onabotulinumtoxinA. At 3 months post injection, 17 of 21 patients were able 
to voluntarily empty their bladder with a Qmax of 10.3 mL/s and mean PVRV 
less than 100 mL (Table 6-2). Prostate volume decreased significantly from 
1 up to 6 months [20]. 
In 2009, Silva et al. [23] reported on the long-term results of a small 
subgroup (n=11) of their initial evaluation [20]. Follow-up was 18 months, 
and although IPSS, PVRV, prostate volume, QoL-I, and serum PSA seemed 
to slowly increase after 6 months, prostate volume remained still significantly 
below baseline values and patients remained on voluntary voiding up to 18 
months [23] (Table 6-2). A total of 200 units onabotulinumtoxinA seem to be 
a valuable alternative treatment for patients who are not suitable for surgery 
because of poor general condition. Especially the fact that indwelling 
catheters could be omitted after the treatment in most of the patients is of 
great value for the patient. 
 
Add-on treatment in patients with large prostates 
Park et al. [19] investigated in 52 patients with LUTS / BPH the effect of 
BoNT/A alone and in combination with α-blocker for 4 weeks. Both groups 
showed significant improvements in IPSS and prostate volume after 1 month 
with sustained effects up to 6 months in those patients who participated in 
the follow-up (Table 6-2). Qmax, PVRV, and QoL-I were not improved at any 
follow-up. The only difference in both groups was demonstrated for IPSS-5 
(weak stream) in favour of the BoNT/A and α-blocker group, which was 
interpreted as relative reinforcement of the adrenergic influence by the 
anticholinergic effect of BoNT/A [19]. 
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Kuo and Liu [22] investigated the effect of BoNT/A on LUTS / BPH in 
patients with ongoing but not sufficient treatment with α-blockers and 5-ARI 
combination therapy since more than 12 months (Table 6-3). Sixty patients 
were either assigned to receive 200 units onabotulinumtoxinA add-on 
intraprostatic injection or continued medical therapy (control group) [22]. 
Additional injections were allowed after 2 months with increasing doses up to 
600 units, if initial treatment results were not satisfactorily [22]. Although 
onabotulinumtoxinA treatment could significantly reduce IPSS, Qol-I, and 
prostate volume and increase Qmax at 6 months, no significant differences 
versus the control group were observed at 12 months regarding prostate 
volume, IPSS, QoL-I, Qmax, and PVRV. The only significant difference was 
observed regarding QoL-I at 6 and 12 months, showing a difference of small 
amplitude in favour of onabotulinumtoxinA treatment [22]. In regard to both, 
the study by Park et al. [19] and Kuo and Liu [22], add-on treatment with 
BoNT/A to α-blocker and / or 5-ARI treatment seems not to result in 
additional benefits. However, study design, patient number and power of 
both studies seem not appropriate to finally conclude on an add-on effect of 
BoNT/A. Future trials should probably include a run-in period and try to 
determine if previous medical treatment might influence responding rate. 
 
Adverse events 
Only very few and generally mild and self-limited adverse events were 
reported in some studies (Table 6-4). Adverse events that occurred were 
gross haematuria, urinary retention and acute prostatitis [15, 22, 24]. In 
some studies post-op indwelling catheter for up to 4 weeks were applied 
routinely [20, 23] (Table 6-4). Whether this is generally necessary remains 
questionable and requires further investigation. 
Although various treatment strategies for BPH may impact sexual 
dysfunction (ejaculatory and erectile disorders) [30], only one yet 
unpublished clinical trial has examined the effects of intraprostatic BoNT/A 
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on sexual function and reported a significant improvement of ejaculatory 
function without any change in erectile function [31]. Thus, further studies 
are needed to investigate the effects of intraprostatic BoNT/A on bladder 
function and to validate its safety on sexual function. 
 
Onset and duration of effect 
In summary of the above-mentioned 10 clinical studies [3, 15, 17-24], mean 
onset of action seems to be around 3.5 weeks (range 1–6 weeks) after 
injection. The mean duration seems to be 11.9 months (range 3–30 months). 
However, none of those studies was designed to evaluate the exact onset 
and duration of effect on LUTS after intraprostatic BoNT/A injection. In most 
studies onset and duration was dependent on the follow-up scheme. Some 
studies even performed early reinjections in patients with insufficient 
outcome after first injection [21, 22] thereby influencing the study outcome 
and analysis of effect duration. Thus, studies investigating the exact start 
and duration of effect are lacking. This is important to be able to estimate 
cost-effectiveness. In relation to this, dose finding studies, investigations on 
repeated injections, and studies specifically investigating the impact of the 
treatment on the QoL using adequate QoL-questionnaires are also missing. 
 
Ongoing studies 
There are currently three active but not yet recruiting phase II studies 
registered at ClinicalTrials.gov investigating efficacy and / or safety of 
BoNT/A intraprostatic injections for the treatment of BPH-related LUTS. One 
is a randomized dose comparison study and two are randomized placebo-
controlled trials. Interestingly, in one study (NCT00284518), the injection 
route of BoNT/A has been changed from transperineal to transrectal, 
showing that there is still an ongoing discussion about the best route of 
application. There is also a phase II randomized active control study 
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investigating intraprostatic BoNT/A injections for chronic prostatitis and / or 
chronic pelvic pain syndrome. Last but not least, there is a randomized, 
placebo-controlled phase II study currently recruiting that investigates the 
influence of intraprostatic BoNT/A injections on semen quality. 
 
Table 6-4 Adverse events in different studies on intraprostatic botulinum neurotoxin A injections 
for benign prostatic hyperplasia-related lower urinary tract symptoms 
Study / Author Adverse events 
Catheterization after 
injection 
Maria et al. 2003 [3] none n/a 
Chuang et al. 2005 [15] 
Transient and mild dysuria and 
haematuria in 3 patients during 
the first 24h post treatment 
For 1 week in 1 patient with 
indwelling catheter 
Kuo 2005 [17] none 
3 patients needed ISC for 2 
weeks post-op 
Chuang et al. 2006 [18] none 
Only in patients with 
indwelling catheter 
Park et al. 2006 [19] none n/a 
Silva et al. 2008 [20] none 
Foley catheter for 1 month in 
all patients 
Brisinda et al. 2009 [21] none n/a 
Kuo et Liu 2009 [22] 
In totally 50 injections, transient 
acute urinary retention occurred 
after three(6%),gross haematuria 
after seven(14%)and acute 
prostatitis after one(2%) injection 
n/a 
Silva et al. 2009 [23] none 
Foley catheter for 1 month in 
all patients 
Nikoobakht et al. 2010 
[24] 
Self-limited gross hematuria in 3 
patients (4.2%) 
n/a 
ISC intermittent self-catheterization 
 
CONCLUSION 
There is a rationale for the use of intraprostatic BoNT/A to impact both static 
and dynamic components of LUTS / BPH. Further preclinical data are 
needed to better investigate these effects and the exact mechanisms of 
action of BoNT/A within the prostate. Clinical studies show very promising 
Botulinum neurotoxin A for treatment of male lower urinary tract symptoms  
164 
results with significant symptom relief in the majority of treated patients. The 
application technique is easily feasible and seems to have a low-risk profile 
with only rare or mild adverse events. However, the level of evidence is still 
very low and in view of that BoNT/A intraprostatic injections are still off-label 
use, no general recommendation for the BPH population can be given. 
There is still very little information on exact onset and duration of effect, on 
the dose–effect relation, on changes in QoL, on comparison to other or 
placebo treatment, and on adverse events on sexual function and semen 
quality. The results of ongoing controlled trials have to be awaited to 
increase the level of recommendation. 
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ABSTRACT 
Purpose: We evaluated the long-term safety and efficacy of an adjustable 
continence device (ACT® or ProACT®) in male and female patients with 
neurogenic SUI (nSUI). 
 
Materials and Methods: Data on patients consecutively treated with 
implantation of an adjustable continence device due to nSUI were reviewed 
from the start of our experience to the current 4-year follow-up. 
 
Results: We reviewed data on 13 male and 24 female patients with nSUI 
due to different forms of pelvic nerve or spinal cord lesions. Mean ± SD age 
at implantation was 46.2 ± 17.4 years. Of the patients 92% performed ISC. 
The device was implanted bilaterally using general and local anesthesia in 
16.2% and 83.8% of cases, respectively. From before implantation to 48-
month follow-up the mean number of urinary incontinence episodes 
decreased from 6.1 ± 2.4 to 2.8 ± 3.1 and the mean number of pads used 
per 24 hours decreased from 4.2 ± 2.7 to 2.2 ± 2.2. Of the patients 54.5% 
indicated more than 50% improvement of SUI symptoms after 48 months, of 
whom 38.9% indicated complete continence. Adverse events included 
erosion / migration, device infection or failure, implantation site pain, bladder 
stone formation and difficult ISC. 
 
Conclusions: Implantation of the ACT® / ProACT® device in patients with 
nSUI is minimally invasive and safe. It can significantly improve nSUI in the 
long term. Thus, it might be a reasonable option for patients who are not 
willing, not suitable or not yet ready for more invasive surgery, such as AUS 
or fascial suspension sling placement.  
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INTRODUCTION 
Neurogenic lesions, e.g. SCI or peripheral lesions of nerve fibers innervating 
the LUT, can cause nSUI due to sphincter and / or bladder neck 
insufficiency. Managing neurogenic sphincter deficiency remains a 
therapeutic challenge since to our knowledge there is no available medical 
treatment. Moreover, most patients must perform ISC to empty the bladder 
and are at higher risk for complications of any prosthetic implant used for 
continence [1]. 
The current, most frequently used surgical options for nSUI are an AUS [2, 
3] or an obstructing fascial sling [4-6]. However, these procedures require 
open abdominal and pelvic surgery using general anesthesia and do not 
provide the opportunity for postoperative adjustment. Some patients do not 
desire or feel uncomfortable with an AUS or they do not have the dexterity to 
use such an implant. Others might not be good candidates for more invasive 
surgery or they might need additional continence support after previous 
surgery, i.e. fascial sling placement. Moreover, in patients with nSUI it would 
be desirable to have an adjustable continence device that allows for 
adaptation in regard to changes in continence function without undergoing 
further surgery or changing the implant. 
The ACT® / ProACT® device offers such adjustable continence support for 
male [7-10] and female [11] patients. The device consists of 2 balloons that 
are implanted in minimally invasive fashion on each side of the urethra. 
Small subcutaneous titanium ports allow refilling or deflation at any time. 
Good mid-term results with a 52% to 80% continence rate were achieved in 
non-neurogenic SUI populations with sphincter deficiency [7, 9-12]. 
However, long-term results of more than 2 years have been reported only for 
single cases. 
There is no available information on using ACT® / ProACT® for nSUI. Thus, 
to our knowledge we retrospectively investigated for the first time the safety 
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and efficacy of the ACT® / ProACT® device in male and female patients with 
nSUI.  
 
PATIENTS AND METHODS 
Data on patients who were consecutively treated at our clinic (Department of 
Urology, Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris, 
University Paris VI) with implantation of the ACT® or ProACT® adjustable 
continence device due to nSUI were reviewed from the start of our 
experience up to the current 4-year follow-up to determine long-term results. 
The frequency of ISC, urinary incontinence episodes (UIEs) and pad use 
was evaluated from follow-up data and compared to preoperative values. In 
addition, balloon volume, operative and postoperative adverse events, and 
patient reported treatment outcomes were evaluated from follow-up data. 
Statistical analysis was performed as applicable between pre-implantation 
and follow-up data using the Wilcoxon signed rank test with SPSS® 17.0. 
 
RESULTS 
A total of 13 male and 24 female patients with nSUI were treated with ACT® 
/ ProACT® at our clinic. Mean ± SD age at implantation was 46.2 ± 17.4 
years. Of the 37 patients 19 had paraplegia at Th3 or below, 7 had spina 
bifida, 4 had cauda equina syndrome and 1 each had poliomyelitis, 
syringomyelitis, lumbar stenosis, multiple sclerosis, tetraplegia, pelvic 
polytrauma and peripheral nerve lesion following major pelvic surgery, each 
with subsequent nSUI (Table 7-1). 
A total of 14 patients received 1 or more previous urological treatments for 
nSUI, 21 underwent or were currently being treated for concomitant NDO 
and 5 received previous urological treatment for reasons other than nSUI or 
NDO (Table 7-1). Before implantation, the micturition mode was ISC and 
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voluntary micturition in 34 and 3 patients, respectively. Additionally, 6 male 
patients used a condom catheter between ISC. 
Urodynamic data before implantation revealed a mean maximum cystometric 
capacity of 424 ± 147 ml, a mean maximum detrusor storage pressure of 
20.2 ± 11.3 cmH2O and a mean bladder compliance of 37.7 ± 21.8 
ml/cmH2O. Mean urethral closure pressure was 22.6 ± 13.2 cmH2O. DO or 
poor bladder compliance was not detected on pre-implantation cystometry, 
which was a prerequisite for the procedure. SUI was noted in each patient 
during pelvic examination. 
All implantations were performed bilaterally under cystoscopic and 
fluoroscopic control by the same surgeon (ECK). All patients received 
prophylactic antibiotics at surgery. The detailed implantation technique was 
described previously [9-11]. The mean volume injected during implantation 
was 2.0 ± 0.3 and 1.9 ± 0.4 ml for the right and the left balloon, respectively. 
Mean operative time was 25 ± 2.4 minutes. 
In 6 patients the procedure was performed under general anesthesia. All 
other patients tolerated implantation well under local anesthesia. Mean 
hospital stay was 1.5 days (range 1 to 2). However, this reflects an 
administrative rather than a medical reason. 
During surgery or the postoperative hospital stay, a labial / scrotal 
hematoma developed in 2 patients, which was surgically removed in 1. In 3 
patients small intraoperative urethral perforations resulted in immediate 
balloon repositioning on the side of the perforation and Foley catheter 
placement for 24 hours. 
Follow-up was performed at 3, 6, 12, 24 and 48 months. Due to incomplete 
and missing data, 1 patient data set was excluded from further analysis. 
Thus, the data sets of 36 patients were used for follow-up analysis. By 48 
months another patient was lost to follow-up and 1 each had died of 
esophageal cancer and cardiac arrest. Thus, at 48-month follow-up 33 
patient data sets were available. 
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Table 7-1 Patient characteristics, previous and current urological treatments 
Pt No. – 
Gender – 
Age [years] at 
implantation 
Neurologic lesion 
(cause) 
ASIA 
impairment 
scale/level 
of lesion 
Previous urological 
treatments 
Current 
urological 
treatments 
1 – F – 72 Poliomyelitis  none none 
2 – F – 41 
Paraplegia 
(infection) 
A/Th9 
Ileum bladder augmentation, 
suburethral sling from muscel 
fascia 
oral oxybutynin 
3 – F – 33 
Paraplegia 
(vascular) 
-/L5 none oral oxybutynin 
4 – F – 36 Paraplegia (trauma) A/Th10 
Botulinum toxin intradetrusor 
injections, Ileum bladder 
augmentation, trans vaginal 
tape 
none 
5 – M – 25 Syringomyelitis  none oral oxybutynin 
6 – M – 42 Spina bifida  Ileum bladder augmentation none 
7 – F – 49 Spina Bifida  Vesico-ureteral-reflux repair none 
8 – M – 69 
Cauda-Equina-
Syndrome (t) 
 
Urethral stent, sacral 
neuromodulation 
oral oxybutynin 
9 – F – 55 Paraplegia (trauma) A/Th12 trans vaginal tape none 
10 – F – 72 
Cauda-Equina-
Syndrome 
(Ca surgery) 
 sacral neuromodulation none 
11 – F – 37 
Peripheral nerve 
lesion following 
major pelvic surgery 
 sacral neuromodulation none 
12 – M – 30 Spina bifida  Ileum bladder augmentation none 
13 – F – 68 Lumbar stenosis  
Ileum bladder augmentation, 
trans vaginal tape 
oral oxybutynin 
14 – F – 46 Multiple sclerosis  
Ileum bladder augmentation + 
continent urinary diversion, 
suburethral sling from muscle 
fascia 
oral oxybutynin 
15 - F – 32 Spina bifida  none none 
16 – F – 30 Paraplegia (trauma) A/Th12 none oral oxybutynin 
17 – F – 26 Pelvic polytrauma  
AMS800 (’88 – ’05), Ileum 
bladder augmentation, vesico-
ureteral-reflux repair 
none 
18 – M – 62 
Paraplegia 
(Ca surgery) 
A/L1 Radical prostaectomy oral oybutynin 
19 – M – 55 
Cauda-Equina-
Syndrome 
 Orchiectomy none 
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Pt No. – 
Gender – 
Age [years] at 
implantation 
Neurologic lesion 
(cause) 
ASIA 
impairment 
scale/level 
of lesion 
Previous urological 
treatments 
Current 
urological 
treatments 
20 – M – 53 Paraplegia (trauma) A/Th11 
Ileum bladder augmentation, 
sphincterotomy 
oral oxybutynin 
21 – F – 58 Paraplegia -/Th12 
Promontofixation, bladder 
neck closure 
oral oxybutynin 
22 – F – 14 Spina bifida  
Sigmoid cystoplasty, bladder 
neck reconstruction 
none 
23 – F – 46 Paraplegia (trauma) A/Th11 
Trans vaginal tape, 
hysterectomy, 
promontofixation, Ileum 
bladder augmentation + 
Mitrofanoff catherizable stoma 
oral oxybutynin, 
intradetrusor 
injections with 
botulinum toxin 
24 – F – 56 Paraplegia A/Th12 
Ileum bladder augmentation + 
Mitrofanoff catherizable stoma, 
trans vaginal tape 
oral oxybutynin 
25 – F – 64 
Paraplagia 
(Ca surgery) 
C/Th3 none none 
26 – F – 27 Paraplegia (trauma) A/L1 
suburethral sling from muscle 
fascia 
none 
27 – F – 83 Spina bifida  none none 
8 – F – 76 
Cauda-Equina-
Syndrome 
(Ca surgery) 
 none none 
29 – M – 36 Paraplegia (trauma) D/Th12 none none 
30 – M – 30 Paraplegia (trauma) A/Th12 
vesico-ureteral-reflux repair, 
bladder stone extraction 
none 
31 – M – 71 Paraplegia (trauma) A/Th10 none none 
32 – M – 36 Paraplegia (trauma) A/Th10 none none 
33 – M – 44 Paraplegia (trauma) A/L5 none oral oxybutynin 
34 – F – 41 Paraplegia (trauma) A/L4 
Promontofixation, trans 
vaginal tape 
none 
35 – F – 23 Spina bifida  
Pippi-Salle procedure, trans 
vaginal tape 
none 
36 – M – 35 Tetraplegia  Urethral stent, urethrotomy oral oxybutynin 
37 – F – 35 Paraplegia (trauma) B/L3 
Promontofixation, trans 
vaginal tape 
oral oxybutynin 
F = female, M = male, ASIA = American Spinal Injury Association, L = lumbar, Th = thoracic 
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Table 7-2 lists balloon volume, the frequency of ISC, UIEs and pad use, and 
patient reported treatment outcomes. The micturition mode did not change in 
any patient postoperatively. 
A total of 74 adverse events involved the 2 balloons or the balloon on only 
one side. Therefore, adverse events are not presented per patient but rather 
per balloon (Table 7-3). Overall, we noted device erosion/migration for 15 of 
the 74 balloons (20.3%), device infection for 5 (6.8%), implantation site pain 
for 5 (6.8%), and device failure (i.e. balloon leakage), bladder stone 
formation and difficult ISC for 2 each (2.7%). Balloons eroded / migrated 
more frequently into the urethra than into the bladder (13 vs 2 of 15). 
Adverse events were generally mild and only temporary due to easy, timely 
balloon explantation as an outpatient procedure without anesthesia. In cases 
of infection additional treatment with oral antibiotics was sufficient. 
The number of patients who required or asked for device explantation was 5 
of 36 (13.8%) at 3 months, 4 of 36 (11.1%) at 6 months, 2 of 36 (5.5%) at 12 
months, 4 of 36 (11.1%) at 24 months and 9 of 33 (27.3%) at 48 months 
(Table 7-3). In 11 patients devices were only temporarily explanted and 
could be successfully re-implanted after 3 to 24 weeks (Table 7-3). Thus, 
the device was permanently explanted by the end of the 48-month follow-up 
in 13 of 33 patients (39.4%). Reasons for permanent removal were adverse 
events and the inefficacy of nSUI treatment. 
Of the patients with permanently removed devices 4 underwent AUS 
implantation, 3 were treated with bladder neck closure combined with 
continent cutaneous urinary diversion and 2 received an ileal conduit. 
 
DISCUSSION 
The implantation of adjustable paraurethral balloons significantly decreased 
the number of UIEs and pad use in patients with nSUI. However, only 21% 
of patients attained complete continence and 39.4% required permanent 
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explantation of the device after 4 years of follow-up. Nevertheless, greater 
than 50% improvement was reported by 67.6% and 64.8% of patients, 
including those who achieved complete continence, at 1 and 2 years of 
follow-up, respectively. 
 
Table 7-2 Results on ballon volume, frequency of intermittend self-catheterization (ISC), urinary 
incontinence episodes (UIE), pad use, and patient reported outcome at baseline and follow-up 
after 3, 6, 12, 24, and 48 months. 
 Baseline 
Follow-up (months) 
3 6 12 24 48 
Mean ± SD 
balloon vol (ml): 
      
right  2.8 ±1.1 3.6 ±1.6 3.7 ±1.8 3.9 ±2.1 4.1 ±2.2 
left  3.0 ±0.8 3.6 ±1.5 3.9 ±1.7 4.2 ±2.0 4.3 ±2.0 
Mean ± SD 
No./24 hrs: 
      
ISCs 5.4 ±1.7 5.1 ±1.6, 5.0 ±1.7 5.2 ±1.7 5.2 ±1.9 5.6 ±1.7 
UIE 6.1 ±2.4 3.9 ±3.2 4.1 ±2.9 3.1 ±3.4 3.2 ±3.4 2.8 ±3.1 
p Value*  0.001 0.002 < 0.001 < 0.001 0.001 
Pad use 4.2 ±2.7 2.3 ±2.2 2.4 ±2.3 1.8 ±2.0 2.4 ±2.5 2.2 ±2.2 
p Value*  0.001 0.004 0.001 < 0.001 0.004 
No. pt reported 
(%): 
 36 36 36 36 33 
complete 
continence 
 6 (16.7) 6 (16.7) 7 (19.4) 5 (13.8) 7 (21.2) 
50% or greater 
improvement 
 14 (39.0) 17 (47.2) 18 (50.0) 19 (52.8) 11 (33.3) 
treatment failure 
or less than 50% 
improvement 
 16 (44.4) 11 (30.5) 8 (22.2) 7 (19.4) 2 (6) 
permanent device 
explantation 
 0 2 (5.6) 3 (8.3) 5 (13.9) 13 (39.4) 
* = significant different vs baseline 
 
Previous groups that investigated the efficacy of the adjustable continence 
device in female and post-prostatectomy SUI cases reported a success rate 
Adjustable continence device for neurogenic stress urinary incontinence 
178 
of 52% to 80% (proportion of completely continent patients) [7, 9-12]. 
However, in the latter studies non-neurogenic patients had at least some 
sphincter and pelvic floor function remaining. In our patient population 
sphincteric and pelvic floor function was absent, explaining the discrepancy 
in efficacy rates between the current and previous studies. The type of 
neurological lesion might have influenced the results but this could not be 
statistically demonstrated in our study due to our small, mixed study 
population. However, according to daily clinical experience the degree of 
disability / mobility seems to be more important for the therapeutic outcome 
than the type of neurological lesion because there is high variability in nSUI 
severity even for the same type of neurological lesion. 
Usually, postoperative adjustment is necessary to optimize the effect on 
urinary continence. Best outcomes were reported after 4 or 5 refillings [9]. In 
our patients refilling was done more rapidly during the first 6 months to 
achieve continence more quickly. Further refilling was needed less 
frequently and performed more cautiously to prevent trouble with ISC. 
The most common intraoperative and postoperative complications using the 
adjustable continence device reported in the current literature are erosion in 
2.5% to 7.5% of cases, urinary retention in 1.2% to 6.3%, migration in 3.8% 
to 5.6%, perforation in 2.5% to 18%, therapy failure in 2.5%, and urinary 
tract infections in 1.9% to 5% [7-12]. Other complications, such as wound 
infection in 0.6% to 8% of cases, implantation site pain in 0.6% to 15%, de 
novo urgency in 5% and device / material failure in 0.6% to 4% were less 
common [11] except in the study by Gilling et al. [7]. In most cases 
complications were described as mild and quickly correctable. The reported 
explantation rate is between 8% and 58% [7-11]. Within 12 months after 
explantation successful reimplantation could be performed in most cases 
[11, 12]. 
Complication and explantation rates in our study of the ACT® / ProACT® 
device in an nSUI population are well within the ranges reported in the 
current literature. However, urinary retention is less relevant in our nSUI 
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population of patients, who perform ISC. The fact that 92% of our patients 
performed ISC and 37.8% of them had undergone previous SUI surgery 
seems not to have negatively affected our complication rate. 
 
Table 7-3 Adverse events in 74 ballon cases during follow-up 
Follow-up 
(months) 
No. Ballons* No. Pts / No. Ballons 
Errosion / 
Migration 
(site) 
Infection 
(type) 
Pain 
Device 
failure 
Other 
(cause) 
Removal 
Re-
implantation 
3 
4 
(urethra) 
2 
(device) 
 
1 
(balloon 
leak) 
 5 / 7 3 / 3 
6 
6 
(5x urethra, 
1x bladder) 
    4 / 7 3 / 5 
12 
1 
(bladder) 
1 
(orchido-
epidydi-
mitis) 
2  
3 
(2x 
bladder 
stone, 
1x difficult 
ISC) 
2 / 4 1 / 2 
24 
2 
(urethra) 
1 
(device) 
2 
1 
(balloon 
leak) 
1 
(difficult 
ISC) 
4 / 7 3 / 5 
48 
2 
(urethra) 
1 
(device) 
1   9 / 17 1 / 1 
Totals 15 5 5 2 4 24 / 42 11 / 16 
*No patient had urethral stricture. ISC intermittend self-catheterisation 
 
Concomitant NDO that is not treated or insufficiently treated can adversely 
influence the complication rate and study outcome in our patient population. 
Thus, in neurogenic cases it is important to strictly determine whether urinary 
incontinence is related to NDO or whether it is true SUI due to sphincter and 
/ or bladder neck insufficiency [13]. This distinction can only be made by 
urodynamic investigations using filling cystometry, as in our study. All of our 
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patients had cystometric parameters within the normal range and no DO. 
Those known to have NDO were under adequate treatment. 
Other surgical therapies for SUI include bulking agents, suburethral or 
bladder neck slings / tapes and AUS implants. Bulking agents comprise 
different products of different materials, eg collagen, autologous fat, silicon, 
carbon, polytetrafluoroethylene and polyacrylamide hydrogel. Due to initially 
rather low therapeutic success and sparse data [14], this therapy form is not 
well established. There are hardly any investigations of the application of 
bulking agents for nSUI. Two studies in children with nSUI showed rather 
unsatisfactory results [15, 16]. Almost all bulking agents migrate, or cause 
erosion or granulomas [14, 17]. Re-injections are frequently required for 
adequate efficacy [14]. 
Autologous suspension slings, i.e. rectus fascia, are often used for female 
and male nSUI with a complete continence rate of 66.6% to 69.2% (mean 
68.3%) in the adult population [4-6] and 14% to 95% (mean 68.4%) in the 
pediatric population [18-20]. However, most sling procedures are performed 
in combination with augmentation cystoplasty, which potentially contributes 
to the beneficial outcome of nSUI [19]. 
Although most patients with nSUI performed ISC, studies of autologous 
fascia slings in adult and pediatric patients with nSUI show only a few, less 
severe adverse events than those reported for tape and sling implantation in 
the more general SUI population [21, 22]. Two available studies show 
midterm and long-term outcomes of tension-free vaginal tape implantation in 
an adult female nSUI population with continence in 83.3% at 2 years [23] 
and in 77% at 10 years [13]. 
The AUS is used in men and less frequently in women [24, 25]. Due to its 
high efficacy in terms of the continence rate of 58% to 88% (proportion of 
completely continent patients), today it is the gold standard treatment for 
male SUI [26]. Patients with nSUI, in whom an AUS is an established 
treatment option, have also largely benefited from this therapy [24]. The 
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success rate (proportion of completely continent patients) for nSUI is 
reportedly between 23% and 91% (mean 73%) [2, 27-30]. 
However, the AUS is expensive and requires a somewhat complex surgical 
procedure that may be associated with significant complication and revision 
rates [12]. Common complications are erosion, infection and mechanical / 
product related failure, causing an overall 16% to 80% revision and 
explantation rate [2, 28-30]. Murphy et al compared treatment outcomes 
between patients with nSUI and those with non-neurogenic SUI [27]. 
According to those results, patients with nSUI seem to have non-mechanical 
/ non-product related complications more frequently, which was attributable 
to a higher rate of previous LUT surgeries in patients with nSUI. ISC and 
wheelchair dependency potentially also contribute to the higher complication 
rate in neurogenic cases. 
Despite the rather average effectiveness in our study, special circumstances 
in patients with nSUI must be considered, such as complete sphincter 
insufficiency and a yawning bladder neck, i.e. in those with spina bifida. 
However, the adjustable balloons offer certain advantages. 1) Application is 
safe with few intraoperative and immediate postoperative complications 
even in neurogenic cases with previous LUT surgery. 2) The short, minimally 
invasive procedure allows for fast healing and a short hospital stay or even 
ambulatory treatment. 3) There is quick, uncomplicated ambulatory 
adaptation of balloon volumes according to patient needs [9]. 4) In contrast 
to slings / tapes or bulking agents, balloons can be explanted as ambulatory 
surgery using local anesthesia in case of adverse events with the option of 
re-implantation at 3 months. 5) Balloon implantation or explantation does not 
limit the implantation of other continence devices, i.e. an AUS, at a later 
time. 
Although to our knowledge this is the first study evaluating the efficacy and 
safety of the ACT® / ProACT® system in an nSUI population, certain 
limitations must be considered. 1) Our study was not a randomized, 
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prospective study. Nevertheless, our data are representative of everyday 
clinical practice. 2) Patient reported outcomes were not obtained 
anonymously from questionnaires but from chart reviews. 3) QoL before and 
after implantation was not systematically assessed and, therefore, could not 
be evaluated.  
 
CONCLUSIONS 
ACT® / ProACT® implantation in patients with nSUI can be performed as a 
short, minimally invasive procedure. The safety profile is good with 
intraoperative and postoperative complications that are self-limited or easily 
manageable, even in neurogenic patients who mainly performed ISC and / 
or underwent previous SUI surgery. Efficacy seems to be somewhat limited, 
probably due to the severity of the continence deficiency in neurogenic 
patients. Nevertheless, UIEs and pad use were significantly decreased 
throughout the 4-year follow-up. The ACT® / ProACT® system appears to 
be an interesting alternative for nSUI, especially for patients who need 
additional continence support after previous nSUI surgery or those who are 
not willing, not suitable or not yet ready for more invasive surgery. 
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GENERAL DISCUSSION 
The adequate management of urine storage dysfunction in the neurological 
patient is highly relevant for the patient’s QoL and general health. A 
thorough diagnostic workup is essential in order to understand the type of 
dysfunction and underlying mechanism, to effectively treat the LUTS / LUTD 
and to prevent (further) deterioration of upper and lower urinary tract 
function. Early diagnosis and prevention are important, as, once 
deterioration of morphology and function of lower and upper urinary tract has 
occurred, it is usually not reversible and further, sometimes invasive 
treatment efforts may become necessary to alleviate symptoms and to avoid 
sequelae and further urinary tract damage. 
Today, a level of patient care has been reached that allows the prevention of 
fatal courses of urinary tract deterioration and the provision of some 
reasonable improvements in the QoL. Neuro-urological research and 
practice has, in recent decades, certainly contributed to the significantly 
improved life expectancy of SCI patients. 
However, still many aspects of human LUT (patho)physiology and the 
mechanisms of action of different, often extant therapies are only poorly 
understood or entirely unknown. Hence, further research, basic and clinically 
oriented, is crucial for improving health care for LUTS / LUTD in the 
neurological patient. 
In this thesis, current LUTS / LUTD treatments in neurological patients have 
been investigated and assessed with regard to the aforementioned research 
questions with a specific focus on BoNT/A intradetrusor injections (chapters 
3-6) using clinical studies (chapters 3-5, 7) and comprehensive literature 
reviews (chapters 2 and 6). In this chapter, the findings of the investigations 
reported in chapters 2-7 are discussed in a broader context of neuro-
urological health care and in view of the most recently available insights into 
the management of urine storage dysfunction in the neurological patient. 
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THERAPEUTIC PRINCIPLES OF URINARY INCONTINENCE IN 
NEUROLOGICAL PATIENTS 
Urinary incontinence in the neurological patient is essentially related to one 
of the following dysfunctional patterns, which may occur either isolated or in 
combination with each other: a) DO which may cause sudden intravesical 
pressure increase that overcomes the subvesical resistance and 
consequently results in overactivity incontinence, b) sphincter insufficiency 
lowering the subvesical resistance and the ability to voluntarily prevent or 
interrupt urinary outflow, resulting in stress urinary incontinence and / or 
aggravated overactivity incontinence in case of coexisting DO and c) hypo- 
or acontractile detrusor resulting in accumulation of PVRU and potentially 
overflow incontinence. 
Although the initial intention of our review was to highlight male-specific 
data, we extended our review to neurological patients in general because, 
on the one hand, male-specific data are very scarce and, on the other, all 
the dysfunctional patterns mentioned above apply equally to both male and 
female patients (Chapter 2, [1]). 
Effective treatment of urinary incontinence in patients with NLUTD is based 
on the treatment of the underlying dysfunctional pattern a) to c). To detect 
which of these patterns applies and to understand the cause of the 
incontinence, urodynamic investigation, i.e. filling cystometry with 
subsequent pressure-flow study, is mandatory. Only such urodynamic 
investigation allows the positing of a complete diagnosis and the selection of 
appropriate treatments. In addition to the urodynamic outcome, which also 
provides an estimate of the risk for upper urinary tract damage, treatment 
selection depends on the severity of symptoms. In general, the more 
advanced the dysfunction and the morphological alterations are, the more 
invasive the treatment requirements become. 
Treatment options for the dysfunctional patterns a) and b), i.e. neurogenic 
DO and sphincter insufficiency, are described in detail in chapters 1 and 2. 
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In addition, a specific treatment option for stress urinary incontinence due to 
neurogenic sphincter insufficiency is highlighted and discussed in chapter 7. 
Hence, the main focus of the following discussion will be placed on the 
dysfunctional pattern c), i.e. neurogenic detrusor hypo- or acontractility. 
Neurogenic detrusor hypo- or acontractility may typically result from 
subsacral or peripheral neuronal lesions [2] related to e.g. trauma, pelvic 
surgery, or progressive polyneuropathy. Suprasacral lesions may also result 
in an acontractile detrusor, e.g. during the spinal shock phase after SCI but 
also in cases of isolated lesions affecting the efferent pathway such as in 
multiple sclerosis [3]. Although less frequently, supraspinal lesions, e.g. 
stroke, Parkinson’s disease, multiple sclerosis, tumors, hemorrhage, may 
also cause detrusor hypo- or acontractility, most probably related to a 
disturbed or disrupted connection to the pontine micturition center, 
preventing its activation and thus the induction of micturition [3-6]. 
A rather extraordinary, yet poorly understood, form of LUT dysfunction, 
including detrusor underactivity with a supposed supraspinal component, is 
“isolated” urinary retention that particularly occurs in younger women without 
any overt neurological dysfunction and is often referred to as Fowler’s 
Syndrome [7]. The currently best-established working hypothesis is that a 
poorly relaxing sphincter causes increased urethral afferent activity, which 
inhibits bladder afferent signaling and leads to poor bladder sensation and 
detrusor underactivity, i.e. an exaggerated guarding reflex [8]. Alongside 
other potentially implicated etiological factors such as autonomic dystonia, 
hormonal dysfunction, opiate use and psychological stress, a supraspinal 
component is likely, supported by recent neuroimaging studies and may also 
explain the extremely good treatment response to sacral neuromodulation 
[9-12]. 
Diseases such as diabetes mellitus may cause detrusor hypocontractility by 
damaging pre- and postsynaptic efferent and afferent fibers in diabetic 
polyneuropathy. In addition, diabetes mellitus may also cause reduced 
substrate supply to the detrusor by vascular damage or even direct 
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myogenic damage and bladder wall remodeling due to hyperglycemia-
related oxidative stress [13-16]. 
Finally, acute, prolonged bladder overdistension or chronic bladder outlet 
obstruction can cause detrusor damage inter alia due to changes in cellular 
architecture and local ischemia, resulting in hypo- or acontractile detrusor 
[17, 18].  
Detrusor hypo- or acontractility can frequently result in a chronic post-void 
residual volume, particularly in male patients who naturally require a higher 
detrusor pressure to empty their bladder due to the prostate and longer 
urethra [19]. Subsequently, this may lead to overflow incontinence during 
accumulation and a reduced functional capacity causing higher urinary day- 
and nighttime frequency. 
 
CATHETERIZATION 
Detrusor hypo- or acontractility may appear simple to treat using a form of 
catheterisation. However, not all patients are able or willing to perform the 
recommended gold-standard ISC and may end up with an either 
transurethral or suprapubic indwelling catheter [20, 21]. Although the EAU 
guidelines on neuro-urology recommend the use of ISC and to avoid 
indwelling catheters whenever possible with grade A, the corresponding 
level of evidence supporting this recommendation is only 3 [22]. Indeed, 
there is no single RCT adequately comparing indwelling versus ISC for long-
term bladder management [23, 24] despite the importance and daily clinical 
relevance of this topic. 
In fact, catheter-associated urinary tract infections are among the most 
common healthcare-associated infections with excess morbidity and health 
care costs [25-28]. This is all the more concerning considering the increasing 
antimicrobial resistance of many uropathogenic bacteria [29-32].  
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Certainly, even indwelling catheters can be useful tools in the management 
of NLUTD and may also serve as a reasonable long-term solution for 
selected patients [33-35], however, they should be used advisedly and the 
indication should be evaluated carefully and reevaluated during regular 
follow-up contacts. In patients with neurogenic bladder dysfunction after SCI, 
indwelling catheters have been identified as the most prevalent risk factors 
for urinary tract infection [36-39] and prior studies have demonstrated that 
patients are at higher risk for upper and lower urinary tract deterioration with 
indwelling catheters [40-49]. More recent studies report that complications 
and urinary tract deterioration in those using suprapubic catheters achieved 
similar morbidity profiles compared to ISC, which is probably related to 
improvements or more consistent implementation of DO treatment, 
appliance of closed loop systems and regular and more frequent follow-up 
including catheter changes, bladder washing regimes, and improved 
catheter material / fabrication [21, 50]. Nevertheless, infection rates are still 
considered to be higher with indwelling catheters [22, 36, 37, 51] which is 
why efforts have been made to improve catheter material by coating or 
impregnating the catheter with antiseptic or antimicrobial substances such 
as silver alloy and nitrofurazone. However, available studies do not provide 
sufficient evidence that catheters coated or impregnated with antimicrobial 
substances significantly reduce the incidence and frequency of catheter 
associated urinary tract infections [27, 38, 52, 53].  
Thus, the best approach for preventing catheter associated UTIs is still to 
avoid unnecessary use of indwelling catheters and to reduce the time period 
during which the catheter is used by removing it as early as possible [27]. 
In addition to the higher risk of UTIs, there are other relevant complications 
of indwelling catheters such as encrustation, stone formation, blockage, 
urinary leakage, urethral stricture, genitourinary trauma, fistula formation and 
reduced bladder capacity and compliance (with continuous drainage) [28, 
49, 54-61]. Due to the longer and sinuous urethra, male patients may be 
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more prone to traumatic complication of long-term indwelling transurethral 
catheter which may be avoided using a suprapubic catheter [62, 63].  
Although still rare, development of bladder malignancies has been reported 
to be more prevalent in patients managed with long-term indwelling 
catheters [55, 64-68] possibly based on the catheter-associated chronic 
inflammatory and mechanical stress to the urothelium [44, 69].  
Another aspect that seems to be negatively affected by the use of indwelling 
catheters, in particular transurethral catheters, is health-related QoL [70, 71]. 
ISC seems to provide less impairment or even improvements in QoL 
compared to other forms of catheterization [72]. However, individual barriers 
and preferences must be considered and patient-tailored instruction and 
education as well as periodical follow-up are important for long-term 
compliance [73-75]. More female than male patients may have difficulties in 
adequately introducing the catheter, especially when wheelchair-bound or 
with lower limb spasticity or poor visual or hand function [75, 76]. In such 
conditions, a catheterizable cutaneous continent urinary diversion composed 
of an abdominal continent stoma with or without combined enterocystoplasty 
can facilitate self-catheterization to maintain independent bladder 
management [77-79]. 
There are different types of catheters (hydrophilic vs non-coated catheters) 
and methods (clean vs sterile and single-use vs multi-use) and, due to an 
insufficient body of evidence, it is still a matter of debate as to which is 
preferred [80-83], although some newer data favour single-use hydrophilic 
catheters in regard to urinary tract infection and urethral trauma [84-86]. 
There are discrepant data on cost-effectiveness [87, 88] and very few data 
on QoL, two very important aspects that need better consideration in further 
randomized controlled trials. 
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NEUROMODULATION 
Of course, not requiring a catheter to empty the bladder is the ideal, but also 
most challenging, aim in neurogenic urinary retention. Sacral 
neuromodulation has been demonstrated to be effective in the treatment of 
non-obstructive urinary retention, i.e. hypo- or acontractile detrusor, in male 
and female patients [89]. However, most previous studies reported results 
from populations with a mixed etiology of the hypo- or acontractile detrusor, 
i.e. neurogenic, myogenic, or even a combination of both [90-92]. The 
rationale for using sacral neuromodulation in patients with neurogenic 
urinary retention is to modulate disease- or lesion-specific pathologically-
altered spinal reflexes and brain networks by stimulation of afferent 
pathways to restore at least some physiological function [93-95]. Similar to 
the supposed inhibitory effect on inappropriate activation of the ‘‘guarding 
reflex’’ (i.e., the spinally mediated reflex whereby the urethral sphincter 
contracts to prevent urinary incontinence on a sudden increase in 
intravesical pressure) in patients with Fowler’s syndrome [93], DSD, which is 
a frequent cause of incomplete micturition in patients with neurogenic urinary 
retention, may be diminished, whereas a normalized pattern of brainstem 
activity may contribute to improved detrusor contractility [11]. 
Although specific data on neurological patients treated with sacral 
neuromodulation for chronic urinary retention are promising, success rates 
seem to be slightly lower than for the treatment of urgency and urgency 
incontinence [93]. In general, RCTs in neurological patients are still lacking 
and it is unclear which population of neurological patients benefits most from 
sacral neuromodulation and which does not [93]. Nevertheless, sacral 
neuromodulation is a fairly minimally invasive procedure that is fully 
reversible and whose efficacy can be individually tested prior to complete 
implantation of the stimulator. The exact mechanism of action of sacral 
neuromodulation in this context is unknown but may be related to the 
transmission of ascending signals to the LUT control centers in the spinal 
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cord and supraspinal regions that modulate efferent output from those 
centers to the pelvic organs [96]. 
 
INTRAVESICAL ELECTRIC STIMULATION 
In contrast, intravesical electric stimulation is thought to act by direct 
stimulation of the intramural motor system, resulting in local muscle 
contractions which promote vegetative afferent activation with consecutive 
central stimulation leading to improved bladder sensation and more 
coordinated, stronger detrusor contractions [97]. Despite initially promising 
results, mainly in pediatric populations with NLUTD due to 
meningomyelocele, [98-100] there is only one RCT available showing no 
beneficial effect on micturition [101]. In addition, the enormous time and 
effort required of therapist and patient in relation to the relatively limited 
treatment outcome has led to scarce application of this treatment currently. 
There is no recommendation in current EAU guidelines [22]. 
 
SUBVESICAL DE-OBSTRUCTION 
In male patients, TURP prior to sacral neuromodulation may optimize 
outcome and even TURP alone has been shown to be sufficient in DU 
conditions for attaining voluntary micturition or at least reducing the risk of 
acute urinary retention in the short and medium term [89]. Of course, male 
patients with NLUTD may also have prostate-related bladder outlet 
obstruction and may benefit from surgical de-obstruction [102]. However, 
prior to performing such irreversible surgery in neurological patients, intact 
urethral sphincter function needs to be verified. If in doubt from the clinical 
examination, sphincteric needle EMG of the urethral or anal sphincter should 
be performed [103, 104]. This can be particularly relevant in the context of 
differentiation between NLUTD from Parkinson’s disease vs multiple system 
atrophy (Table 1-1) [105, 106]. If still in doubt, or there is any sign of 
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sphincter deficiency, TURP should be omitted due to the elevated risk of 
postoperative incontinence [107-110]. In such cases, ISC may be the better 
alternative [111]. Using a temporary prostatic stent to simulate TURP is an 
option for avoiding unpleasant surprises and to evaluate which patient would 
benefit most from a TURP as permanent solution [112]. 
Although bladder outlet obstruction is difficult to objectify in urodynamics of 
patients with hypo- or acontractile detrusor, a urodynamic workup to 
evaluate current detrusor contractility is mandatory, especially prior to 
choosing surgical treatment options [113, 114]. However, while an 
acontractile detrusor is fairly precisely defined as lack of any contraction 
during urodynamic studies [115] hypocontractile detrusor is a less-precisely 
defined term due to the lack of and difficulty in defining urodynamic cut-off 
values for normal and abnormal, i.e. hypocontractile, reduced detrusor 
contraction strength [18, 116]. Nevertheless, to fully understand the 
dynamics behind the symptoms and to create precedents for future 
comparison, urodynamic investigations are indispensable, as they are the 
only tool to allow diagnosis and quantification of detrusor hypo- and 
acontractility [113, 114]. In addition, recently developed nomograms have 
been demonstrated to allow better quantification of the relationship between 
detrusor contractility and bladder outlet obstruction in male patients [117]. 
 
NEUROPROSTHESIS 
A very sophisticated treatment for regaining detrusor control of voluntary 
micturition in NLUTD is the implantation of an electrical neuroprosthesis. 
Currently, the only established neuroprothesis for the LUT is the sacral 
anterior root stimulator, also known as the Fintech-Brindley neurostimulator, 
which produces direct electrical stimulation of the efferent fibers in the 
anterior root to induce detrusor contraction [118-121]. Such devices can 
significantly contribute to improvements in quality of life and continence [122, 
123]. However, it should be reserved for a highly-selected patient population, 
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since it requires prior sacral deafferentation (posterior rhizotomy) with 
permanent loss of any potentially preserved sensation of the pelvis and 
lower limbs and sexual function. Thus, patients with complete, chronic (≥ 1 
year after SCI) tetra- or paraplegia are most suitable for an anterior root 
stimulator as they would suffer the least functional loss from posterior 
rhizotomy due to their pre-existing neuronal lesion. Instead, they gain from 
abolished or at least significantly reduced autonomic dysreflexia and 
detrusor overactivity incontinence and independent bladder management 
even with impaired hand function [124]. This latter aspect applies particularly 
to male tetraplegic patients who cannot transfer to a toilet but can use a 
condom catheter to drain the voided urine or paraplegic patients who can 
independently transfer to a toilet seat for micturition using the anterior root 
stimulator. 
 
 
SPREAD AND DIFFUSION OF BOTULINUM TOXIN A AFTER 
INTRADETRUSOR INJECTION 
Since the first BoNT/A intradetrusor injections for the treatment of NDO in 
SCI patients at Balgrist University Hospital, Zürich, Switzerland in 1998, its 
use has become widespread as a minimally-invasive treatment option [125]. 
Last but not least, this is also related to the simple administrative route using 
a rigid and, later, also a flexible cystoscope [126]. Although BoNT/A has 
been used in the treatment of local striated muscle dystonias decades 
before application into the detrusor [127], the main difference and novelty 
with intradetrusor injections was the use in a smooth, autonomically 
innervated muscle. Fortunately, for NDO patients, BoNT/A intadetrusor 
injections yield a significantly longer duration of action (~ 8 months) than 
injections in striated muscle (~ 3 months) [128]. In addition to this, as yet 
unexplained, phenomenon, many aspects regarding the injection technique 
and mechanism of action also await elucidation. 
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So far, protocols of different injection locations, number of injections, 
volumes / concentrations per injection and injection depths have been used 
[129, 130]. Due to the lack of reliable comparative data on different injection 
techniques, there is not yet a single best technique. However, the phase III 
studies for approval of BoNT/A in the context of NDO describe a technique 
using 300 or 200 units of onabotulinumtoxinA in 30 injections of 1 mL each 
with an injection depth of 2 mm sparing the trigone [131, 132]. Since 300 
units did not show any clinically relevant benefit over 200 units, the currently 
approved standard dosage for NDO treatment is 200 units, resulting in a 
concentration of 6.66 units per mL per injection [131, 132].  
Nevertheless, different physicians may still use “their” technique and the 
number of injection sites in particular is a matter of discussion as fewer 
injection sites may be equally effective but less traumatic and faster [133-
136]. Those latter aspects are of relevance as the BoNT/A injections have 
emerged as an out-patient or office-based procedure under local anesthesia 
[126, 134]. The reason for the fairly equivalent treatment effect observed 
despite using different numbers of injection sites may be the injection-related 
spread and naturally-occurring diffusion within the target tissue [134, 137, 
138]. In this context, injection depth may be relevant as the degree of spread 
and diffusion may differ between different bladder wall layers, i.e. 
suburothelium vs detrusor. However, injection depth is less easily controlled 
than number of injection sites and it remains unclear how an injection depth 
of exactly 2 mm can be guaranteed and reproduced as suggested by the 
phase III NDO trials [131, 132]. Certainly, needle length is an option for 
controlling injection depth but individual bladder wall properties and filling-
dependent thickness during the procedure can influence the final injection 
depth and injected tissue layer. In particular, patients with NDO in whom 
existing morphological alterations such as bladder wall trabeculation has 
occurred may no longer show equal bladder wall thickness. Visual feedback 
is unreliable and may be only useful during pure suburothelial injections 
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[139]. The latter have been demonstrated to be effective but not superior to 
conventional intradetrusor injections [139]. 
To visualize how BoNT/A spreads and diffuses within the bladder wall after 
intradetrusor injection, we added the contrast medium gadopentate to the 
BoNT/A solution (300 units onabotulinumtoxinA) and perfomed MR scans to 
measure the extent of contrast medium enhancement within the bladder wall 
(Chapter 3). Our findings indicate that the onabotulinumtoxinA / gadopentae 
solution spreads not only within the bladder wall but also beyond. We found 
small amounts of contrast medium (17.6 %) outside the bladder wall in the 
perivesical fatty tissue at the lateral aspects of the bladder dome [140]. This 
extravasation of contrast medium outside the bladder wall is most likely due 
to perforation of the injection needle through the bladder wall which in turn 
may be related to the relatively long needle tip (8mm) used in our study. 
Using a shorter needle, as nowadays recommended [130], may have 
prevented external leakage, but this remains to be clarified. Another related 
factor may be bladder volume during the procedure, which was not 
standardized but adapted to the individual procedure-related condition. 
BoNT/A leakage beyond the bladder wall may be responsible for adverse 
events in adjacent organs, e.g. the bowel. Reported adverse events on 
bowel function following BoNT/A intradetrusor injections seem to be rare 
[129, 141, 142]. On the other hand, specific bowel-related adverse events 
have never been systematically investigated.  
Interestingly, the mean contrast-enhanced detrusor volume did not exceed 
one-third of the total detrusor volume. Nevertheless, 5 of 6 patients had a 
subjectively and urodynamically sufficient effect with a mean reduction of 
maximum storage detrusor pressure of 27 cmH2O and mean increase in 
maximum bladder capacity of 225 mL [140]. Hence, it does not seem 
necessary to cover the full or even 50% of detrusor to achieve relevant 
clinical improvements. However, there was a trend towards a positive 
correlation between the percentage of detrusor coverage and urodynamic 
improvements, i.e. the more detrusor volume enhanced with contrast as a 
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representation of the onabotulinumtoxinA distribution, the larger was the 
reduction in maximum detrusor pressure and increase in bladder capacity. 
The one patient who did not benefit from the BoNT/A treatment showed the 
least detrusor volume coverage with contrast medium (17.84 %) indicating 
limited distribution of BoNT/A as potential reason for the lack of clinical and 
urodynamic efficacy. 
Regarding the number of injection sites, i.e. 10 vs. 30, there was a slightly 
larger percentage of detrusor coverage with contrast medium in the group 
treated with 30 injection sites (33.3 % vs 25.3 %) [140]. This small difference 
between both groups was also reflected in the urodynamic improvements 
with larger detrusor pressure decreases (-27 cmH2O vs -18.3 cmH2O) and 
bladder capacity increases (214 mL vs 153 mL) in the group treated with 30 
injection sites. However, the total study group was too small to perform a 
reliable subgroup analysis and the inferior mean values in the group treated 
with 10 injections were mainly driven by the one patient who did not benefit 
from the BoNT/A treatment. Considering recent literature regarding the 
number of injection sites, there seems to be no relevant difference between 
the standard amount of injections and the reduced number of injection sites 
[133, 134, 136]. More evidence is needed to clarify this. In this regard, 
injection volume / dilution as well as location of injection are important 
factors that need to be considered as they can significantly affect spread / 
diffusion and consequently treatment outcome [143]. Multiple smaller 
injections are generally considered to provide a more even distribution and 
less spread beyond the target muscle compared to one or very few larger 
bolus injections [143, 144]. In terms of location, sparing the trigone has 
become the commonly used and currently approved technique [131, 132] 
although the initial fear of consecutive VUR could be disproven [145-148] 
and recent randomized trials even suggest a better treatment outcome in 
NDO and IDO using intradetrusor injections that include the trigone [147-
149]. Considering that afferent nerve terminals are particularly dense within 
the trigone, there is also a neurophysiological rationale and explanation for 
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injecting the trigone and obtaining a superior treatment effect [150]. 
However, in addition to the still poorly-understood effect and mechanism of 
action of injecting specific areas of the bladder, i.e. trigone or bladder dome, 
there is also evidence for unexplained primary and secondary treatment 
failures and treatment discontinuation [142, 151-155], which require a more 
systematic analysis than currently available to better understand the causes. 
In this regard, toxin spread beyond the bladder but also backflow into the 
bladder from the injection site may play a role [138]. Increased backflow, 
which may, again, depend on injection volume, injection depth, and bladder 
wall tension in relation to the degree of bladder volume / filling during 
injection, can cause loss of toxin and, consequently, reduced efficacy. 
Hence, prior to performing repeated injections, increasing dosage or 
switching to another formulation or BoNT type in case of treatment failure, it 
might be worthwhile to first clarify if application precision is adequate, i.e. the 
ability to bring the toxin to the right location in the right amount. This is poorly 
investigated but highly relevant in regard to optimizing risk / benefit and cost 
/ effect ratios.  
Different formulations of BoNT/A, i.e. onabotulinumtoxin vs 
abobotulinumtoxin, may display different spread and diffusion 
characteristics, i.e. more migration using abobotulinumtoxin [156, 157], 
which could at least partly explain the more frequent observation of 
generalized muscle weakness with abobotulinumtoxin [141, 158]. However, 
such findings need to be observed with some caution as the applied dose 
and dilution affect spread and diffusion of BoNT/A and controversy as to the 
real dose equivalence between different BoNT/A formulations complicates a 
reliable comparison resulting in conflicting study outcomes [159]. 
Despite that our study has limitations in regard to sample size and the fact 
that gadopentate cannot fully replicate the diffusion of BoNT/A as it is not 
attached to the BoNT/A molecule and may have different diffusion 
characteristics, it is the first study to provide a more detailed insight into the 
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behavior of the BoNT/A-solution after bladder wall injection. Further studies 
using radio- / isotopic- labeled BoNT/A molecules and appropriate imaging 
such as scintigraphy, PET-CT, or MR-spectroscopy can improve our 
understanding on the pathways and dynamics of BoNT/A diffusion within the 
human bladder wall after injection [160]. In addition, distant spread and 
migration beyond the bladder including retrograde axonal transport could be 
monitored and quantified. Such novel insights in accordance with standard 
clinical parameters would contribute to a better understanding of mechanism 
of action, treatment failures and distant / systemic adverse events. 
Moreover, visualization of diffusion characteristics in relation to area-specific 
injections, i.e. trigone or bladder dome only, could help in clarifying and 
understanding differences in location-specific diffusion and effects. It could 
be imagined, for example, that trigone-only BoNT/A injections mainly act by 
central desensitization via retrograde axonal transport to the dorsal root 
ganglion [160] and less by the classic mode acting on the neuromuscular 
junction resulting in a predominant sensory effect, i.e. reduction of urgency 
with a relatively lower effect on detrusor contractility and voiding function 
[161, 162]. 
In conclusion, understanding where toxin distributes after injections into the 
bladder wall and what it does at the sites it reaches is key to better 
application precision and control of safety and efficacy. Precise application 
will permit precise dosing and consequently limit wasting of toxin and the risk 
of adverse events such as elevated post void residual urine (PVRU) or 
urinary retention resulting in de novo ISC, which still counts among the most 
frequent adverse events after BoNT/A intadetrusor injections [163-165]. 
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EFFECT OF LOW-DOSE BOTULINUM TOXIN A ON OVERACTIVE 
BLADDER SYMPTOMS IN PATIENTS WITH MULTIPLE 
SCLEROSIS 
The issue of PVRU elevation and de novo ISC is most relevant in patients 
with OABS and, less frequently, in patients with NDO who more often 
already perform ISC due to the usually more severe impairment of bladder 
control and the commonly NDO associated pattern of DSD.  
However, although NDO / DSD are relevant and frequently-encountered 
dysfunctional patterns in NLUTD, they do not represent the underlying 
urodynamic pattern of all LUTS in neurological patients. Moreover, there is 
quite a large population of neurological patients, in particular MS or PD 
patients, who may not require or are unable or unwilling to perform ISC [20, 
166, 167]. Unwillingness or reservations in performing ISC may be due to 
several factors such as fear of infection and pain, previous negative 
experiences with attempts to perform ISC and the feeling of losing another 
body function adding to the already preexisting disease related disabilities 
and causing further separation from a normal and enjoyable life [168]. 
Despite the fact that most reservations and fears about ISC can be 
addressed and overcome by adequate education, instruction and follow-up 
[73, 168], it would still be most desirable to alleviate detrusor overactivity and 
associated symptoms such as urinary incontinence and urgency without 
causing or increasing urinary retention. 
Prior to our study presented in chapter 4 [169], NDO refractory to 
antimuscarinic drugs was usually treated with onabotulinumtoxinA using 300 
units [129] and, since the recent phase III RCTs, with 200 units in the 
majority of cases [131, 132]. However, treatment of NDO using 300 units 
onabotulinumtoxinA most likely results in urinary retention or at least 
significantly elevated residual urine requiring ISC. 
In contrast, treatment of OABS in patients without a clear neurological cause 
for their symptoms using only 100 units of onabotulinumtoxin A resulted in 
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significant symptomatic improvement without impairing voiding function 
[170]. Clearly, this is also at least partly related to the different etiology and 
characteristics of neurogenic vs non-neurogenic LUTD. Nevertheless, we 
were interested if a dose reduction of onabotulinumtoxinA to 100 units for 
the treatment of NDO in MS patients would also be effective without 
impairing voluntary micturition. Therefore, we applied the same protocol 
used in patients with idiopathic OABS [170] in a group of MS patients. In 
keeping with our hypothesis, we observed alleviation of NDO and associated 
symptoms. However, voiding function was also affected, showing decreased 
voided volume and Qmax and increased PVRU [169]. Hence, our treatment 
goal was not fully achieved, although only two patients needed ISC once to 
twice daily while one patient needed a suprapubic catheter. 
Yet the decision as to who requires ISC and when, can, but not necessarily 
must, be related to a predefined PVRU threshold and thus may significantly 
affect the outcome of different studies [165]. This leads us to the still 
unsettled and ongoing debate on how much PVRU is too much and requires 
treatment. In our view, a strict and inflexible PVRU threshold does not 
appear to be reasonable and our preferred patient-tailored approach is also 
now becoming recognized in the more recent literature [171]. PVRU itself is 
not harmful considering that the bladder is specifically designed and lined to 
store urine. Moreover, there seems to be no clear or significant correlation 
between PVRU and symptomatic urinary tract infections in non-neurogenic 
LUTD [172-174]. However, this may be different in patients with NLUTD 
[175, 176] who usually present with more severe LUTD and in whom PVRU 
often causes symptoms that are bothersome and / or harmful and thus 
require treatment. Such symptoms include all kinds of storage symptoms but 
also recurrent urinary tract infections. PVRU can also be the reason for 
persistence of LUTS despite treatment due to loss of functional bladder 
capacity. 
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Hence, it may be more reasonable to decide on the necessity and frequency 
of ISC based on the symptoms rather than a fixed threshold which is anyway 
not yet firmly established [174-176]. 
In conclusion, dose reduction of onabotulinumtoxinA to 100 units for the 
treatment of NDO does not completely prevent impairment in voiding, 
probably due to the pre-existing and persisting pattern of NLUTD, i.e. 
persistence of DSD in our MS patient group. Nevertheless, the positive 
treatment effect was comparable to studies using 200 units, whereas the 
increase in PVRU was less pronounced [169], contributing to a lower rate of 
ISC. Unfortunately there is not yet a prognostic clinical or urodynamic tool 
that would allow for a reliable prediction of the BoNT/A dose required for 
each patient [177]. However, to provide a more tailored treatment for the 
individual patient, it may be worthwhile to follow a more stepwise treatment 
approach starting with lower doses of BoNT/A and to increase the dose only 
if urodynamically or symptomatically indicated. Larger RCTs considering 
cost-effectiveness and QoL of low-dose BoNT/A applications in NDO 
treatment are highly warranted. Such trials should also allow subgroup 
analysis regarding mobility and dexterity since most previous trials 
presented mixed neurological etiologies of NDO such as MS, SCI, and PD 
although each of them has a different disease course with different 
concomitant disabilities and support requirements. 
In favor of a stepwise approach aiming to apply only as much BoNT/A as 
actually required, it may be necessary to also reconsider the fact that 
BoNT/A is the most powerful available neurotoxin and should be used with 
appropriate caution, especially in view of the increasing number of medical 
indications and consequently higher chance of multiple or parallel treatments 
[178]. This is also of relevance in view of the limited control of injection 
precision and spread beyond the bladder (chapter 3, [140]). 
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SYSTEMIC EFFECTS OF BOTULINUM TOXIN A AFTER 
URINARY BLADDER INJECTIONS 
Considering our findings from chapter 3, spread and / or diffusion of BoNT/A 
can reach beyond the bladder wall and may cause systemic side effects 
[140, 144, 179]. Distant effects related to diffusion, leakage into the 
circulation and retrograde axonal transport has been previously described 
for BoNT/A applied in striated muscles [180-183]. Reviewing the literature on 
BoNT/A intradetrusor injections, mainly procedure- and detrusor-related 
adverse events have been reported with almost no systemic side effects 
[141, 165] except for some scarce reports on generalized muscle weakness 
in a few patients [184, 185]. However, “not reported“ does not necessarily 
mean “not present”, especially when distant effects have not yet been 
assessed systematically. There is no rationale that such distant effects 
should occur after injections in striated muscle only but not in smooth 
muscle. Indeed, a very recent investigation on retrograde transport of 
radiolabelled BoNT/A after bladder injections in rats demonstrated traces of 
the BoNT/A in the intestine and stomatch in addition to within the bladder 
and L6-S1 dorsal root ganglion [160]. Furthermore, the reports of patients 
with generalized muscle weakness after BoNT/A intradetrusor injections 
[184, 185] resemble those patients with contralateral weakness and fatigue 
after high-dose BoNT/A poststroke spasticity management [186, 187]. 
Based on its primary mechanism of action, BoNT/A frequently also affects, in 
addition to the neuromuscular junction of striated muscles, the autonomic 
nervous system [188-190]. An important neuromuscular structure under 
autonomic control is the heart and previous investigations have 
demonstrated that BoNT/A injections can cause distant effects on cardiac 
autonomic function [190-195]. Such autonomic and cardiovascular effects 
may be subtle and remain subclinical but reliable data, especially in the long-
term, are lacking.  
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Therefore, we assessed in the study described in chapter 5, for the first 
time, potential distant effects of onabotulinumtoxinA intradetrusor injections 
on the autonomic nervous system using heart rate variability (HRV) [196]. 
HRV analysis is an inexpensive and easily applicable tool to assess even 
subtle alterations of autonomic control on cardiac function including vagal 
and sympathetic components [188, 197, 198]. HRV is based on ECG 
recording that can be easily performed prior to and during follow-up after 
BoNT/A treatment. In this first study including a control group and 4 
measurement timepoints, i.e. 2 weeks and 10 minutes prior and 30 minutes 
and 6 weeks after onabotulinumtoxinA intradetrusor injections, we could not 
detect any significant HRV changes [196]. However, we investigated resting 
conditions only and cannot expand our conclusion to situations of physical 
stress. Furthermore, all patients were treatment-naïve without parallel 
treatment for other indications. Hence, BoNT/A distant effects on autonomic 
cardiovascular function need to be further elucidated also in conditions of 
physical stress and under repeated and / or parallel treatments. The latter is 
of particular relevance since dose-dependent effects on autonomic cardiac 
function has been reported [192, 194]. 
There are currently three known routes by which BoNT/A can reach distant 
sites: 1) diffusion or spread into neighboring tissue, 2) retrograde axonal 
transport, and 3) hematogenic distribution by leakage into the circulation 
[144]. In addition, indirect reorganizational effects on the CNS related to its 
effect on the neuromuscular synapse and muscle spindles have been 
described [144, 199]. The most realistic route by which BoNT/A reaches the 
heart following bladder injections is hematogenic spread [144]. Retrograde 
axonal transport could be another possibility but, although transsynaptic 
transmission of BoNT/A has been demonstrated in animal models [200, 
201], the potential route from the bladder to the heart in humans remains 
questionable and may be too long to reach the heart prior to inactivation of 
the toxin [199]. BoNT/A binds with high affinity to peripheral cholinergic 
nerve terminals and is thus quite rapidly removed from the circulation. At the 
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heart, BoNT/A can affect a) parasympathetic control on the sinoatrial and 
atrioventricular node by acting on vagal nerve terminals and b) sympathetic 
control by acting on preganglionic nerve terminal in the sympathetic chain 
[195, 202, 203]. 
In addition to effects on the heart after BoNT injections for striated muscle 
dystonia, there are also reports of systemic side effects on other 
autonomously-innervated organs including the bladder, e.g. urinary 
retention, [183, 194]. Such autonomic side effects seem to be more 
pronounced with BoNT/B than with BoNT/A [194, 204]. Although BoNT/B 
has been proposed as alternative treatment to BoNT/A-resistant DO [205, 
206], the more pronounced autonomic side effects and significantly shorter 
effect duration render its use the exception [207, 208]. Moreover, BoNT/B 
seems to be highly antigenic, particularly in patients who are 
immunoresistant to BoNT/A, resulting in cross-reactivity which may explain 
the rapidly progressive unresponsiveness after a few treatments [183]. 
Cardiovascular monitoring in the context of NLUTD is not only useful for 
assessing potential adverse events of different treatments in neuro-urology 
or to identify patients at risk for certain treatments affecting the CV system 
but also to duly detect acute complications such as autonomic dysreflexia. 
Monitoring of treatment-related adverse cardiovascular effects not only 
concern BoNT/A but also antimuscarinic drugs [209-212] and beta-3-
receptor agonists which are occasionally applied in NDO treatment in higher 
doses than approved [213-215] or in combination with each other [216, 217]. 
Increased dosing or combined therapy of antimuscarinics and beta-3-
receptor agonists may increase cardiovascular adverse events. 
Although AD should occur less frequently and less intensively after NDO 
treatment using BoNT/A due to the reduction of NDO that usually triggers 
AD [218, 219], severe AD may occur during the cystoscopic injection 
procedure [158, 220]. Hence, to adequately assess onset and severity of 
autonomic dysreflexia or other cardiovascular events, e.g. micturition 
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syncope, during urological procedures such as urodynamics or cystoscopy, 
continuous recording of blood pressure and heart rate, at the least, is 
mandatory, especially in all patients with evident or suspected suprasacral 
spinal cord lesions [220-222]. Other measures of autonomic function such as 
HRV that can be derived even retrospectively from the ECG, can 
supplement cardiovascular monitoring as needed. Since essential parts of 
the LUT, e.g. the detrusor and bladder neck, are exclusively autonomously 
innervated, further insights into autonomic function during urodynamics may 
help to add previously missing pieces to the puzzle and to better understand 
certain symptoms and dysfunction [223-228]. 
 
 
INTRAPROSTATIC APPLICATION OF BOTULINUM TOXIN A FOR 
TREATMENT OF MALE LOWER URINARY TRACT SYMPTOMS 
In addition to the distant and central effects of BoNT/A mentioned above, 
increasing evidence suggests that BoNT/A causes other additional effects 
within the LUT than just smooth muscle paralysis. Of special interest are the 
properties and effects of BoNT/A on LUTS related to prostatic enlargement 
and / or obstruction. Currently only a few pharmacological treatment options 
are available, i.e. plant extracts, alpha-blockers, and 5-alpha-reductase 
inhibitors that have proven but somewhat limited efficacy [229-231]. This 
also bears relevance to the neurological male patient, as it can be 
challenging to differentiate the proportions of prostatic and neurogenic 
involvement in the LUTS as presented [116, 232]. TURP in case of failure of 
conservative treatment may still be an option in selected neurological 
patients [102]. However, if neurogenic sphincter deficiency is present and 
hidden behind an anatomical cause and / or NDO is not adequately treated, 
post-TURP urinary incontinence may occur [107-110]. 
There are two prostatic components proposed to be involved in LUT 
dynamics and consequently also in the development of LUTS; a static 
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component related to prostate growth and a dynamic component related to 
the contractile tone of the smooth muscle cells in the prostate and prostatic 
urethra. Since the static component is under parasympathetic and 
sympathetic and the dynamic component under sympathetic influence [233], 
both components may be susceptible to BoNT/A intraprostatic injections due 
to its chemo-denervative properties that can modulate the autonomic 
prostatic innervation [234, 235]. 
In Chapter 6 we reviewed the current evidence on the mechanism of action 
of BoNT/A on the static and dynamic prostatic component and its application 
and efficacy in clinical practice [236]. 
At the level of animal research, it has been demonstrated that the effect of 
BoNT/A on the static component is related to prostatic apoptosis [237-242]. 
This would well explain the observed prostatic atrophy by means of reduced 
prostate size and weight in rats and dogs [237-241, 243, 244]. The 
mechanism by which BoNT/A may induce prostatic apoptosis is not yet fully 
understood but it is proposed that BoNT/A activates apoptotic pathways in 
the prostate through sympathetic outflow impairment [242]. This is mainly 
based on the observation that phenylephrine administration after BoNT/A 
injection into the gland, which is expected to replace the normal neuronal 
sympathetic drive impaired by the neurotoxin, prevents the apoptotic 
reaction [242]. 
However, most animal studies were performed on normal rats, not using 
specific BPH-models, and there are conflicting results relating to the 
occurrence of prostatic atrophy in humans [245-248]. 
Regarding the effect of BoNT/A on the dynamic prostatic component, it has 
been demonstrated that BoNT/A downregulates the expression of alpha-1A-
adrenoreceptors in the rat prostate [237]. This represents a strong argument 
to use BoNT/A intraprostatic injections for the treatment of enlarged 
prostate-related LUTS as alpha-1A-adrenoreceptor expression has been 
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found to be significantly increased in BPH compared to normal prostate 
tissue [249]. 
In line with these considerations, Lin et al. demonstrated reduced in-vivo 
urethral pressure responses to i.v. norepinephrine and reduced contractility 
of in-vitro prostate strips in response to KCL, epinephrine and 
electrostimulation after intraprostatic injection of 200 units 
onabotulinumtoxinA [243]. The underlying mechanism is suggested to be 
two-fold: a) impaired release of norepinephrine from adrenergic nerves and 
b) impaired intracellular contractile machinery in smooth muscle cells due to 
increased expression of outward current potassium channels as has been 
demonstrated to occur after SNAP-25 cleavage in oesophageal smooth 
muscle cells [250]. 
In clinical practice, BoNT/A can be injected into the prostate via three routes, 
transperineal, transrectal, and transurethral. Transperineal and transrectal 
ultrasound guided routes have been most frequently used [236, 251] of 
which the transperineal approach may be less prone to infections [235]. 
Intraprostatic injections are performed using a 20-22 G, 15-20 cm long 
needle and 2-4 injections per side with typically 200 units diluted in 4 mL 
[235]. Other dosages ranging from 100-300 units and dilutions have been 
used and the few existing dose-ranging studies do not provide reasonable 
evidence in favor of one dosage over another [235]. The mean onset of 
action seems to be around 3.5 weeks (range 1-6 weeks) and the mean 
duration 12 months (range 3-30 months) after injection but further, more 
specific, data on the onset and duration are required to further verify these 
time specifications in relation to the dosage [236]. Adverse events include 
gross hematuria, urinary retention and acute prostatitis which seem to be 
more procedure- than BoNT/A-related, as placebo injections showed no 
difference in adverse events compared to BoNT/A [248]. However, other 
important potential adverse events such as the effect of BoNT/A 
intraprostatic injections on sexual function have not been evaluated 
systematically. There is only one non-RCT reporting no effect on sexual 
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function following BoNT/A intraprostatic injections [252]. Despite promising 
results in initial trials, recent RCTs and meta-analyses do not provide 
evidence for significant differences with intraprostatic injections with BoNT/A 
compared to placebo [235, 248]. Nevertheless, at the current stage of 
understanding, the processes within the prostate after BoNT/A injections and 
the influence of the prostate and its functional and structural alterations on 
LUTS are still obscure, therefore it is too early to omit BoNT/A intraprostatic 
injections as a treatment option. It may serve as therapy in a selected patient 
population such as poor surgical candidates [253]. More basic knowledge on 
the physiological and pathophysiological processes of the prostate on LUT 
function and LUTS is required to address clear hypotheses and design 
adequate clinical trials. 
 
 
TREATMENT OF STRESS URINARY INCONTINENCE 
ASSOCIATED WITH NEUROGENIC SPHINCTER DEFICIENCY 
Despite efficient treatment for DO, urinary incontinence may persist due to 
sphincter deficiency. The motor neurons of the external urethral sphincter 
are located in the ventral part of the anterior sacral horn between S1 and S3, 
an area also called Onuf’s nucleus [254]. These neurons send their axons 
via the pudendal nerve to the EUS. Hence, any damage at or below the 
sacral level or of the pudendal nerve can result in sphincter deficiency. In 
addition to patients with iatrogenic nerve damage due to pelvic surgery, 
patients with spina bifida constitute a population that is often affected by 
neurogenic sphincter deficiency [255].  
Pelvic floor muscle training may be a conservative treatment option, but only 
in patients with at least some preserved voluntary EUS control, which is, 
however, typically lost or severely impaired in nSUI. Since there is no 
effective medical therapy for nSUI, treatment is mainly limited to surgical 
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solutions. However, the level of evidence of surgical treatments for nSUI is 
generally low due to the lack of RCTs [256]. 
Of the available surgical treatment options for nSUI (see chapter 1 and 2), 
urethral suspension using autologous fascia or synthetic slings and the 
artificial urinary sphincter have been most commonly and successfully used 
[256]. The use of autologous fascia slings requires abdominal surgery and is 
therefore frequently used in combination with bladder augmentation for 
treatment of concomitant NDO. Synthetic slings can be applied less 
invasively in a single procedure but may be prone to higher postoperative 
morbidity and complication rates [257-259]. In addition, explantation of 
synthetic slings in case of complications, i.e. infection, pain, and erosion, can 
be challenging. Therefore, in patients requiring a tight sling to virtually close 
the urethra when supplied with a catheterizable diversion, synthetic 
materials should not be used. 
The implantation of an artificial urinary sphincter system is a very effective 
therapy for nSUI, but, due to the more sophisticated approach, is associated 
with a higher rate of complications and reoperations [256]. Neurogenic 
patients in particular seem to have a higher risk of non-mechanical device 
failure, e.g. device infection and cuff erosion [260]. This may be related to 
the fact that many patients with NLUTD perform ISC which causes higher 
mechanical strain on the urethra and consequently any peri-urethral implant 
with the risk of erosion and perforation. Correspondingly, cuffs or slings 
placed at the bulbar urethra resulted in a higher rate of complication when 
compared to implantation at the bladder neck [256]. Despite introduction of a 
simplified AUS with the possibility of postoperative adjustment of cuff 
pressure that seems to cause less complications and revisions [261], we 
were interested in investigating an adjustable device that is simple to implant 
but also simple to explant in case of complications. 
Our results show that using the ACT® and ProACT® devices for treatment 
of nSUI in female and male neurological patients, respectively, incontinence 
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episodes were significantly decreased from 6.1 ±2.4 to 2.8 ±3.1 at 48 
months follow-up (chapter 7, [262]). However, only a fairly small proportion 
(21%) of patients gained full continence. This may be at least partly related 
to the heterogeneous study population including patients with complete and 
incomplete SCI, MS, surgical trauma to the pelvis, and meningomyelocele, 
resulting in different degrees of incontinence. Nevertheless, the number of 
fully continent patients remained stable throughout 4 years follow-up and 
more than half of patients had a ≥ 50% improvement in their incontinence.  
Although these results are inferior compared to those of AUS and slings, the 
ACT® / ProACT® devices combine certain advantages [262]: 1) Application 
is safe with few intraoperative and immediate postoperative complications 
even in neurogenic cases with previous LUT surgery. 2) The short, 
minimally-invasive procedure allows for fast healing and a short hospital stay 
or even outpatient treatment. 3) Outpatient adjustment of balloon volume 
according to the patient’s needs is quick and uncomplicated. 4) In contrast to 
slings / tapes or bulking agents, balloons can be explanted as an outpatient 
surgical procedure using local anesthesia in case of adverse events with the 
option of reimplantation at 3 months. 5) Balloon implantation or explantation 
does not preclude the implantation of other continence devices, ie an AUS, 
at a later stage. 
Although there are limited data on the use of ACT® / ProACT®, particularly 
after failed previous incontinence surgery [263, 264], there are currently no 
data available on the efficacy and safety of multiple subsequent ACT® / 
ProACT® implantations in the same patient group. Animal studies in dogs 
have demonstrated that a fibrous capsule of variable thickness and well-
organized layers of mature collagen develops around the device 
components which can be considered a typical and predictable foreign body 
reaction towards the device [265, 266]. Such fibrotic capsules may persist 
after explantation and, on the one hand, contribute to prolonged efficacy 
despite explantation but may also interfere with subsequent implantations at 
the same location and adjustment of balloon volume. 
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In conclusion, the ACT® / ProACT® device seems to be a valuable 
treatment option for nSUI in patients unwilling, unable or unsuitable for more 
invasive procedures or more complex implants, albeit for rather mild to 
moderate incontinence. The aforementioned low level of evidence for 
treatments of nSUI certainly applies also to this retrospective cohort study 
but it remains the only study on the use of ACT® / ProACT® in nSUI. Thus, 
first RCTs on this relevant topic would be highly appreciated. 
Independent of the surgical technique or device used or determined to be 
the best, NDO has to be excluded or appropriately treated prior to and again 
after surgery or implantation. Not following this principle may put the UUT in 
jeopardy, as with persistent or de novo DO combined with improved 
subvesical continence mechanisms, intravesical pressures will raise even 
higher during DO. 
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CONCLUSIONS AND FUTURE PERSPECTIVES 
There is a range of conservative and invasive treatment options available for 
the management of urine storage dysfunction in neurological patients, of 
which ISC, antimuscarinic drugs, intradetrusor BoNT/A injections, 
augmentation cystoplasty, urinary diversion, and AUS still represent the 
therapeutic cornerstones. Although this has not changed much recently, 
BoNT/A intradetrusor injections as a minimally-invasive therapy have 
contributed to reduce the large gap between conservative pharmacological 
and invasive surgical treatments. 
BoNT/A intradetrusor injections are readily applicable as an outpatient 
procedure and have a favorable efficacy / safety profile without evidence of 
significant distant or systemic effects, for instance on resting state cardiac 
function. However, elevated PVRV or even urinary retention is an issue in 
neurological patients. Adjustments of dosing, i.e. starting with a lower dose, 
can alleviate PVRV and allows for some adaptation of therapy to individual 
patient requirements according to symptom severity and urodynamic 
outcomes. Nevertheless, the precision of application using current 
techniques is limited and spread of BoNT/A beyond or outside the target 
tissue may reduce efficacy and affect adjacent organs such as the rectum. 
Moreover, the potential auxiliary mechanisms of BoNT/A on the afferent 
neuronal pathways need further elucidation. Other therapeutic indications of 
BoNT/A such as intraprostatic injections for LUTS related to BPH have a 
scientific rationale but still lack convincing clinical evidence and thus may 
currently serve as an off-label alternative for poor surgical candidates only. 
In contrast to NDO, effective treatment of urinary incontinence due to 
neurogenic sphincter deficiency much more frequently requires 
reconstructive or prosthetic surgery. The ACT® / ProACT® device may be a 
minimally-invasive option for mild to moderate incontinence due to 
neurogenic sphincter deficiency with the possibility of post-operative 
adjustment in an outpatient setting. In case of complications, the device is 
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easily explanted under local anesthesia without limiting the potential for 
(re)implantation of the same or other continence devices at a later stage. 
Although modern neuro-urological work- and follow-up have contributed to 
significant improvements in life-expectancy and QoL for many neurological 
patients affected by NLUTD, the management of urine storage dysfunction in 
the neurological patient is still a challenge and often requires a combination 
of treatments or multidisciplinary treatment approaches. This is, on the one 
hand, due to frequently-occurring co-disabilities caused by the underlying 
neurological lesion / disease but, on the other, also due to the limitations of 
the currently available treatments. It is, for example, still a major difficulty to 
effectively reduce or abolish DO in the storage phase without compromising 
detrusor contractility in the voiding phase and to effectively treat DSD or 
detrusor underactivity without using catheters. 
This may be in turn related to (1) the complex multilevel neurogenic control 
of the LUT that is still not fully understood in detail and (2) our still 
incomplete comprehension of the mechanisms of action, best patient 
selection, and reasons for treatment failures in available therapies such as 
neuromodulative treatments and BoNT/A intradetrusor injections. In addition, 
there are major difficulties in transferring findings and conclusions from the 
numerous available in-vitro and animal models to humans. This is mainly 
due to many models only focusing on just one specific mechanism, 
disregarding other mechanisms compensating for a specific system failure. 
This advocates for more models following an integrative, system-based 
physiological approach. Then again, there is a distinct lack of adequate and 
reliable assessment tools and biomarkers to objectively investigate 
functional and structural correlates of LUTD / LUTS and their treatment in 
more detail directly in humans. 
To better address in the future the challenges in the management of urine 
storage dysfunction in neurological patients, further research should not only 
focus on discovery of new treatment targets but also strive to amplify our 
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knowledge and understanding of currently existing therapies. This will help 
to more effectively use therapies that are already available to our patients. 
Our own results and findings from animal studies [140, 160] have shown that 
BoNT/A intradetrusor injections involve spread and migration of the toxin 
beyond the LUT. In addition, there are, on the one hand, known yet 
unexplained primary and secondary treatment failures of BoNT/A 
intradetrusor injections and, on the other, auxiliary effects of BoNT/A that are 
not yet fully understood. Therefore, the following research questions should 
be addressed next: Are we always able to apply the toxin to the right 
location, i.e. detrusor muscle, in the right amount / concentration? How 
relevant is the exact BoNT/A application for a favorable treatment outcome? 
To which locations and through which pathways does the toxin migrate after 
intradetrusor injections? 
To address these questions and to understand to where the toxin exactly 
migrates and where potential auxiliary effects may be exerted would require 
tracing of the toxin, which is challenging in vivo. Methods such as radio- / 
isotopic-labeling of the toxin in combination with specific imaging techniques 
such as scintigraphy, PET-CT, or MR-spectroscopy may be applicable but 
require further exploration and evaluation. Nevertheless, the ability to 
visualize and monitor the distribution of BoNT/A within the target tissue, i.e. 
detrusor muscle, and to correlate how relevant this is in relation to the 
treatment outcome will be of special importance for patients who did not 
show the expected response to their BoNT/A treatment and may provide 
relevant information on how to prevent such treatment failures including 
reconsideration of application technique and precision. BoNT/A tracing will 
help to explore methods of more targeted application that may reduce the 
number of treatment failures and prevent more invasive treatments. Future 
alternatives to injections, e.g. simple instillation using a carrier [267], can be 
assessed in regard to the real diffusion behavior, i.e. if BoNT/A is diffusing 
into the muscle or even beyond or mainly remains at the mucosal level.  
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Both BoNT/A intradetrusor injections and antimuscarinic drugs are thought 
to act in a manner supplementary to their conventional mechanism of action 
on LUT afferents. This is of relevance, as alterations of LUT afferent function 
seem to play an important role in the pathophysiology of LUTD / LUTS. 
However, to quantify and understand alterations of function and integrity of 
LUT afferents related to neurological disease or lesion and treatments, it is 
mandatory to provide a reliable and objective assessment of LUT afferents 
in humans. LUT sensory evoked potentials, as recently investigated by our 
group [268, 269], may be such a tool to objectively assess LUT afferent 
function in more detail. Methodological considerations are currently being 
studied in larger groups of healthy subjects and first investigations in 
neurological patients will follow to evaluate diagnostic potential 
(NCT02272309). 
Such a tool may finally also contribute to the understanding of the effect of 
neuromodulation on LUT afferents. In conjunction with functional and 
structural neuroimaging, sensory evoked potentials may provide an essential 
piece in the puzzle of how to improve our knowledge on the mechanism of 
action of neuromodulation on spinal and supraspinal neuronal LUT control.  
Considering that the underlying cause of LUTD is a neurological lesion or 
disease that in most cases cannot be completely cured or reversed, 
treatments using implantable neuro-prosthesis or non-implantable 
neuromodulation or -stimulation to control or modulate neurogenic tissue to 
bridge or compensate for neurological defects appear to be most promising 
and worthwhile to invest more research efforts in the future [95, 270]. 
Currently, neuromodulative therapies appear to be the only option that would 
allow alleviation of NDO and DSD without impairing a preserved voluntary 
voiding contraction. However, except for exploring and using sacral 
neuromodulation also for neurogenic LUTD, not much has changed or 
advanced in regard to this technique during the last two decades. The same 
applies to the only available LUT neuroprosthesis, the Brindley Finetech 
anterior root stimulator. In this regard, a broader and more profound 
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collaboration between neuroscientists, engineers and urologists would be 
highly desirable and would inspire and promote development on this seminal 
sector. 
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SUMMARY 
Neurogenic lower urinary tract (LUT) dysfunction is a frequent sequela to 
neurological disease or trauma with devastating consequences to patients’ 
general health and quality of life (QoL). Since the causative neurological 
condition usually cannot be cured or reversed and even with a less 
progressive or putative “stable” neurological disease / lesion, the LUT 
dysfunction (LUTD) may worsen, patients require life-long, specialized 
neuro-urological care and follow-up. 
This thesis describes important aspects of urine storage dysfunction in 
neurological patients and their current treatment options with a special focus 
on therapies using botulinum neurotoxin A (BoNT/A). The studies presented 
in this thesis contribute novel insights into the management of LUT 
dysfunction (LUTD) / LUT symptoms (LUTS) in neurological patients and 
provide starting points for future research. 
Chapter 1 provides a comprehensive overview of the neurophysiological 
background of LUT function and the LUT related pathophysiological changes 
occurring as a result of neurological disease or trauma. Epidemiological data 
are presented and both urodynamic and clinical findings are matched with 
the related symptoms and typical neurological lesions. Finally, currently 
available treatment options are summarized with a focus on restoration of 
bladder and urethral urine storage function. 
Chapter 2 presents a literature review on the management of urinary 
incontinence in the male neurological patient, highlighting the most recent 
and relevant publications related to this topic. The cornerstones of urine 
storage dysfunction management in neurological patients, such as 
intermittent self-catheterization (ISC), antimuscarinic drugs, intradetrusor 
BoNT/A injections, augmentation cystoplasty, urinary diversion, and artificial 
urinary sphincter, are largely unchanged. However, with the exception of 
onabotulinumtoxinA intradetrusor injections, the level of evidence for many 
therapy options is quite low. In addition, current findings are mainly derived 
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from multiple sclerosis and spinal cord injury patients without gender-specific 
outcomes, limiting generalization of the results. 
Chapter 3 describes a first-of-its-kind study in humans on the distribution of 
the onabotulinumtoxinA solution mixed with gadopentate using MR imaging 
after intradetrusor injections. The onabotulinumtoxinA / gadopentate solution 
showed spreading within the bladder wall, but also beyond, as 17.6 % of 
contrast medium was found outside the bladder wall in the perivesical fatty 
tissue. Although the mean contrast enhanced detrusor volume did not 
exceed one-third of the total detrusor volume, 83% of patients demonstrated 
sufficient efficacy of the treatment. However, a larger area of detrusor 
coverage appears to result in a larger reduction of maximum detrusor 
pressure and a greater increase in bladder capacity.  
Chapter 4 reports, for the first time, a study using low dose, i.e. 100 units, 
onabotulinumtoxinA intradetrusor injections to treat neurogenic detrusor 
overactivity (NDO) in patients with multiple sclerosis. The aim was the 
reduction of overactive bladder symptoms (OABS) to a satisfactory level 
without causing impaired voiding, which would require ISC. Our results 
showed that treatment with 100 units significantly reduced all symptoms. 
However, post void residual volume (PVRV) initially increased, requiring 
16% of patients to use ISC twice daily and one patient to have a suprapubic 
catheter. The main difficulty in interpreting these results is the lack of PVRV 
cut-off values indicating when to start with ISC. It is, however, questionable if 
such a cut-off value is really needed and clinically useful, as the decision as 
to when to use ISC should be made based on symptoms. This would allow 
more patient- and QoL-oriented management. 
Chapter 5 describes a study investigating systemic, distant effects of 
onabotulinumtoxinA on cardiac function after intradetrusor injections for the 
treatment of NDO. Resting electrocardiogram was recorded for 15 minutes 
from patients and age-matched healthy controls during 4 consecutive visits. 
Patients received 300 unit onabotulinumtoxinA intradetrusor injections 
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between visits 2 and 3. The recorded electrocardiograms were evaluated, 
including the time and frequency domain parameters of heart rate variability 
(HRV) analysis. Despite a short-term increase in total power (TP) between 
visits 2 and 3 in the patient group, no further alterations of resting state 
cardiac function were observed. The observed changes in TP are a rather 
positive sign, indicating elevated HRV, potentially in response to procedure-
related discomfort, and were not different compared to the healthy group or 
to normative values from the literature. 
Chapter 6 provides a review on the current pre-clinical and clinical evidence 
for intraprostatic BoNT/A injections to treat LUTS related to benign prostatic 
enlargement (BPE). There is some evidence that intraprostatic BoNT/A 
injections affect both the static and dynamic component of BPE-related 
LUTS by reducing prostate volume and the number of alpha-adrenoceptors. 
The reduction of prostate volume seems to be mainly related to apoptosis 
and glandular atrophy. Despite the rather simple and apparently safe 
application technique and initially promising clinical results, the current level 
of evidence is still surprisingly low. Hence, randomized controlled trials are 
required to provide more reliable recommendations on BoNT/A treatment for 
this indication. 
Chapter 7 presents a first-of-its-kind investigation into the use of an 
adjustable continence device (ACT®, ProACT®) to treat stress urinary 
incontinence due to neurogenic sphincter insufficiency. The majority of 
patients (92%) used ISC as the main mode of bladder emptying. The ACT® / 
ProACT® device was implanted under local anesthesia in most cases 
(84%). Complete continence was achieved in 21% of patients, at least 50% 
improvement or more was achieved in 54% of patients, and 6% of patients 
had less than 50% improvement after 48 months follow-up. Permanent 
device explantation was performed in 40% of patients after 48 months 
follow-up due to insufficient efficacy and / or adverse events such as erosion 
/ migration, infection, pain, and device failure. Explantation is safe and 
relatively easy and can be performed in an outpatient setting in most cases.  
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Although the efficacy seems to be lower compared to previous studies, most 
likely due to the severity of continence deficiency in our neurogenic 
population, the safety profile is good with minor, mainly self-limiting 
intraoperative and postoperative complications. The ACT® / ProACT® 
device seems to be a reasonable option for treating neurogenic stress 
urinary incontinence in patients who have minor symptoms and / or are not 
willing, not suitable or not yet ready for more invasive surgery. 
Chapter 8 comprises the general discussion in which all aforementioned 
studies of this thesis are critically discussed in the context of the current 
literature. Generally, we have an improved understanding on the 
pathophysiological processes that alter LUT function in consequence to 
neurological disease and trauma. However, we still have an incomplete 
understanding of mechanisms of action, best patient selection, and reasons 
for treatment failure of currently-applied therapies such as sacral 
neuromodulation and BoNT/A intradetrusor injections. BoNT/A 
revolutionized the treatment of NDO and helped to reduce the gap between 
conservative drug treatment and invasive surgery. Despite its success and 
widespread use, the full potential and range of BoNT/A application in the 
LUT has not yet been fully exploited. 
Future research should thus not only focus on the discovery of new 
treatment targets, which may take decades to become a genuine treatment 
option, but also on the exploration of the full potential and possibilities of 
treatment options that are currently available. Enabling real-time 
visualisation of BoNT/A distribution after intradetrusor injections in vivo 
would allow a better comprehension of the distribution and locations of 
action of the toxin within the human LUT and adjacent structures. This may 
also help to clarify reasons for treatment failures and strategies to prevent 
them. Objective and quantitative assessment of human LUT afferents, e.g. 
using LUT sensory evoked potentials, would allow more detailed evaluations 
of the changes in the afferent system in LUTD / LUTS conditions. This may 
create a better understanding of the mechanism of action of therapies 
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targeting the LUT afferents such as antimuscarinics, BoNT/A, and 
neuromodulative therapies. The latter and the more sophisticated 
neuroprostheses have great potential in bridging or compensating for 
neurological deficits and restoring LUT function. However, more efforts are 
necessary to make meaningful advances and interdisciplinary collaboration 
between neuroscientists, engineers, neurologists, rehabilitation physicians, 
and urologists is crucial to this endeavour. 
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NEDERLANDSE SAMENVATTING 
Neurogene disfunctie van de lage urinewegen (LUT) is een vaak 
voorkomend gevolg van neurologische ziekten en trauma en heeft zeer 
ingrijpende consequenties voor de algemene gezondheid van patiënten en 
hun kwaliteit van leven. Gegeven het feit dat de neurologische conditie 
veelal niet kan worden genezen en de disfunctie van de lage urinewegen 
zelfs bij minder progressieve of vermeend „stabiele“ neurologische ziekte 
gewoonlijk progressief is, is levenslange gespecialiseerde neuro-urologische 
zorg en follow-up noodzakelijk. 
Dit proefschrift beschrijft belangrijke aspecten van een verstoorde urine 
opslag bij neurologische patiënten en de nu voor handen zijnde 
behandelopties hiervoor, met speciale aandacht voor Botuline neurotoxine A 
(BoNT/A) injecties. De studies die in dit proefschrift worden gepresenteerd 
dragen bij aan nieuwe inzichten in het omgaan met de verstoring van de 
functie van de lage urinewegen en de gerelateerde symptomen (LUTS) in 
neurologische patiënten. Daarnaast wordt aangegeven welke nieuwe 
onderzoeksinitiatieven ontwikkeld kunnen worden voor deze problematiek. 
Hoofdstuk 1 schetst een beeld van de neurofysiologische controle van de 
lage urinewegen en de veranderingen die kunnen optreden als gevolg van 
neurologische ziekte of trauma van het centrale of perifere zenuwstelsel. 
Epidemiologische data worden gepresenteerd in combinatie met 
urodynamische en klinische bevindingen in de context van de specifieke 
neurologische laesies. Tot slot worden momenteel beschikbare 
behandelopties samengevat met de focus op herstel van de opslagfunctie 
van de lage urinewegen.  
Hoofdstuk 2 geeft een overzicht van de beschikbare literatuur over de 
aanpak van urine-incontinentie bij de mannelijke neurologische patiënt. De 
meest recente publicaties worden besproken betreffende intermittente 
zelfkatheterisatie (ISC), antimuscarinerge medicatie, BONT/A injecties in de 
blaasspier (detrusor), augmentatie cystoplastiek, urineweg afleiding met 
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darm en de kunstmatige sluitspierprothese. Het bewijs van de effectiviteit 
van bovenstaande therapieën is over het algemeen laag behalve voor 
BONT/A detrusor injecties. De bevindingen zijn overigens wel hoofdzakelijk 
gebaseerd op studies met patiënten met multiple sclerose (MS) of een 
dwarslaesie zonder verschil te maken tussen mannen en vrouwen. Dit 
beperkt de toepasbaarheid in de algemene populatie. 
Hoofdstuk 3 beschrijft een eerste studie bij mensen waarin met behulp van 
een MRI gekeken werd naar de verspreiding van een oplossing van 
onabotulinumtoxine A gemengd met het MRI contrastmiddel gadopentate na 
injecties in de detrusor. Van deze oplossing bleek 17,6 % niet in de blaas 
terecht te komen maar in het omgevende vetweefsel. Hoewel de patiënten in 
minder dan een derde van de blaas de geïnjecteerde botuline toxine met 
MRI contrast lieten zien, werd toch in 83% van de patiënten een positief 
effect van de behandeling gevonden. Wel bleek dat een groter 
behandeloppervlak geassocieerd was met een grotere blaascapaciteit 
postoperatief.  
Hoofdstuk 4 presenteert de resultaten van een studie waarbij voor de 
eerste keer een lage dosis van 100 units onabotulinumtoxine A is gebruikt 
voor de behandeling van neurogene detrusor overactiviteit in MS patiënten. 
Het doel van deze studie was om de symptomen van een overactieve blaas 
adequaat te reduceren en minder patiënten zouden worden gezien met een 
residu na mictie waarvoor katheterisatie nodig zou zijn. Er werd vastgesteld 
dat de symptomen significant verbeterden na de behandeling, maar 16 % 
van de patiënten moesten 2 x per dag katheteriseren en 1 patiënt had een 
suprapubische katheter nodig. Doordat er geen algemeen geldende 
afkapwaarde bestaat voor het residu waarop gekatheteriseerd moet worden, 
is een conclusie moeilijk. De vraag blijft of een afkapwaarde nodig is en of 
niet beter zou kunnen worden beslist aan de hand van klinische symptomen. 
Dit laatste is een praktische aanpak en leidt wellicht tot een betere kwaliteit 
van leven.  
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Hoofdstuk 5 beschrijft een studie naar systemische en specifieke effecten 
van onabotulinumtoxineA op hartfunctie na blaasinjecties. Een ECG in rust 
werd opgenomen gedurende 15 minuten bij patiënten en bij gezonde 
controles gedurende 4 opeenvolgende bezoeken. Tussen visite 2 en 3 werd 
bij de patiënten een behandeling met intradetrusorinjecties met 
onabotulinumtoxine A gegeven. Behalve een kortdurende periode met 
hogere kracht (TP: total power) tussen visite 2 en 3 konden geen 
veranderingen worden gezien in Hart rust functie. De TP-verhoging zijn juist 
een positief teken van verhoogde hartritme variabiliteit mogelijk gerelateerd 
aan procedure of ongemak, deze bevinding is niet anders dan wat bij 
gezonde proefpersonen of in de literatuur wordt gezien.  
Hoofdstuk 6 is een overzicht van de huidige preklinische en klinische data 
betreffende de behandeling van LUTS en benigne prostaat hyperplasie met 
intraprostatische BoNT/A injecties. Er is enig bewijs dat BONT/A invloed 
heeft op, zowel de statische en dynamische component van de aan benigne 
prostaat vergroting gerelateerde LUTS door het verkleinen van het 
prostaatvolume en door het verlagen van het aantal alfa receptoren. De 
volumereductie lijkt vooral te wijten aan apoptose en klier atrofie.  
Hoofdstuk 7 beschrijft een eerste onderzoek naar het gebruik van de 
aanpasbare continentie behandeling middels ACT® en PRO ACT® 
ballonnetjes voor de behandeling van stress incontinentie bij neurogene 
sluitspier dysfunctie. Het grootste deel van de onderzochte patiënten paste 
intermittente katheterisatie toe om de blaas te ledigen. De ballonnetjes 
konden worden ingebracht onder lokale anesthesie bij 84% van de 
patiënten. Volledige continentie werd bereikt bij 21% van de patiënten, ten 
minste 50% verbetering werd gezien bij 54% van de patiënten en 6 % had 
minder dan 50 % verbetering na 48 maanden follow-up. Permanente 
explantatie was geïndiceerd bij 40 % wegens te weinig effect of ongewenste 
nevenwerking zoals erosie, migratie, infectie of pijn. Explantatie is eenvoudig 
en veilig en kan in de meerderheid van de gevallen poliklinische gebeuren.  
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Hoewel het therapeutisch effect minder is dan bij eerdere studies, wat 
waarschijnlijk het gevolg is van ernstiger incontinentie in deze populatie, is 
het veiligheidsprofiel van deze procedure goed met meestal beperkte 
complicaties. Daarom is de ACT en PRO ACT een realistische optie voor de 
behandeling van neurogene stress incontinentie voor patiënten met beperkte 
symptomen die geen of nog geen invasieve chirurgische behandeling willen 
of kunnen ondergaan. 
Hoofdstuk 8 is de algemene discussie. Hierin worden alle hiervoor 
besproken studies kritische bediscussieerd in de context van momenteel 
beschikbare literatuur. De pathofysiologische processen die de functie van 
de lage urinewegen veranderen als gevolg van neurologische ziekte of 
trauma zijn beter bekend. Toch is er nog een onvolledig begrip van 
werkingsmechanismen, patiënt selectie technieken en redenen voor het toch 
regelmatig falen van huidige therapie zoals neuromodulatie en BoNT/A 
behandeling. 
BoNT/A heeft de behandeling van neurogeen blaaslijden revolutionair 
veranderd en heeft de kloof overbrugd tussen conservatieve 
medicamenteuze therapie en invasieve chirurgie. Ondanks het succes van 
deze therapie zijn nog niet alle mogelijkheden en toepassingen van deze 
therapie op de lage urinewegen te volle benut.  
Daarom zal toekomstig onderzoek niet alleen nieuwe behandeldoelen en 
soorten moeten onderzoeken, maar ook zullen alle mogelijkheden met 
momenteel beschikbare therapieën verder moeten worden geperfectioneerd 
en benut. De gelijktijdige visualisatie in vivo tijdens BoNT/A injecties zou een 
beter inzicht kunnen bieden in de verdeling en de plaats van injectie. Dit kan 
zorgen voor betere injectietechniek en falen van behandelingen voorkomen. 
Objectief en kwantitatief in kaart brengen van afferente zenuwen van de lage 
urinewegen door bijvoorbeeld Evoked Potentials van de Lage Urinewegen 
kan meer inzicht geven in normale en pathologische condities van het 
afferente systeem bij LUTS. Dit kan ook helpen bij het begrijpen van 
werkingsmechanismen van andere therapieën zoals antimuscarinica, 
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BoNT/A en neuromodulatie. Deze laatsten en gesofisticeerde neuro-
prosthetische toepassingen hebben een enorme potentie LUT functie te 
corrigeren vooral door het overbruggen of compenseren van neurologische 
afwijkingen. Hiervoor is interdisciplinaire samenwerking nodig tussen 
neurowetenschappers, technische ingenieurs, neurologists, revalidatieartsen 
en urologen. 
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ZUSAMMENFASSUNG IN DEUTSCH 
Funktionsstörungen des unteren Harntraktes sind häufige Folge 
neurologischer Erkrankungen oder Verletzungen der versorgenden 
zentralen und / oder peripheren Nervenbahnen mit verheerenden Folgen für 
die Gesundheit und Lebensqualität der betroffenen Patienten. Da die 
zugrundeliegende neurologische Erkrankung oder Verletzung meist nicht 
geheilt werden kann und selbst bei gering progressiven oder vermeintlich 
„stabilen“ neurologischen Erkrankungen / Verletzungen eine 
Verschlechterung der Funktionsstörung des unteren Harntraktes eintreten 
kann, ist eine lebenslange, spezialisierte neuro-urologische Nachsorge 
notwendig. 
Die vorliegende Dissertation beschreibt die wesentlichen Aspekte und 
aktuellen Behandlungsoptionen von Harnspeicherstörungen bei 
neurologischen Patienten wobei der Fokus auf Therapien mit Anwendung 
von Botulinum Neurotoxin A (BoNT/A) liegt. Die in dieser Dissertation 
enthaltenen Studien leisten einen Beitrag zu neuen Erkenntnissen in der 
Behandlung von neurogenen Funktionsstörungen und Symptomen des 
unteren Harntraktes und liefern relevante Ansatzpunkte für zukünftige 
Forschungsprojekte auf diesem Gebiet. 
Kapitel 1 vermittelt eine umfassende Übersicht über die 
neurophysiologischen Grundlagen der Funktion des unteren Harntraktes 
sowie der pathophysiologischen Veränderungen dieser Funktion als Folge 
eines neurologischen Traumas oder Erkrankung. Es werden sowohl 
epidemiologische Daten präsentiert als auch typische urodynamische 
Befunde mit der entsprechenden klinischen Symptomatik und der 
zugrundeliegenden neurologischen Erkrankung / Verletzung 
gegenübergestellt. Zudem wird ein Überblick über die zurzeit verfügbaren 
Therapieoptionen mit Fokus auf die Wiederherstellung einer adäquaten 
Harnspeicherfunktion gegeben. 
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Kapitel 2 präsentiert das Ergebnis einer ausgiebigen Literaturrecherche zur 
Behandlung von Harninkontinenz bei männlichen Patienten mit 
neurologischer Erkrankung. Die Grundstöcke der Therapie von 
Harnspeicherstörungen bei neurologischen Patienten wie z.B. 
intermittierender Selbstkatheterismus, antimuskarinerge Medikamente, 
BoNT/A Intradetrusorinjektionen, Harnblasenaugmentation, operative 
Harnableitung und Schliessmuskelprothese, haben sich im wesentlichen 
nicht verändert. Dennoch sind die Evidenzniveaus der meisten Therapien 
mit Ausnahme von BoNT/A Intradetrusorinjektionen immer noch gering. 
Zudem basieren die aktuellen Erkenntnise im Wesentlich auf Daten von 
Patienten ausschliesslich mit Querschnittlähmung oder Multipler Sklerose 
ohne Angaben geschlechtsspezifischer Befunde, wodurch eine 
Generalisierung bzw. Übertragbarkeit der Resultate auf andere 
Patientengruppen eingeschränkt ist.  
Kapitel 3 berichtet über die Ergebnisse einer erstmaligen Studie zur 
Untersuchung der in vivo Verteilung der BoNT/A-Lösung nach 
Intradetrusorinjektionen. Dazu wurde das BoNT/A mit Gadolinium-basiertem 
Kontrastmittel gemischt und nach den Intradetrusorinjektionen eine MRT 
Untersuchung durchgeführt. Dabei zeigte sich, dass die BoNT/A / 
Gadolinium-Mischung sich sowohl in der Blasenwand als auch ausserhalb 
verteilt. 17.6% der Kontrastmittelmenge wurde im perivesikalen Fettgewebe 
identifiziert. Obwohl das kontrastierte Detrusorvolumen maximal ein Drittel 
des gesamten Detrusorvolumens ausmachte, zeigten 83% der Patienten 
eine suffiziente Therapiewirkung. Dennoch lies sich ein Trend erkennen, bei 
dem eine grössere Abdeckung des Detrusors mit der BoNT/A / Gadolinium-
Lösung in einer stärkeren Reduktion der maximalen Detrusordrücke und 
höheren Blasenkapazität resultierte. 
Kapitel 4 beschreibt eine Studie bei der erstmals eine niedrige BoNT/A 
Dosis, d.h. 100 Einheiten Botox®, zur Therapie der neurogenen 
Detrusorüberaktivität bei Patienten mit Multipler Sklerose eingesetzt und 
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evaluiert wurde. Mit Verwendung der niedrigen Dosis sollte die nachteilige 
Wirkung der Therapie auf die Harnblasenentleerung vermieden bzw. 
zumindest reduziert werden, bei gleichzeitig guter Wirkung auf die 
Detrusorüberaktivität und die konsekutive Drang- und 
Inkontinenzsymptomatik. Die Ergebnisse zeitgen, dass mit 100 Einheiten 
Botox® eine signifikante Abnahme von Detrusorüberaktivität sowie Drang- 
und Inkontinenzsymptomen erzielt werden konnte. Allerdings kam es initial 
zu einem Ansteig der postmiktionellen Restharnmengen, so dass in 16% der 
Patienten ein Selbstkatheterismus 2x/d und in einem Fall die Versorgung mit 
einen suprapubischen Katheter notwendig wurde. Eine wesentliche 
Schwierigkeit bei der Interpretation dieser Resultate ist das Fehlen einer 
einheitlichen Restharnschwelle ab der mit dem intermittierendem 
Selbstkatheterismus begonnen werden sollte. Es ist jedoch andererseits 
fraglich ob ein strikter Schwellenwert für den klinischen Alltag geeignet ist 
und nicht vielmehr eine symptombasierte Entscheidung das bessere 
Vorgehen wäre im Sinne der Lebenqualität. 
Kapitel 5 beschreibt eine Studie bei der mittels 
Herzfrequenzvariabilitätsanalyse systemische Nebenwirkungen auf die 
Herzfunktion durch BoNT/A nach Intradetrusorinjektionen untersucht 
wurden. Dazu wurde bei Patienten und altersgleichen gesunden Probanden 
ein Ruheelektrokardiogramm über 15 Minuten an vier konsekutiven Visiten 
aufgezeichnet. Zwischen Visite 2 und 3 erhielten die Patienten 300 Einheiten 
OnabotulinumtoxinA in den Detrusor. Die aufgezeichneten 
Elektrokardiogramme wurden in Hinblick auf Parameter der Zeit- und 
Frequenzdomäne der Herzfrequenzvariabilitätsanalyse ausgewertet. Ausser 
einem kurzzeitigen Anstieg der Herzfrequenz-Gesamtpower zwischen den 
Visiten 2 und 3 in der Patientengruppe konnten keine weiteren 
Veränderungen der kardialen Ruhefunktion beobachtet werden. Die 
Zunahme der Gesamtpower ist als Zeichen für einen leichten Anstieg der 
Herzfrequenzvariabilität positiv zu werten und möglicherweise durch 
interventionsbedingte Beschwerden oder Anspannung verursacht. Im 
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Vergleich zwischen Patienten und gesunden Probanden zeigte die 
Gesamtpower keinen Unterschied und lag auch im Rahmen der 
beobachteten Erhöhung stets im Normbereich. 
Kapitel 6 beinhaltet eine Übersichtsarbeit zur Anwendung von BoNT/A in 
der Therapie von Symptomen des unteren Harntraktes, die mit einer 
gutartigen Vergrösserung der Prostata assoziiert sind. Es wird die 
präklinische als auch klinische Datenlage beschrieben. Dabei zeigten sich 
Hinweise für eine Wirkung des BoNT/A sowohl auf die statische als auch 
dynamische Komponente der prostatabezogenen Beschwerden des unteren 
Harntraktes. Dies scheint einerseits über die Reduktion des 
Prostatavolumens durch eine BoNT/A induzierte Apoptose und durch eine 
verminderte Expression von Alpha-Adrenorezeptoren zu erfolgen. Trotz der 
relativ einfachen und weitgehend sicheren Applikation, mit guten initialen 
Erfolgen, ist das Evidenzniveau noch immer sehr gering, so dass nun 
randomisierte, kontrollierte Studien folgen müssen. 
Kapitel 7 zeigt die Ergebnisse einer erstmaligen Untersuchung zur 
Anwendung eines paraurethralen, justierbaren Kontinenzsystems (ACT® / 
ProACT®) bei neurogener Belastungsharninkontinenz. Die Mehrzahl der 
untersuchten Patienten (92%) führte zur Harnblasenentleerung den 
intermittierenen Selbstkatheterismus durch. Die Implantation der ACT® / 
ProACT® Prothesen erfolgte in den meisten Fällen (84%) in 
Lokalanästhesie. Nach 48 Monaten konnte eine mindestens 50%ige 
Verbesserung in 54% der Patienten erzielt werden, davon 21% mit 
vollständiger Kontinenz. 6% der Patienten hatten weniger als 50% 
Verbesserung und in 40% der Patienten musste das Kontinenzsystem 
explantiert werden auf Grund von fehlender Effektivität oder 
Nebenwirkungen wie Arrosion / Migration, Infektion und Schmerz. Die 
Explantationen liessen sich sicher und meist einfach im ambulanten Setting 
durchführen. Obwohl die Effizienz der ACT® / ProACT® Prothese im 
Vergleich zu Daten aus vorherigen Studien bei nicht-neurogener 
Belastungsharninkontinenz in unserer Cohorte etwas geringer war, bedingt 
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durch die ausgeprägtere Funktionsstörung mit Sphinkterinsuffizienz bei den 
neurologischen Patienten, konnte ein gute Anwendungssicherheit 
festgestellt werden mit wenigen, meist selbstlimitierenden und nicht 
schwerwiegenden Nebenwirkungen. Die ACT® / ProACT® Prothese scheint 
insbesondere für Patienten geeignet, die eine milde bis moderate neurogene 
Belastungsinkontinenzsymptomatik aufweisen und / oder für die invasivere 
Optionen ungeeignet oder nicht gewünscht sind. 
Kapitel 8 beinhaltet die allgemeine Diskussion, in der alle vorhergehenden 
Kapitel und entsprechenden Studien dieser Dissertation kritisch und im 
Kontext der aktuellen Literatur diskutiert werden. 
Obwohl wir mittlerweile ein verbessertes Grundverständnis von den 
pathophysiologischen Prozessen, die zu den Funktionsstörungen des 
unteren Harntraktes nach neurologischer Erkankung oder Trauma führen, 
haben, besteht eine nur unzureichende Kenntnis über die genauen 
Wirkmechanismen, die ideale Patientenselektion und Gründe für 
Therapieversagen bei aktuell bereits angewendeten Behandlungen wie 
Sakrale Neuromodulation und BoNT/A Intradetrusorinjektionen. BoNT/A hat 
die Behandlung der therapierefraktären neurogenen Detrusorüberaktivität in 
den letzten Jahrzehnten revolutioniert und die grosse Lücke zwischen 
konservativ medikamentöser Therapie und offen chirurgischer Lösungen 
erheblich verringert. Trotz dieses Erfolges und der weitläufigen Anwendung, 
wurde das volle Potential dieser Therapie bislang noch nicht ausgeschöpft. 
Daher sollten sich zukünftige Forschungsbestrebungen nicht immer nur auf 
die Entdeckung neuer potentieller Therapieziele fokussieren, die 
möglicherweise noch Jahrezehnte bis zur klinischen Anwendbarkeit 
benötigen, sondern auch dazu beitragen, die bisherigen Therapieoptionen 
deutlich besser zu verstehen, um das volle Potential dieser Therapien 
ausnutzen zu können. 
In vivo echtzeit Visualisierung der BoNT/A Ausbreitung nach 
Intradetrusorinjektionen würde ein besseres Verständnis der Verteilung 
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innerhalb und ausserhalb des unteren Harntraktes ermöglichen. Durch ein 
solches Verfahren könnten sich möglicherweise auch Gründe für ein 
Therapieversagen feststellen lassen und Optimierungen der 
Injektionstechnik vorgenommen werden. 
Die objektive, quantitative Evaluation der afferenten Bahnen des unteren 
Harntraktes mittels sensorisch evozierter Potentiale kann dazu beitragen, 
dass die Rolle der afferenten Fasern und Bahnen im Rahmen von 
Funktionsstörungen des unteren Harntraktes besser verstanden wird und 
der Wirkungsmechanismus von Behandlungen, die auf die afferenten 
Bahnen des unteren Harntraktes abzielen (z.B. antimuskarinerge 
Medikamente, BoNT/A, neuromodulative Therapien) genauer verstanden 
und evaluiert werden kann. 
Aus therapeutischer Sicht haben neuromodulative Verfahren und 
Neuroprothesen (z.B. Brindley-Finetech Stimulator) das grösste Potential 
durch Überbrückung und / oder Kompensation von neurologischen Defiziten 
eine Restauration der Funktion des unteren Harntraktes zu erreichen. Um 
diesbezüglich in Zukunft relevante Fortschritte zu erzielen, ist eine verstärkte 
interdisziplinäre Zusammenarbeit von Neurowissenschaftlern, Ingenieuren, 
Neurologen, Rehabilitationsmedizinern und Urologen essentiell. 
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VALORISATION 
Neurological disorders or lesions can readily impair LUT function due to its 
dependency on complex, multilevel neuronal control. The overall prevalence 
of neurological disorders and lesions impairing LUT function is very high and 
affects millions of people worldwide. The most common neurological 
disorders typically associated with LUTD are multiple sclerosis, Parkinson’s 
disease, and cerebrovascular disease with a world-wide crude prevalence 
per 100’000 population of 20-100, 100-200, and 500-1000, respectively [1]. 
In addition there are hereditary and acquired spinal cord lesions such as 
spina bifida, and traumatic and non-traumatic (e.g. ischemic, infectious, 
malignancy related) spinal cord injuries with world-wide crude prevalence 
rates of 30-40 per 100’000 pregnancies [2], 30-130 per 100’000 population, 
and 40-120 per 100’000 population, respectively [3]. Finally, there is a large 
group of patients suffering from peripheral nerve damage secondary to 
diabetes mellitus or pelvic surgery.  
Depending on the extent and progression, all these neurological diseases 
and lesions cause LUTD / LUTS in at least 15% and up to 99% of affected 
patients [4, 5], making NLUTD a frequent health problem with an enormous 
economic burden for every healthcare system. This becomes even more 
obvious considering that almost none of the underlying neurological 
diseases or lesions are curable, which makes life-long neuro-urological 
follow-up a necessity. 
NLUTD may occur immediately or during the course of a neurological 
disease leading to (1) additional psychological burden due to 
embarrassment, depression, and eventually social isolation related to LUTS 
such as urinary frequency and incontinence and (2) physical damage such 
as skin ulcers, recurrent urinary tract infections, and renal impairment [4].  
Adequate management and follow-up of NLUTD is thus mandatory for 
improving quality of life and preventing secondary damage to health. 
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Although this principle appears obvious, it still lacks sufficient 
implementation in many healthcare systems [6]. 
This thesis provides, on the one hand, a comprehensive overview of the 
neuropathophysiological background and current management of NLUTD 
and, on the other, several first-of-its-kind studies on important but previously 
unknown clinical aspects of currently available treatments for NLUTD. The 
chosen focus on BoNT/A intradetrusor injections in this thesis is due to its 
revolutionary impact on NLUTD management. Prior to BoNT/A intradetrusor 
injections, patients refractory to antimuscarinic treatment were restricted to 
surgery, e.g. bladder augmentation, ileal conduit. Nowadays, BoNT/A 
intradetrusor injections have significantly improved the QoL of many patients 
with NLUTD and helped to protect their upper urinary tract function without 
major surgery. However, despite the benefits of this treatment, many 
aspects of BoNT/A intradetrusor injections remain unknown and require 
further investigation before we can fully explore and utilize the true potential 
of this drug. 
The output of this thesis may help to (1) raise awareness of urologists, 
neurologists, and rehabilitation physicians of the importance of diagnosis, 
treatment, and follow-up of NLUTD, (2) optimize the use of BoNT/A 
intradetrusor injections for NLUTD in multiple sclerosis and other 
neurological patients, (3) improve treatment of neurogenic stress urinary 
incontinence in neurological patients, and (4) stimulate new research into the 
use of BoNT/A in the treatment of NLUTD to improve its benefit / risk ratio 
and explore proposed accessory effects to make the full treatment potential 
of BoNT/A available. 
Hence, this thesis provides new treatment concepts for NLUTD but also 
suggests new pathways and targets for further research specifically on 
BoNT/A injections within the LUT. The great advantage of exploiting and 
optimizing treatments that are already on the market and approved, as 
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presented in this thesis, is the direct availability and applicability for our 
patients. 
 
1. WHO. Neurological disorders: public health challenges. World Health 
Organization, 2006 ISBN 978 92 4 156336 9 Available from: 
http://www.who.int/mental_health/neurology/neurological_disorders_report_we
b.pdf. 
2. Kondo A, Kamihira O, Ozawa H. Neural tube defects: prevalence, etiology 
and prevention. Int J Urol. 2009;16(1):49-57. 
3. WHO. International Perspectives on Spinal Cord Injury. World Health 
Organization, 2013 ISBN 978 92 4 069186 5 Available from: 
http://apps.who.int/iris/bitstream/10665/94190/1/9789241564663_eng.pdf. 
4. Dorsher PT, McIntosh PM. Neurogenic bladder. Adv Urol. 
2012;2012:816274. 
5. Mehnert U, Nehiba M. [Neuro-urological dysfunction of the lower urinary 
tract in CNS diseases: pathophysiology, epidemiology, and treatment options]. 
Urologe A. 2012;51(2):189-97. 
6. Manack A, Motsko SP, Haag-Molkenteller C, Dmochowski RR, Goehring EL, 
Jr., Nguyen-Khoa BA, et al. Epidemiology and healthcare utilization of neurogenic 
bladder patients in a US claims database. Neurourol Urodyn. 2011;30(3):395-401. 
 
Chaper 9 
265 
LIST OF ABBREVIATIONS 
 
AD autonomic dysreflexia 
ARI Alpha reductase inhibitor 
ATP adenosine triphosphate 
AUA-SI American Urological Association Symptom Index 
AUS artificial urinary sphincter 
BoNT/A botulinum neurotoxin A 
BPH benign prostatic hyperplasia 
DU detrusor underactivity 
DES discrete event series 
DO detrusor overactivity 
DSD detrusor-sphincter-dyssynergia 
ECG Electrocardiogram 
EDSS extended disability symptom scale 
EMG electromyogramme 
EUS external urethral sphincter 
FDV first desire to void 
HF high frequency 
HRV heart rate variability 
IDO idiopathic detrusor overactivity 
IPSS international prostate symptom score 
ISC intermittent self-catheterisation 
LF low frequency 
LUT lower urinary tract 
LUTD lower urinary tract dysfunction 
LUTS lower urinary tract symptoms 
MCC maximum cystometric capacity 
MR magnetic resonance 
MRI magnetic resonance imaging 
MS multiple sclerosis 
MSA multiple system atrophy 
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nSUI neurogenic stress urinary incontinence 
NDO neurogenic detrusor overactivity 
NLUTD neurogenic lower urinary tract dysfunction 
NNOAB non-neurogenic overactive bladder 
OABS overactive bladder symptoms 
PD Parkinson’s disease 
pDetmax maximum detrusor pressure 
PFMT pelvic floor muscle training 
PSA prostate specific antigen 
PTNS percutaneous tibial nerve stimulation 
PVRV post void residual volume 
Qmax maximum Flowrate 
QoL quality of life 
RCT randomized controlled trials 
rHR resting heart rate 
RMSSD 
root mean square of the sum of differences between 
adjacent NN intervals 
SBP systolic blood pressure 
SCI spinal cord injury 
SDNN 
standard deviation of the normal to normal 
(NN or RR, i.e. interval between two R peaks) intervals 
SMC smooth muscle cell 
SNM sacral neuromodulation 
SUI stress urinary incontinence 
TP total power 
TRP transient receptor potential 
TTNS transcutaneous tibial nerve stimulation 
UIE urinary incontinence epidsodes 
UTI urinary tract infection 
UUT upper urinary tract 
VAS visual analogue scale 
VLF very low frequency 
VUR vesico-ureteral reflux 
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